<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><style scope="figure-callout">figure-callout:not([filenames=""]) a.figure-callout {
  cursor: zoom-in;
  text-decoration: underline;
  text-decoration-color: #ddd;
}</style><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><style scope="iron-dropdown">iron-dropdown {
  position: fixed;
}

#contentWrapper.iron-dropdown  > * {
  overflow: auto;
}

#contentWrapper.animating.iron-dropdown  > * {
  overflow: hidden;
}</style><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><style scope="dropdown-menu">dropdown-menu {
  display: inline-block;
        line-height: 24px;
}

.label.dropdown-menu {
  cursor: pointer;
        color: #666;
        align-items: center;
        margin-right: 8px;
        display: inline-block;
        padding: 2px 0;
}

#selected.dropdown-menu {
  color: #212121;
}

.label[open].dropdown-menu {
  border-color: #e0e0e0;
}

iron-dropdown.dropdown-menu {
  margin-top: 26px;
}

iron-icon.dropdown-menu {
  height: 15px;
        width: 15px;
}

#menu.dropdown-menu {
  max-height: 300px;
        padding: 8px 0;
        background: white;
        display: block;
        border-radius: 2px;
        box-shadow: 0 0 2px rgba(0,0,0,0.12), 0 2px 2px rgba(0,0,0,0.24);
}

.item.dropdown-menu {
  cursor: pointer;
        color: rgba(0,0,0,.87);
        font-size: 13px;
        line-height: 18px;
        padding: 6px 18px;
}

.item.dropdown-menu:hover {
  background-color: #e0e0e0;
}

.item[selected].dropdown-menu {
  background-color: #e0e0e0;
}

[multi].dropdown-menu .item.dropdown-menu {
  padding: 6px 18px 6px 34px;
}

[multi].dropdown-menu .item[selected].dropdown-menu {
  background-image: url('https://www.gstatic.com/images/icons/material/system/2x/done_grey600_24dp.png');
        background-position: 8px center;
        background-size: 16px;
        background-repeat: no-repeat;
}</style><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><style scope="image-carousel">image-carousel {
  display: block;
}

.thumbnails.image-carousel {
  display: block;
        background-color: transparent;
        padding: 7px;
        white-space: nowrap;
        overflow: auto;
        font-size: 0;
}

.thumbnails.image-carousel img.image-carousel {
  margin-right: 7px;
        cursor: zoom-in;
}

.thumbnails.image-carousel img[selected].image-carousel {
  outline: solid 3px #4285f4;
}

.thumbnails.image-carousel img.image-carousel:last-of-type {
  margin-right: 0;
}</style><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: "…"
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>US9242012B2 - Methods for killing PSMA-expressing, taxane-resistant cancer cells 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/US9242012B2/en">
    <meta name="description" content="
     Methods of killing prostate-specific membrane antigen (PSMA)-expressing, taxane-resistant cancer cells are provided. In particular, PSMA-expressing, taxane-resistant cancer cells are contacted with an antibody-drug conjugate (ADC) that comprises an antibody or antigen-binding fragment thereof that specifically binds to PSMA conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine. 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Methods for killing PSMA-expressing, taxane-resistant cancer cells 
       ">
    <meta name="DC.date" content="2011-02-17" scheme="dateSubmitted">
    <meta name="DC.description" content="
     Methods of killing prostate-specific membrane antigen (PSMA)-expressing, taxane-resistant cancer cells are provided. In particular, PSMA-expressing, taxane-resistant cancer cells are contacted with an antibody-drug conjugate (ADC) that comprises an antibody or antigen-binding fragment thereof that specifically binds to PSMA conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine. 
   
   ">
    <meta name="citation_patent_application_number" content="US:13/030,105">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/36/87/d1/57d084836b6ef4/US9242012.pdf">
    <meta name="citation_patent_number" content="US:9242012">
    <meta name="DC.date" content="2016-01-26" scheme="issue">
    <meta name="DC.contributor" content="Dangshe Ma" scheme="inventor">
    <meta name="DC.contributor" content="William C. Olson" scheme="inventor">
    <meta name="DC.contributor" content="Stephen Morris" scheme="inventor">
    <meta name="DC.contributor" content="Robert J. Israel" scheme="inventor">
    <meta name="DC.contributor" content="PSMA Development Co LLC" scheme="assignee">
    <meta name="DC.relation" content="WO:1994009820:A1" scheme="references">
    <meta name="DC.relation" content="US:5538866" scheme="references">
    <meta name="DC.relation" content="US:7105159" scheme="references">
    <meta name="DC.relation" content="US:7070782" scheme="references">
    <meta name="DC.relation" content="US:20060177450:A1" scheme="references">
    <meta name="DC.relation" content="US:6953668" scheme="references">
    <meta name="DC.relation" content="US:20070148662:A1" scheme="references">
    <meta name="DC.relation" content="WO:1996026272:A1" scheme="references">
    <meta name="DC.relation" content="US:7037647" scheme="references">
    <meta name="DC.relation" content="US:20040001846:A1" scheme="references">
    <meta name="DC.relation" content="AU:717937:B2" scheme="references">
    <meta name="DC.relation" content="US:5935818" scheme="references">
    <meta name="DC.relation" content="US:6569432" scheme="references">
    <meta name="DC.relation" content="US:20040105865:A1" scheme="references">
    <meta name="DC.relation" content="US:5773292" scheme="references">
    <meta name="DC.relation" content="US:20020015704:A1" scheme="references">
    <meta name="DC.relation" content="WO:1996039185:A1" scheme="references">
    <meta name="DC.relation" content="US:5788963" scheme="references">
    <meta name="DC.relation" content="WO:1997004802:A1" scheme="references">
    <meta name="DC.relation" content="US:20040253246:A1" scheme="references">
    <meta name="DC.relation" content="US:20100303715:A1" scheme="references">
    <meta name="DC.relation" content="US:7201900" scheme="references">
    <meta name="DC.relation" content="US:7476513" scheme="references">
    <meta name="DC.relation" content="US:7381407" scheme="references">
    <meta name="DC.relation" content="US:6150508" scheme="references">
    <meta name="DC.relation" content="US:20040024188:A1" scheme="references">
    <meta name="DC.relation" content="US:6962981" scheme="references">
    <meta name="DC.relation" content="WO:1997035616:A1" scheme="references">
    <meta name="DC.relation" content="US:20070128671:A1" scheme="references">
    <meta name="DC.relation" content="US:7163680" scheme="references">
    <meta name="DC.relation" content="US:6136311" scheme="references">
    <meta name="DC.relation" content="US:7112412" scheme="references">
    <meta name="DC.relation" content="US:20060275212:A1" scheme="references">
    <meta name="DC.relation" content="US:20030003101:A1" scheme="references">
    <meta name="DC.relation" content="US:20030031673:A1" scheme="references">
    <meta name="DC.relation" content="US:20090238755:A1" scheme="references">
    <meta name="DC.relation" content="US:7666425" scheme="references">
    <meta name="DC.relation" content="US:6107090" scheme="references">
    <meta name="DC.relation" content="US:6649163" scheme="references">
    <meta name="DC.relation" content="US:6770450" scheme="references">
    <meta name="DC.relation" content="US:5804602" scheme="references">
    <meta name="DC.relation" content="WO:1998002463:A1" scheme="references">
    <meta name="DC.relation" content="WO:1998003873:A1" scheme="references">
    <meta name="DC.relation" content="WO:1999047554:A1" scheme="references">
    <meta name="DC.relation" content="US:6383759" scheme="references">
    <meta name="DC.relation" content="WO:1999056779:A1" scheme="references">
    <meta name="DC.relation" content="US:6200765" scheme="references">
    <meta name="DC.relation" content="WO:1999061097:A2" scheme="references">
    <meta name="DC.relation" content="WO:2000014257:A1" scheme="references">
    <meta name="DC.relation" content="WO:2000061605:A1" scheme="references">
    <meta name="DC.relation" content="EP:1553414:A1" scheme="references">
    <meta name="DC.relation" content="WO:2000062063:A1" scheme="references">
    <meta name="DC.relation" content="US:20060234271:A1" scheme="references">
    <meta name="DC.relation" content="EP:1512755:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001009192:A1" scheme="references">
    <meta name="DC.relation" content="EP:1710256:A1" scheme="references">
    <meta name="DC.relation" content="WO:2001019956:A2" scheme="references">
    <meta name="DC.relation" content="US:6653129" scheme="references">
    <meta name="DC.relation" content="WO:2001085798:A2" scheme="references">
    <meta name="DC.relation" content="WO:2001087325:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002043661:A2" scheme="references">
    <meta name="DC.relation" content="US:20050009751:A1" scheme="references">
    <meta name="DC.relation" content="US:7098308" scheme="references">
    <meta name="DC.relation" content="US:6884869" scheme="references">
    <meta name="DC.relation" content="US:7423116" scheme="references">
    <meta name="DC.relation" content="WO:2002088172:A2" scheme="references">
    <meta name="DC.relation" content="US:7256257" scheme="references">
    <meta name="DC.relation" content="WO:2002096460:A1" scheme="references">
    <meta name="DC.relation" content="US:20040213791:A1" scheme="references">
    <meta name="DC.relation" content="US:7514078" scheme="references">
    <meta name="DC.relation" content="US:20040120958:A1" scheme="references">
    <meta name="DC.relation" content="US:7666414" scheme="references">
    <meta name="DC.relation" content="US:20060088539:A1" scheme="references">
    <meta name="DC.relation" content="WO:2002098897:A2" scheme="references">
    <meta name="DC.relation" content="US:7045605" scheme="references">
    <meta name="DC.relation" content="WO:2003024388:A2" scheme="references">
    <meta name="DC.relation" content="US:20030161832:A1" scheme="references">
    <meta name="DC.relation" content="US:7192586" scheme="references">
    <meta name="DC.relation" content="WO:2003026577:A2" scheme="references">
    <meta name="DC.relation" content="US:7553816" scheme="references">
    <meta name="DC.relation" content="US:7091186" scheme="references">
    <meta name="DC.relation" content="US:20110165081:A1" scheme="references">
    <meta name="DC.relation" content="US:8470330" scheme="references">
    <meta name="DC.relation" content="US:7850971" scheme="references">
    <meta name="DC.relation" content="US:20080286284:A1" scheme="references">
    <meta name="DC.relation" content="US:8114965" scheme="references">
    <meta name="DC.relation" content="US:20040033229:A1" scheme="references">
    <meta name="DC.relation" content="US:20140286859:A1" scheme="references">
    <meta name="DC.relation" content="US:20040161776:A1" scheme="references">
    <meta name="DC.relation" content="US:20050215472:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003040169:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003057921:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003064612:A2" scheme="references">
    <meta name="DC.relation" content="WO:2003064606:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004010957:A2" scheme="references">
    <meta name="DC.relation" content="US:20060074008:A1" scheme="references">
    <meta name="DC.relation" content="US:7659241" scheme="references">
    <meta name="DC.relation" content="US:20040136998:A1" scheme="references">
    <meta name="DC.relation" content="WO:2004063701:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004072262:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004073656:A2" scheme="references">
    <meta name="DC.relation" content="WO:2004098535:A2" scheme="references">
    <meta name="DC.relation" content="WO:2005001038:A2" scheme="references">
    <meta name="DC.relation" content="US:20090047296:A1" scheme="references">
    <meta name="DC.relation" content="US:7498298" scheme="references">
    <meta name="DC.relation" content="WO:2005081711:A2" scheme="references">
    <meta name="DC.relation" content="US:20080248051:A1" scheme="references">
    <meta name="DC.relation" content="US:20050238649:A1" scheme="references">
    <meta name="DC.relation" content="US:20080248053:A1" scheme="references">
    <meta name="DC.relation" content="US:20080226657:A1" scheme="references">
    <meta name="DC.relation" content="WO:2005070456:A2" scheme="references">
    <meta name="DC.relation" content="WO:2005084390:A2" scheme="references">
    <meta name="DC.relation" content="WO:2005094882:A1" scheme="references">
    <meta name="DC.relation" content="WO:2006002438:A2" scheme="references">
    <meta name="DC.relation" content="WO:2006028999:A2" scheme="references">
    <meta name="DC.relation" content="WO:2006039418:A2" scheme="references">
    <meta name="DC.relation" content="US:20080300192:A1" scheme="references">
    <meta name="DC.relation" content="WO:2006132670:A2" scheme="references">
    <meta name="DC.relation" content="WO:2006076525:A2" scheme="references">
    <meta name="DC.relation" content="WO:2006089230:A2" scheme="references">
    <meta name="DC.relation" content="WO:2006089231:A2" scheme="references">
    <meta name="DC.relation" content="WO:2006110745:A2" scheme="references">
    <meta name="DC.relation" content="WO:2007002222:A2" scheme="references">
    <meta name="DC.relation" content="US:20070160617:A1" scheme="references">
    <meta name="DC.relation" content="US:20090018086:A1" scheme="references">
    <meta name="DC.relation" content="US:20090111756:A1" scheme="references">
    <meta name="DC.relation" content="WO:2007008603:A1" scheme="references">
    <meta name="DC.relation" content="WO:2007008848:A2" scheme="references">
    <meta name="DC.relation" content="WO:2007011968:A2" scheme="references">
    <meta name="DC.relation" content="WO:2007038658:A2" scheme="references">
    <meta name="DC.relation" content="US:20090311225:A1" scheme="references">
    <meta name="DC.relation" content="US:7750116" scheme="references">
    <meta name="DC.relation" content="WO:2007103288:A2" scheme="references">
    <meta name="DC.relation" content="US:20110250216:A1" scheme="references">
    <meta name="citation_reference" content="[No Author Listed] &quot;Medarex Announces Filing of Investigational New Drug Application for MDX-070; Fully Human Anti-PSMA Antibody Candidate for Prostate Cancer.&quot; Press Release. PR Newswire. Monday, Jan. 6, 2003, 4:36 P.M. 2 pages." scheme="references">
    <meta name="citation_reference" content="[No Author Listed] &quot;Medarex: Pipeline.&quot; Available at http://www.medarex.com/Development/Pipeline.html. Last accessed Mar. 17, 2009." scheme="references">
    <meta name="citation_reference" content="[No Author Listed] &quot;Promising Findings&quot; from Novel Antibody-Chemotherapeutic MLN2704 Prostate Cancer Clinical Trial . . . PSA Rising. Feb. 22, 2005. Available at http://www.psa-rising.com/med/chemo/millennium05.html. Last accessed Jan. 19, 2010. 8 pages." scheme="references">
    <meta name="citation_reference" content="[No Author Listed] Latest Cancer Findings Presented at ASCO Meeting by Physician-scientists. Medical News Today. http://www.medicalnewstoday.com/articles/109424.php. Jun. 2, 2008. 3 pages. Last accessed online Oct. 29, 2008." scheme="references">
    <meta name="citation_reference" content="[No Author Listed] New York-Presbyterian/Weill Cornell Physician-Scientists Present Latest Cancer Findings at American Society of Clinical Oncology (ASCO) Meeting http://www.nyp.org/news/hospital/nypwc-presents-asco.html. May 30, 2008. 3 pages. Last accessed Oct. 29, 2008." scheme="references">
    <meta name="citation_reference" content="[No Author Listed] NYP/ Weill Cornell physician-scientists present latest cancer findings at ASCO meeting. Bio-Medicine. http://bio-medicine.org/medicine-news-1/NYP-Weill-Cornell-physician-scientists-p . . . May 31, 2008. 4 pages. Last accessed Oct. 29, 2008." scheme="references">
    <meta name="citation_reference" content="[No Author Listed] Physician-Scientists Present Latest Cancer Findings at ASCO Meeting. Newswise. http://www.newswise.com/articles/view/541288. Released: May 30, 2008. 08:00 ET. 3 pages. Last accessed Oct. 28, 2008." scheme="references">
    <meta name="citation_reference" content="[No Author Listed] Progenics and Cytogen Report Positive Preclinical Results for Experimental Prostate Cancer Drug-In laboratory studies, human monoclonal antibody killed prost. Progenics Pharmaceuticals, Inc. Press Release. Washington, D.C. Sep. 23, 2002. Available at http://www.lifesciencesworld.com/life-science-news/view/535?page=1495. Last accessed Jul. 26, 2011. 1 page." scheme="references">
    <meta name="citation_reference" content="[No Author Listed] Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate Cancer. Progenics Pharmaceuticals Press Release. Sep. 8, 2008. 3 pages." scheme="references">
    <meta name="citation_reference" content="[No Author Listed] Radiolabeled J591 Antibody Delivers Lethal Hit to Advanced Prostate Cancers in Phase 1 Trial. Cancer Biol &amp; Ther. 2004;3(8):699-700." scheme="references">
    <meta name="citation_reference" content="[No Author Listed] Seattle Genetics and PSMA Development Company Announce Antibody-Drug Conjugate Collaboration. Business Wire. Jun. 20, 2005. Available at http://www.thefreelibrary.com/Seattle+Genetics+and+PSMA+Development+Company+Announce+Antibody-Drug . . . -a0133363839. Last accessed Jan. 24, 2011. 4 pages." scheme="references">
    <meta name="citation_reference" content="[No Author Listed], FDA: Pfizer voluntarily withdraws cancer treatment Mylotarg from U.S. market. FDA News Release. Jun. 21, 2010. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216448.htm on Aug. 10, 2012. Last updated Jun. 22, 2010." scheme="references">
    <meta name="citation_reference" content="[No author listed], Progenics Pharmaceuticals initiates Phase 2 clinical trial of PSMA ADC in prostate cancer patients. Press Release Sep. 28, 2012. 2 pages." scheme="references">
    <meta name="citation_reference" content="Abdel-Nabi et al., Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol. Feb. 1992;10(1):45-54." scheme="references">
    <meta name="citation_reference" content="Ablin &quot;Immunotherapy for prostatic cancer. Previous and Prospective Considerations1&quot;, Oncology (1975) vol. 31, 177-202." scheme="references">
    <meta name="citation_reference" content="Allen, Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. Oct. 2002;2(10):750-63." scheme="references">
    <meta name="citation_reference" content="Arlen et al., Therapeutic vaccines for prostate cancer: a review of clinical data. Curr Opin Investig Drugs. Jun. 2005;6(6):592-6." scheme="references">
    <meta name="citation_reference" content="Axelrod et al., &quot;Preclinical results and human immunohistochemical studies with 90Y-CYT-356: A new prosate cancer therapeutic agent&quot;. AUA 87th Annual Meeting. 1992:Abstract #596." scheme="references">
    <meta name="citation_reference" content="Bander et al., Phase I radioimmunotherapy (RIT) trial of humanized monoclonal (mAb) antibody J591 to the extracellular domain of prostate specific membrane antigen (PSMAext) radiolabeled with 1771eutetium (177Lu) in advanced prostate cancer (Pca). 2003 ASCO Annual Meeting. Proc Am Soc Clin Oncol. 2003;22. Abstract 1612." scheme="references">
    <meta name="citation_reference" content="Bander et al., Phase I radioimmunotherapy (RIT) trials of humanized monoclonal antibody (mAb) J591 to the extracellular domain of prostate specific membrane antigen (PSMA ext) radiolabeled with 90Y or 177Lu in advanced prostate cancer (Pca). 2002 ASCO Annual Meeting. Biologic and Targeted Therapies; Antibodies. Abstract No. 18." scheme="references">
    <meta name="citation_reference" content="Bander et al., Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part 1. 2007;25(18S). Abstract 15523." scheme="references">
    <meta name="citation_reference" content="Bander et al., Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol. Oct. 2003;30(5):667-77." scheme="references">
    <meta name="citation_reference" content="Bander, Current status of monoclonal antibodies for imaging and therapy of prostate cancer Semin Oncol. Oct. 1994;21(5):607-12." scheme="references">
    <meta name="citation_reference" content="Bander, Immunotherapy of Prostate Cancer. State of the Science. Genitourinary. Dec. 13-14, 2002. 9 pages." scheme="references">
    <meta name="citation_reference" content="Basler et al., Advances in prostate cancer immunotherapies. Drugs Aging. 2007;24(3):197-221." scheme="references">
    <meta name="citation_reference" content="Bhaskar et al., E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res. Oct. 1, 2003;63(19):6387-94." scheme="references">
    <meta name="citation_reference" content="Bocchia et al., Antitumor vaccination: where we stand. Haematologica. Nov. 2000;85(11):1172-206." scheme="references">
    <meta name="citation_reference" content="Bodey et al., Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. Jul.-Aug. 2000;20(4):2665-76." scheme="references">
    <meta name="citation_reference" content="Carter, Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. Nov. 2001;1(2):118-29." scheme="references">
    <meta name="citation_reference" content="Chang et al., Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer-focus on prostate-specific membrane antigen? Review Article. Curr Opin Urology. 1999;9(5):391-95." scheme="references">
    <meta name="citation_reference" content="Chen et al., Antibody-cytotoxic agent conjugates for cancer therapy. Expert Opin Drug Deliv. Sep. 2005;2(5):873-90." scheme="references">
    <meta name="citation_reference" content="Damle, Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin Biol Ther. Sep. 2004;4(9):1445-52." scheme="references">
    <meta name="citation_reference" content="Darshan et al., Taxanes inhibit AR nuclear accumulation and signaling in cells and metastatic prostate cancer patients. Novel Drug Targets, Agents, and Mechanisms: Poster Presentations-Proffered Abstracts. 99th AACR Annual Meeting. Apr. 12-16, 2008. Abstract 2808." scheme="references">
    <meta name="citation_reference" content="Donovan et al., Antibody and vaccine therapies targeting prostate specific membrane antigen (PSMA). Proceedings of the Annual Meeting of the AACR. New York, NY. Mar. 24, 2001;42:818. Abstract 4389." scheme="references">
    <meta name="citation_reference" content="Donovan et al., Clinical development of immunotherapies targeting prostate specific membrane antigen. 38th Annual Meeting American Society of Clinical Oncology. Alexandria, VA. May 18-21, 2002. Presentation. PSMA Development Company, LLC. Tarrytown, NY (joint venture between Progenics Pharmaceuticals, Inc. and Cytogen Corporation) and The Cleveland Clinic, Cleveland, OH. Proceedings of ASCO. 2002;21:25b. Abstract #1909." scheme="references">
    <meta name="citation_reference" content="Donovan et al., Development of PSMA-based immunotherapies for prostate cancer. AACR Meeting. San Francisco, CA. Apr. 6-10, 2002. PSMA Development Company, LLC. Tarrytown, NY (joint venture between Progenics Pharmaceuticals, Inc. and Cytogen Corporation) and The Cleveland Clinic, Cleveland, OH. Abstract 456." scheme="references">
    <meta name="citation_reference" content="Doronina et al., Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. Jul. 2003;21(7):778-84. Epub Jun. 1, 2003. Erratum." scheme="references">
    <meta name="citation_reference" content="Doronina et al., Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. Jan.-Feb. 2006;17(1):114-24." scheme="references">
    <meta name="citation_reference" content="Doronina et al., Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy. Abstracts of papers. ACS National Meeting. Aug. 2004;228:U908. Cited as AACR meeting abstracts online, Pro Amer Assoc Cancer Res v45 Experimental and Molecular Therapeutics 6: Novel Delivery Strategies, Abstract #623." scheme="references">
    <meta name="citation_reference" content="Doronina et al., Novel linkers for monoclonal antibody-mediated delivery of anticancer agents AACR. Anaheim, CA. Apr. 16-20, 2005. Abstract No. 1421." scheme="references">
    <meta name="citation_reference" content="Doronina et al., Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem. Oct. 2008;19(10):1960-3. Epub Sep. 20, 2008." scheme="references">
    <meta name="citation_reference" content="Francisco et al., cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. Aug. 15, 2003;102(4):1458-65. Epub Apr. 24, 2003." scheme="references">
    <meta name="citation_reference" content="Galsky et al., Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. May 1, 2008;26(13):2147-54. Epub Mar. 24, 2008." scheme="references">
    <meta name="citation_reference" content="Ghose et al., The design of cytotoxic-agent-antibody conjugates. CRC Critical Reviews in Therapeutic Drug Carrier Systems. 2000;3:263-359." scheme="references">
    <meta name="citation_reference" content="Gong et al., Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev. 1999;18(4):483-90" scheme="references">
    <meta name="citation_reference" content="Graves et al., Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody. Clin Cancer Res. Apr. 1999;5(4):899-908." scheme="references">
    <meta name="citation_reference" content="Harada et al., Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol. Aug. 2003;8(4):193-9." scheme="references">
    <meta name="citation_reference" content="Holmes, PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs. Mar. 2001;10(3):511-9." scheme="references">
    <meta name="citation_reference" content="Huang et al., Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate. Sep. 15, 2004;61(1):1-11." scheme="references">
    <meta name="citation_reference" content="Huang et al., Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res. Oct. 15, 2002;62(20):5720-6." scheme="references">
    <meta name="citation_reference" content="Hynecek et al., 177Lu-J591 monoclonal antibody (Lu-J591) therapy in metastatic castrate-resistant prostate cancer (metCRPC): Correlation of antibody-tumor targeting and treatment response Oncology-Basic Science: Therapy, Metrics &amp; Intervention Imaging for Assessment of Response Therapy Planning. J Nucl Med. 2008;49(Supplement 1):144P. 2 pages." scheme="references">
    <meta name="citation_reference" content="Jacobs et al., Clinical use of tumor markers in oncology. Curr Probl Cancer. Nov.-Dec. 1991;15(6):299-350." scheme="references">
    <meta name="citation_reference" content="Jain et al., Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res. Mar. 1, 2007;13(5):1374-82. Epub Feb. 19, 2007." scheme="references">
    <meta name="citation_reference" content="Jaracz et al., Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem. Sep. 1, 2005;13(17):5043-54." scheme="references">
    <meta name="citation_reference" content="Jayaprakash et al., Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. ChemMedChem. Mar. 2006;1(3):299-302." scheme="references">
    <meta name="citation_reference" content="Lambert, Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. Oct. 2005;5(5):543-9." scheme="references">
    <meta name="citation_reference" content="Lapidus et al., Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate. Dec. 1, 2000;45(4):350-4." scheme="references">
    <meta name="citation_reference" content="Law et al., Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res. Dec. 1, 2004;10(23):7842-51." scheme="references">
    <meta name="citation_reference" content="Li et al., Trastuzumab-auristatin immunoconjugates inhibit growth and induce apoptosis of human breast cancer cells in vitro. Department of Translational Oncology. Genentech, Inc. South San Francisco, CA. Department of Biochemistry, Seattle Genetics, Inc. Bothell, WA. Poster#6184, 2005." scheme="references">
    <meta name="citation_reference" content="Lin et al., A functional role of prostate-specific membrane antigen in prostate cancer metastasis Tumor Biology 30: Proteases: Protease Inhibitors and Cancer. Proc Amer Assoc Cancer Res. 2006;47. Abstract 4373." scheme="references">
    <meta name="citation_reference" content="Ma et al., Fully human anti-PSMA antibodies for prostate cancer therapy. Proc AACR. Jul. 2003;44(2):1295. Abstract #6471." scheme="references">
    <meta name="citation_reference" content="Ma et al., Fully human monoclonal antibodies to PSMA selectively target cytotoxins, radiotoxins and host immunity to prostate cancer. J Clin Oncol. ASCO Annual Meeting Proceedings. 2004;22:14S. Abstract No. 2546. Abstract Only." scheme="references">
    <meta name="citation_reference" content="Ma et al., Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res. Apr. 15, 2006;12(8):2591-6." scheme="references">
    <meta name="citation_reference" content="Ma et al., PSMA targeted toxin and radio-labelled antibody therapies for prostate cancer. J Urology. 2003;169:211. Poster 817." scheme="references">
    <meta name="citation_reference" content="Mays et al., MDX-070, a human anti-plasma antibody, administered as either a single dose or as multiple doses to patients with hormone-refractory prostate cancer. ASCO Annual Meeting, 2006. Abstract #14549." scheme="references">
    <meta name="citation_reference" content="McDevitt et al., An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. Nov. 1, 2000;60(21):6095-100." scheme="references">
    <meta name="citation_reference" content="Mega et al., Prostate specific membrane antigen antibody drug conjugate (PSMA ADC): A Phase I trial in subjects with castration-resistant metastatic prostate cancer (CRMPC) previously treated with taxane. Poster presented Feb. 2012 Genitourinary Cancers Symposium." scheme="references">
    <meta name="citation_reference" content="Milowsky et al., Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. Jul. 1, 2004;22(13):2522-31. Epub Jun. 1, 2004." scheme="references">
    <meta name="citation_reference" content="Milowsky et al., Phase I trial results of yttrium-90 (90Y)-labeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 in the treatment of patients with advanced prostate cancer (PC). 2003 ASCO Annual Meeting. Proc Am Soc Clin Oncol. 2003;22. Abstract 1583." scheme="references">
    <meta name="citation_reference" content="Monson, Recent progress in the use of monoclonal antibodies for imaging and therapy. Curr Opin Gen Surg. 1993:334-9." scheme="references">
    <meta name="citation_reference" content="Moreno et al. (Urology. 2001, 58: 386-92)." scheme="references">
    <meta name="citation_reference" content="Morris et al., Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res. May 1, 2007;13(9):2707-13." scheme="references">
    <meta name="citation_reference" content="Morris et al., Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. Oct. 15, 2005;11(20):7454-61." scheme="references">
    <meta name="citation_reference" content="Muprhy et al., Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. Jul.-Aug. 1995;15(4):1473-9." scheme="references">
    <meta name="citation_reference" content="Nanus et al., Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol. Dec. 2003;170(6 Pt 2):S84-8; discussion S88-9. Abstract only." scheme="references">
    <meta name="citation_reference" content="Olson et al., Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. Sep. 2007;2(3):182-90." scheme="references">
    <meta name="citation_reference" content="Partin et al., The clinical usefulness of prostate specific antigen: update 1994. Urol. Nov. 1994;152(5 Pt 1):1358-68. Review." scheme="references">
    <meta name="citation_reference" content="Pastuskovas et al., Tissue distribution, metabolism, and excretion of the antibody-drug conjugate herceptin-monomethyl auristatin E in rats. Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, Inc. South San Francisco, CA. Seattle Genetics, Bothell, WA. Poster #5063, 2005." scheme="references">
    <meta name="citation_reference" content="Petrylak et al., Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): a phase I trial in taxane-refractory prostate cancer. Poster presented Feb. 17, 2011 Genitourinary Cancers Symposium General Poster Session B. Abstract published ASCO Meeting Abstracts Mar. 29, 2011:158. J Clin Oncol 29: Mar. 2011 (suppl 7; abstr 158)." scheme="references">
    <meta name="citation_reference" content="Petrylak, BRD E18: A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). 2014 Genitourinary Cancers Symposium (abstract 83)." scheme="references">
    <meta name="citation_reference" content="Riechmann et al., Reshaping human antibodies for therapy. Nature. Mar. 4, 1988;332(6162):323-7." scheme="references">
    <meta name="citation_reference" content="Saijo, What are the reasons for negative phase III trials of molecular-target-based drugs? Cancer Sci. Oct. 2004;95(10):772-6." scheme="references">
    <meta name="citation_reference" content="Sanderson et al., In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. Jan. 15, 2005;11(2 Pt 1):843-52." scheme="references">
    <meta name="citation_reference" content="Schuelke et al., Human prostate specific membrane antigen (PSMA) is expressed as a non-covalent dimer and provides an attractive target for cancer immunotherapy. Eur J Cancer. Nov. 2002;38:S153. Poster 510." scheme="references">
    <meta name="citation_reference" content="Schulke et al., The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA. Oct. 28, 2003;100(22):12590-95." scheme="references">
    <meta name="citation_reference" content="Senter, Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. Jun. 2009;13(3):235-44. Epub May 4, 2009." scheme="references">
    <meta name="citation_reference" content="Sharkey et al., Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. Jul.-Aug. 2006;56(4):226-43." scheme="references">
    <meta name="citation_reference" content="Small, Monoclonal antibody therapy for prostate cancer: finally a reality? J Clin Oncol. Jul. 1, 2004;22(13):2515-6. Epub Jun. 1, 2004." scheme="references">
    <meta name="citation_reference" content="Smith-Jones et al., In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. Sep. 15, 2000;60(18):5237-43." scheme="references">
    <meta name="citation_reference" content="Smith-Jones et al., Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med. Apr. 2003;44(4):610-7." scheme="references">
    <meta name="citation_reference" content="Su et al., Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res. Apr. 1, 1995;55(7):1441-3." scheme="references">
    <meta name="citation_reference" content="Sweat et al., Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastatses. Urology. Oct. 1998;52(4):637-40." scheme="references">
    <meta name="citation_reference" content="Tagawa et al., Phase II trial of 177Lutetium radio-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). 2008 ASCO Annual Meeting. J Clin Oncol. 2008;26(May 20 Suppl.). Abstract 5140." scheme="references">
    <meta name="citation_reference" content="Trail et al., Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother. May 2003;52(5):328-37. Epub Jan. 16, 2003." scheme="references">
    <meta name="citation_reference" content="Tralongo et al., Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study. Tumori. Jan.-Feb. 2003;89(1):26-30. Abstract only." scheme="references">
    <meta name="citation_reference" content="US 6,290,956, 09/2001, Bander (withdrawn)" scheme="references">
    <meta name="citation_reference" content="Vitetta et al., Immunotoxins. Annu Rev Immunol. 1985;3:197-212." scheme="references">
    <meta name="citation_reference" content="Vriesendorp et al., Radiolabeled immunoglobulin therapy: old barriers and new opportunities. Expert Rev Anticancer Ther. Oct. 2001;1(3):461-78." scheme="references">
    <meta name="citation_reference" content="Wang et al. (Mol Cancer Ther., 2011, 10: 1728-1739)." scheme="references">
    <meta name="citation_reference" content="Wang et al. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther. Sep. 2011;10(9):1728-39." scheme="references">
    <meta name="citation_reference" content="Webb et al., Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system. J Urol. Aug. 1989;142(2 Pt 1):425-32." scheme="references">
    <meta name="citation_reference" content="Weill Medical College of Cornell University: &quot;177 Lu Radiolabeled Monoclonal Antibody HuJ591 (177 Lu-J591) and Ketoconazole in Patients with Prostate Cancer&quot;. ClinicalTrials.gov, Mar. 10, 2008, XP055139382." scheme="references">
    <meta name="citation_reference" content="Weill Medical College of Cornell University: &quot;Docetaxel/Prednisone Plus Fractionated177 Lu-J591 Antibody for metastatic, castrate-resistant prostate cancer&quot; ClinicalTrials.gov, Jun. 5, 2009, pp. 1-6, XP055139381." scheme="references">
    <meta name="citation_reference" content="Weiner et al., New approaches to antibody therapy. Oncogene. Dec. 11, 2000;19(53):6144-51." scheme="references">
    <meta name="citation_reference" content="Williams et al., Discontinued drugs in 2006: oncology drugs. Expert Opin Investig Drugs. Mar. 2008;17(3):269-83." scheme="references">
    <meta name="citation_reference" content="Wolf, Herstellung und Charakterisierung rekombinanter Immunotoxine aus anti-PSMA single-chain-Antikörperfragmenten zur Therapie des Prostatakarzinoms. Ph.D. Thesis. Dec. 2005. 33 pages. 2 page German abstract. 31 page English translation." scheme="references">
    <meta name="citation_reference" content="Wood et al., Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol. Aug. 2001;1(4):370-7." scheme="references">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            Methods for killing PSMA-expressing, taxane-resistant cancer cells 
       </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA167751205" lang="EN" load-source="patent-office" class="style-scope patent-text">
    <div id="p-0001" num="0000" class="abstract style-scope patent-text">Methods of killing prostate-specific membrane antigen (PSMA)-expressing, taxane-resistant cancer cells are provided. In particular, PSMA-expressing, taxane-resistant cancer cells are contacted with an antibody-drug conjugate (ADC) that comprises an antibody or antigen-binding fragment thereof that specifically binds to PSMA conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine.</div>
  </abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              
                <section id="thumbnails" class="style-scope patent-result">
                  <h3 class="style-scope patent-result">Images (<span class="style-scope patent-result">16</span>)</h3>
                  <image-carousel id="figures" class="style-scope patent-result">
    
    
      <div class="thumbnails style-scope image-carousel">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/10/2f/0d/6b086c859ee1b9/US09242012-20160126-D00001.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/42/2d/35/9742b33771b71b/US09242012-20160126-D00002.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/5e/58/21/73345bc8e83f9a/US09242012-20160126-D00003.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/a6/48/41/a3e7f680dc2cc4/US09242012-20160126-D00004.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/fc/05/7a/443e941c38e58b/US09242012-20160126-D00005.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/67/0d/16/7480eee51a7d17/US09242012-20160126-D00006.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/16/60/e3/953bcec38690c4/US09242012-20160126-D00007.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/3c/f7/a2/440efdae2681bc/US09242012-20160126-D00008.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/c7/e1/b1/824778f1ae3b59/US09242012-20160126-D00009.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/e1/c7/c6/39b41fd324ff4f/US09242012-20160126-D00010.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/5b/6c/51/a1b9d06f4c9f1b/US09242012-20160126-D00011.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/94/a1/c7/effd2ae8dc4cab/US09242012-20160126-D00012.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/02/67/72/f15ff36dbd5101/US09242012-20160126-D00013.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/32/d9/95/a087a90b9ed1d6/US09242012-20160126-D00014.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/8b/8a/d8/ef130d007a7e7d/US09242012-20160126-D00015.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/54/8e/25/b93639e03ccb32/US09242012-20160126-D00016.png">
        <template is="dom-repeat" as="img" class="style-scope image-carousel"></template>
      </div>
    <template is="dom-if" class="style-scope image-carousel"></template>
  </image-carousel>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="A61K47/48415"><a id="link" href="#" class="style-scope state-modifier">A61K47/48415</a></state-modifier>
                  <span class="description style-scope classification-tree"></span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6801"><a id="link" href="#" class="style-scope state-modifier">A61K47/6801</a></state-modifier>
                  <span class="description style-scope classification-tree">Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6803"><a id="link" href="#" class="style-scope state-modifier">A61K47/6803</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="A61K47/6811"><a id="link" href="#" class="style-scope state-modifier">A61K47/6811</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/48638"><a id="link" href="#" class="style-scope state-modifier">A61K47/48638</a></state-modifier>
                  <span class="description style-scope classification-tree"></span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6869"><a id="link" href="#" class="style-scope state-modifier">A61K47/6869</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/04"><a id="link" href="#" class="style-scope state-modifier">A61P35/04</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents specific for metastasis</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 5 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Life Sciences &amp; Earth Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Life Sciences &amp; Earth Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">US9242012B2</h2>
                  <p class="tagline style-scope patent-result">United States</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Patent ( having previously published pre-grant publication)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/36/87/d1/57d084836b6ef4/US9242012.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;psma&quot;,&quot;subject&quot;,&quot;antibody&quot;,&quot;adc&quot;,&quot;tumor&quot;]" data-before="20080908"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/US9242012B2"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Dangshe Ma"><a id="link" href="#" class="style-scope state-modifier">Dangshe Ma</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="William C. Olson"><a id="link" href="#" class="style-scope state-modifier">William C. Olson</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Stephen Morris"><a id="link" href="#" class="style-scope state-modifier">Stephen Morris</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Robert J. Israel"><a id="link" href="#" class="style-scope state-modifier">Robert J. Israel</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    PSMA Development Co LLC
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2009</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP2326350B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP09789284.8A</div>
                <div class="style-scope application-timeline">Filing date: 2009-09-08</div>
                <div class="style-scope application-timeline">Legal status: Not-in-force</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PL2326350T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PL09789284T</div>
                <div class="style-scope application-timeline">Filing date: 2009-09-08</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2438495T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES09789284.8T</div>
                <div class="style-scope application-timeline">Filing date: 2009-09-08</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP2727606A3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP13182516.8A</div>
                <div class="style-scope application-timeline">Filing date: 2009-09-08</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PT2326350E/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PT</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PT97892848T</div>
                <div class="style-scope application-timeline">Filing date: 2009-09-08</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/DK2326350T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">DK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: DK09789284.8T</div>
                <div class="style-scope application-timeline">Filing date: 2009-09-08</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2010027513A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/US2009/005064</div>
                <div class="style-scope application-timeline">Filing date: 2009-09-08</div>
                <div class="style-scope application-timeline">Legal status: Application Filing</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2011</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US9242012B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US13/030,105</div>
                <div class="style-scope application-timeline">Filing date: 2011-02-17</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HK1159474A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">HK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HK11112651.2A</div>
                <div class="style-scope application-timeline">Filing date: 2011-11-22</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application US13/030,105 events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2011-02-17</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="PSMA Development Co LLC"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by PSMA Development Co LLC</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="priority style-scope application-timeline">2011-02-17</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US9242012B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority to US13/030,105</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2011-10-13</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20110250216A1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of US20110250216A1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2016-01-26</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2016-01-26</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US9242012B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of US9242012B2</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Active</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2031-11-08</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Adjusted expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      
        <div class="event layout horizontal expand style-scope application-timeline">
          Show all events <iron-icon style="height: 15px; width: 15px;" icon="expand-more" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M16.59 8.59L12 13.17 7.41 8.59 6 10l6 6 6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope application-timeline"></template>
          <template is="dom-if" class="style-scope application-timeline"></template>
        </div>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (86)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#nplCitations" class="style-scope patent-result">Non-patent citations (107)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (18)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;p=1&amp;u=/netahtml/PTO/srchnum.html&amp;r=1&amp;f=G&amp;l=50&amp;d=PALL&amp;s1=9242012.PN.">USPTO</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patentcenter.uspto.gov/applications/13030105">USPTO PatentCenter</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://assignment.uspto.gov/patent/index.html#/patent/search/resultFilter?searchInput=9242012">USPTO Assignment</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&amp;NR=9242012B2&amp;KC=B2&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/patent/US/9242012/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/US9242012">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PDES99682912" lang="EN" load-source="patent-office" class="description style-scope patent-text">
    
    <heading id="h-0001" class="style-scope patent-text">RELATED APPLICATIONS</heading>
    <div id="p-0002" num="0001" class="description-paragraph style-scope patent-text">This application is a continuation-in-part of International Application No. PCT/US2009/005064 designating the United States, filed Sep. 8, 2009, which claims the benefit under 35 U.S.C. §119 of U.S. provisional application 61/095,300, filed Sep. 8, 2008 and U.S. provisional application 61/205,395, filed Jan. 20, 2009, the contents of each of which are incorporated herein by reference in their entirety.</div>
    
    
    <heading id="h-0002" class="style-scope patent-text">BACKGROUND OF THE INVENTION</heading>
    <div id="p-0003" num="0002" class="description-paragraph style-scope patent-text">Prostate cancer is the most common malignancy and the second leading cause of cancer death in men in the United States (Jemal A, et al., <i class="style-scope patent-text">CA Cancer J Clin </i>2005; 55:10-30). Localized prostate cancer typically is treated with surgery or radiation, and recurrent disease can be controlled temporarily with androgen ablation (Klein E A, et al., <i class="style-scope patent-text">Urol Clin North Am </i>2003; 30:315-30). However, almost all prostate carcinomas eventually become hormone refractory and then rapidly progress (Denmeade S R, et al., <i class="style-scope patent-text">Nat Rev Cancer </i>2002; 2:389-96). Hormone-refractory or androgen-independent prostate cancer has proven to be largely resistant to conventional chemotherapy. With the exception of palliative care, the only approved chemotherapy is docetaxel in combination with prednisone, which offers a modest (2.4 month) survival benefit (Gulley J, et al., <i class="style-scope patent-text">Am J Ther. </i>2004; 351:1513-20; Petrylak D P, et al., <i class="style-scope patent-text">New Engl J Med </i>2004; 351:1513-20).</div>
    <heading id="h-0003" class="style-scope patent-text">SUMMARY OF THE INVENTION</heading>
    <div id="p-0004" num="0003" class="description-paragraph style-scope patent-text">The present invention relates, at least in part, to the surprising discovery that antibody-drug conjugates (ADCs) comprising an antibody or antigen-binding fragment thereof that specifically binds PSMA conjugated to a <figure-callout id="10" label="dolastatin" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">dolastatin</a></figure-callout> 10 derivative, in particular auristatins such as, MMAE (also referred to herein as monomethylauristatin E or monomethylauristatin norephedrine) or MMAF (also referred to herein as monomethylauristatin F or monomethylauristatin phenylalanine) can be used to kill PSMA-expressing, taxane-resistant cancer cells and to treat PSMA-expressing, taxane-resistant cancer. Provided herein, therefore, are methods for killing PSMA-expressing, taxane-resistant cancer cells. Also provided herein, are methods for treating a subject with a PSMA-expressing, taxane-resistant cancer. In one embodiment of the latter methods, the methods involve killing PSMA-expressing, taxane-resistant cancer cells. In another embodiment of the latter methods, the methods involve delaying or inhibiting progression of the cancer. In a further embodiment of the latter methods the method involves alleviating or decreasing pain in a subject (e.g., a human patient) having progressive, castration resistant, taxane-resistant metastatic prostate cancer comprising administering PSMA ADC in an amount effective to alleviate or decrease the level of pain in the subject. In one embodiment, the pain is bone pain. In one embodiment, the amount effective to alleviate or decrease the level of pain (e.g., bone pain) in the subject is a dose of PSMA ADC of at least 1.6 mg/kg or greater. In another embodiment, the amount effective is a dose of at least 1.8 mg·kg or greater. In yet another embodiment, the amount effective is a dose of at least 2.0 mg/kg or greater. In one embodiment, the dose is administered at 1, 2, 3 or 4 week intervals or more. In another embodiment, the dose is administered intravenously at 3 week intervals. In still other embodiments, the treatment is effective to reduce pain (e.g., bone pain) and the number of CTC cells in a subject. In yet another embodiment, the treatment is effective to reduce pain (e.g., bone pain) and PSA levels in a subject. In still other embodiments, the treatment is effective to reduce pain (e.g., bone pain), the number of CTC cells and PSA levels in a subject. In still another embodiment of the latter methods, the methods involve increasing survival of the subject as compared to the median survival of subjects not been treated with the PSMA ADC and that have progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. In yet another embodiment of the latter methods, the methods involve decreasing a circulating level of circulating tumor cells (CTCs) compared to a baseline level. In a further embodiment of the latter methods, the methods involve decreasing or stabilizing a serum level of PSA compared to a baseline level of PSA.</div>
    <div id="p-0005" num="0004" class="description-paragraph style-scope patent-text">In one aspect, therefore, a method for killing PSMA-expressing, taxane-resistant cancer cells comprising contacting the PSMA-expressing, taxane-resistant cancer cells with an antibody-drug conjugate in an amount effective to kill the PSMA-expressing, taxane-resistant cancer cells, wherein the antibody-drug conjugate comprises a monoclonal antibody or antigen-binding fragment thereof that specifically binds to prostate-specific membrane antigen (PSMA) conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine, and wherein the sequence of PSMA is the sequence set forth in SEQ ID NO: 1, is provided.</div>
    <div id="p-0006" num="0005" class="description-paragraph style-scope patent-text">In another aspect, a method for treating a subject that has a PSMA-expressing, taxane-resistant cancer comprising administering to the subject that has the PSMA-expressing, taxane-resistant cancer an antibody-drug conjugate in an amount effective to treat the PSMA-expressing, taxane-resistant cancer, wherein the antibody-drug conjugate comprises a monoclonal antibody or antigen-binding fragment thereof that specifically binds to prostate-specific membrane antigen (PSMA) conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine, and wherein the sequence of PSMA is the sequence set forth in SEQ ID NO: 1, is also provided. In one embodiment, the method involves killing PSMA-expressing, taxane-resistant cancer cells. In another embodiment, the method involves delaying or inhibiting progression of the cancer. In a further embodiment, the method involves alleviating or decreasing pain in a subject (e.g., a human patient) having progressive, castration resistant, taxane-resistant metastatic prostate cancer comprising administering PSMA ADC in an amount effective to alleviate or decrease the level of pain in the subject. In one embodiment, the pain is bone pain. In one embodiment, the amount effective to alleviate or decrease the level of pain (e.g., bone pain) in the subject is a dose of PSMA ADC of at least 1.6 mg/kg or greater. In another embodiment, the amount effective is a dose of at least 1.8 mg·kg or greater. In yet another embodiment, the amount effective is a dose of at least 2.0 mg/kg or greater. In one embodiment, the dose is administered at 1, 2, 3 or 4 week intervals or more. In another embodiment, the dose is administered intravenously at 3 week intervals. In still other embodiments, the treatment is effective to reduce pain (e.g., bone pain) and the number of CTC cells in a subject. In yet another embodiment, the treatment is effective to reduce pain (e.g., bone pain) and PSA levels in a subject. In still other embodiments, the treatment is effective to reduce pain (e.g., bone pain), the number of CTC cells and PSA levels in a subject. In still another embodiment, the method involves increasing survival of the subject as compared to the median survival of subjects not been treated with the PSMA ADC and that have progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. In yet another embodiment, the method involves decreasing a circulating level of circulating tumor cells (CTCs) compared to a baseline level. In a further embodiment, the method involves decreasing or stabilizing a serum level of PSA compared to a baseline level of PSA.</div>
    <div id="p-0007" num="0006" class="description-paragraph style-scope patent-text">In yet another aspect, a method for treating a subject having progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy, comprising administering an effective amount of an antibody-drug conjugate, wherein the antibody-drug conjugate comprises a monoclonal antibody or antigen-binding fragment thereof that specifically binds to prostate-specific membrane antigen (PSMA) conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine, and wherein the sequence of PSMA is the sequence set forth in SEQ ID NO: 1, is also provided. In one embodiment, the PSMA antibody drug conjugate (also referred to herein as “PSMA ADC” or “ADC”) consists essentially of a human monoclonal antibody to PSMA conjugated to monomethylaurastatin norephedrine (MMAE) via a valine-citrulline linker. In one embodiment, the method involves killing PSMA-expressing, taxane-resistant cancer cells. In another embodiment, the method involves delaying or inhibiting progression of the cancer. In a further embodiment, the method involves alleviating or decreasing pain in a subject (e.g., a human patient) having progressive, castration resistant, taxane-resistant metastatic prostate cancer comprising administering PSMA ADC in an amount effective to alleviate or decrease the level of pain in the subject. In one embodiment, the pain is bone pain. In one embodiment, the amount effective to alleviate or decrease the level of pain (e.g., bone pain) in the subject is a dose of PSMA ADC of at least 1.6 mg/kg or greater. In another embodiment, the amount effective is a dose of at least 1.8 mg·kg or greater. In yet another embodiment, the amount effective is a dose of at least 2.0 mg/kg or greater. In one embodiment, the dose is administered at 1, 2, 3 or 4 week intervals or more. In another embodiment, the dose is administered intravenously at 3 week intervals. In still other embodiments, the treatment is effective to reduce pain (e.g., bone pain) and the number of CTC cells in a subject. In yet another embodiment, the treatment is effective to reduce pain (e.g., bone pain) and PSA levels in a subject. In still other embodiments, the treatment is effective to reduce pain (e.g., bone pain), the number of CTC cells and PSA levels in a subject. In still another embodiment, the method involves increasing survival of the subject as compared to the median survival of subjects not been treated with the PSMA ADC and that have progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. In yet another embodiment, the method involves decreasing a circulating level of circulating tumor cells (CTCs) compared to a baseline level. In a further embodiment, the method involves decreasing or stabilizing a serum level of PSA compared to a baseline level of PSA.</div>
    <div id="p-0008" num="0007" class="description-paragraph style-scope patent-text">In one embodiment of the methods provided, the effective amount of the ADC is sufficient to 1) delay or inhibit progression of the cancer, 2) increase survival of the subject as compared to the median survival of subjects who have not been treated with PSMA ADC and who have progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy, 3) decrease a circulating level of circulating tumor cells (CTCs) compared to a baseline level, 4) decrease or stabilize a serum level of prostate specific antigen (PSA) compared to a baseline level of PSA; and/or 5) alleviate or decrease a level of pain (e.g., bone pain) in a subject (e.g., human patient).</div>
    <div id="p-0009" num="0008" class="description-paragraph style-scope patent-text">In one embodiment, the killing of the PSMA-expressing, taxane-resistant cancer cells or the delay or inhibition of progression of the cancer is demonstrated by radiographic image changes in tumor burden compared to a baseline radiographic image in the subject prior to the administration of the PSMA ADC. In one embodiment, the radiographic image change is a change of at least 10%. In another embodiment, the radiographic image change is a change of at least 20%. In still another embodiment, the radiographic image change is a change of at least 30%. In yet another embodiment, the radiographic image change is a change of at least 40%. In a further embodiment, the radiographic image change is a change of at least 50%. In still a further embodiment, the radiographic image change is a change of at least 60%.</div>
    <div id="p-0010" num="0009" class="description-paragraph style-scope patent-text">In another embodiment of the methods provided, the killing of the PSMA-expressing, taxane-resistant cancer cells or the delay or inhibition of progression of cancer is demonstrated by a change in at least one biomarker for bone metastasis and bone metabolism compared to a baseline value prior to the administration of the PSMA ADC. In one embodiment, the biomarker is N-telopeptide, bone alkaline phosphatase, osteocalcin, calcitonin, calcium, pyridinoline or deoxypyridinoline.</div>
    <div id="p-0011" num="0010" class="description-paragraph style-scope patent-text">In still another embodiment of the methods provided, treatment with the PSMA ADC results in increased survival for the subject, wherein the survival is increased in comparison to the median survival time of subjects with PSMA-expressing, taxane-resistant cancer not treated with PSMA ADC. In one embodiment, survival in the subject is increased by four weeks. In another embodiment, survival in the subject is increased by six weeks. In still another embodiment, survival in the subject is increased by two months. In yet another embodiment, survival in the subject is increased by four months. In a further embodiment, survival in the subject is increased by six months. In another embodiment, survival in the subject is increased by eight months. In still another embodiment, survival in the subject is increased by ten months. In yet another embodiment, survival in the subject is increased by twelve months. In still another embodiment, survival in the subject is increased by fourteen months.</div>
    <div id="p-0012" num="0011" class="description-paragraph style-scope patent-text">In yet another embodiment of the methods provided, treatment with the PSMA ADC results in an improvement in the subject's quality of life as compared to the quality of life of the subject prior to treatment with the PSMA ADC. An improvement in the subject's quality of life may include an alleviation or decrease in pain levels in the subject (e.g., human patient). The pain may be any discomfort or physical suffering. The pain may also be localized pain, but is not necessarily so. The alleviation or decrease in pain levels in a subject is any perceived lessening or elimination of pain by the subject or improvement in the subject's comfort as a result of treatment with a PSMA ADC. The lessening can be determined by assessing the level of pain in the subject at least two time points. The first time point can, in some embodiments, be at baseline, or before the administration of any PSMA ADC, while the second time point is anytime after the administration of a PSMA ADC. In other embodiments, the first time point occurs after the administration of a PSMA ADC, and the second occurs anytime subsequent to the first. In some embodiments, the first time point occurs before a particular dose of PSMA ADC, and the second occurs subsequent to that particular dose of PSMA ADC. The alleviation or decrease in pain levels in a subject can be determined by asking the subject to provide a quantification of their level of pain at one time point and comparing a quantification of their level of pain at a second time point. As an example, a subject's level of pain can be assessed by asking the subject to rate their level of pain according to the Modified Brief Pain Inventory Assessment shown below in Example 10. In some embodiments, the subject's level of pain is alleviated or decreased when the subject's reported quantification of pain for any one of (or combination of) <figure-callout id="1" label="questions" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="2" label="questions" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="3" label="questions" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">questions</a></figure-callout> </a></figure-callout> </a></figure-callout> 1, 2, 3 and 4 is lower at a second time point as compared to a first time point. Other methods for determining whether or not there is an alleviation or decrease in pain levels in a subject are known to those of ordinary skill in the art. As mentioned elsewhere herein, the pain may be bone pain. Generally, it is thought that bone pain is a result of metastatic prostate cancer in the bone. As used herein, “bone pain” refers to any pain a subject believes emanates from bone in the subject. The bone pain may be perceived to emanate from a particular bone or particular portion of a bone. The bone pain may also, in some embodiments, be perceived to emanate from one or more bones or one or more portions of a bone. The PSMA ADC of the present invention alleviates or decreases pain (e.g., bone pain) such that the subject has an improved quality of life, including improved ambulation.</div>
    <div id="p-0013" num="0012" class="description-paragraph style-scope patent-text">In a further embodiment of the methods provided, the PSMA-expressing, taxane-resistant cancer cells are resistant to docetaxel or paclitaxel. In still a further embodiment of the methods provided, the PSMA-expressing, taxane-resistant cancer is resistant to docetaxel or paclitaxel.</div>
    <div id="p-0014" num="0013" class="description-paragraph style-scope patent-text">In another embodiment of the methods provided, the PSMA-expressing, taxane-resistant cancer cells are prostate cancer cells or non-prostate cancer cells. In one embodiment, the non-prostate cancer cells are bladder cancer cells, pancreatic cancer cells, liver cancer cells, lung cancer cells, kidney cancer cells, sarcoma cells, breast cancer cells, brain cancer cells, neuroendocrine carcinoma cells, colon cancer cells, testicular cancer cells or melanoma cells.</div>
    <div id="p-0015" num="0014" class="description-paragraph style-scope patent-text">In still another embodiment of the methods provided, the PSMA-expressing, taxane-resistant cancer is prostate cancer or non-prostate cancer. In one embodiment, the non-prostate cancer is bladder cancer, pancreatic cancer, liver cancer, lung cancer, kidney cancer, sarcoma, breast cancer, brain cancer, neuroendocrine carcinoma, colon cancer, testicular cancer or melanoma.</div>
    <div id="p-0016" num="0015" class="description-paragraph style-scope patent-text">In a further embodiment of the methods provided, the PSMA-expressing, taxane-resistant cancer cells are of a tumor. In still a further embodiment of the methods provided, the PSMA-expressing, taxane-resistant cancer is a tumor. In one embodiment, the volume of the tumor is at least 100 mm<sup class="style-scope patent-text">3 </sup>prior to initiation of the method using PSMA ADC. In another embodiment, the volume of the tumor is at least 200 mm<sup class="style-scope patent-text">3</sup>. In still another embodiment, the volume of the tumor is at least 300 mm<sup class="style-scope patent-text">3</sup>. In a further embodiment, the volume of the tumor is at least 400 mm<sup class="style-scope patent-text">3</sup>. In still a further embodiment, the volume of the tumor is at least 500 mm<sup class="style-scope patent-text">3</sup>. In yet another embodiment, the volume of the tumor is at least 600 mm<sup class="style-scope patent-text">3</sup>. In still another embodiment, the volume of the tumor is at least 700 mm<sup class="style-scope patent-text">3</sup>. In a further embodiment, the volume of the tumor is at least 800 mm<sup class="style-scope patent-text">3</sup>. In yet a further embodiment, the volume of the tumor is at least 900 mm<sup class="style-scope patent-text">3</sup>. In another embodiment, the volume of the tumor is at least 1000 mm<sup class="style-scope patent-text">3</sup>. In yet another embodiment, the volume of the tumor is at least 1200 mm<sup class="style-scope patent-text">3</sup>. In still another embodiment, the volume of the tumor is at least 1400 mm<sup class="style-scope patent-text">3</sup>. In yet a further embodiment, the volume of the tumor is at least 1600 mm<sup class="style-scope patent-text">3</sup>.</div>
    <div id="p-0017" num="0016" class="description-paragraph style-scope patent-text">In another embodiment of the methods provided, treatment or contact with the PSMA ADC results in a reduction of tumor volume by at least 10% compared to the tumor volume prior to the treatment or contact with the PSMA ADC. In yet another embodiment, the volume of the tumor is reduced by at least 20%. In still another embodiment, the volume of the tumor is reduced by at least 30%. In a further embodiment, the volume of the tumor is reduced by at least 40%. In still a further embodiment, the volume of the tumor is reduced by at least 50%. In yet a further embodiment, the volume of the tumor is reduced by at least 60%. In another embodiment, the volume of the tumor is reduced by at least 70%. In still another embodiment, the volume of the tumor is reduced by at least 80%. In yet another embodiment, the volume of the tumor is reduced by at least 90%. In a further embodiment, the volume of the tumor is reduced by at least 95%. In yet a further embodiment, the tumor is eradicated.</div>
    <div id="p-0018" num="0017" class="description-paragraph style-scope patent-text">In one embodiment, the tumor has a length of at least 5 mm prior to initiation of the method using PSMA ADC. In another embodiment, the tumor has a length of at least 6 mm. In still another embodiment, the tumor has a length of at least 7 mm. In yet another embodiment, the tumor has a length of at least 8 mm. In another embodiment, the tumor has a length of at least 9 mm. In still another embodiment, the tumor has a length of at least 10 mm. In yet another embodiment, the tumor has a length of at least 11 mm. In a further embodiment, the tumor has a length of at least 12 mm. In still a further embodiment, the tumor has a length of at least 13 mm. In still a further embodiment, the tumor has a length of at least 14 mm. In another embodiment, the tumor has a length of at least 15 mm. In yet another embodiment, the tumor has a length of at least 16 mm. In still another embodiment, the tumor has a length of at least 17 mm. In a further embodiment, the tumor has a length of at least 18 mm. In yet a further embodiment, the tumor has a length of at least 19 mm. In still a further embodiment, the tumor has a length of at least 20 mm. In another embodiment, the tumor has a length of at least 21 mm. In still another embodiment, the tumor has a length of at least 22 mm. In yet another embodiment, the tumor has a length of at least 23 mm. In a further embodiment, the tumor has a length of at least 24 mm. In still a further embodiment, the tumor has a length of at least 25 mm. In yet a further embodiment, the tumor has a length of at least 30 mm.</div>
    <div id="p-0019" num="0018" class="description-paragraph style-scope patent-text">In another embodiment of the methods provided, treatment or contact with the PSMA ADC results in a reduction of tumor length by at least 10% compared to the tumor length prior to the treatment or contact with the PSMA ADC. In yet another embodiment, the length of the tumor is reduced by at least 20%. In still another embodiment, the length of the tumor is reduced by at least 30%. In a further embodiment, the length of the tumor is reduced by at least 40%. In still a further embodiment, the length of the tumor is reduced by at least 50%. In yet a further embodiment, the length of the tumor is reduced by at least 60%. In another embodiment, the length of the tumor is reduced by at least 70%. In still another embodiment, the length of the tumor is reduced by at least 80%. In yet another embodiment, the length of the tumor is reduced by at least 90%. In a further embodiment, the length of the tumor is reduced by at least 95%. In yet a further embodiment, the length of the tumor is reduced by at least 99%.</div>
    <div id="p-0020" num="0019" class="description-paragraph style-scope patent-text">In a further embodiment of the methods provided, administration of the PSMA ADC to a subject results in the gain of body weight in the subject (as compared to the weight of the subject prior to administration of the PSMA ADC to the subject). The gain in body weight may result from a single administration of the PSMA ADC or a course of treatment with the PSMA ADC (i.e., more than one administration). In one embodiment, the gain is at least a 5% gain in body weight. In another embodiment, the gain is at least a 10% gain. In still another embodiment, the gain is at least a 15% gain. In still a further embodiment, the gain is at least a 20% gain. In yet another embodiment, the gain is at least a 25% gain. In a further embodiment, the gain is at least a 30% gain. In another embodiment, the gain is a 5% gain in body weight. In another embodiment, the gain is a 10% gain. In still another embodiment, the gain is a 15% gain. In still a further embodiment, the gain is a 20% gain. In yet another embodiment, the gain a 25% gain. In a further embodiment, the gain is a 30% gain.</div>
    <div id="p-0021" num="0020" class="description-paragraph style-scope patent-text">In one embodiment of the methods provided, the PSMA-expressing, taxane-resistant cancer cells are of a metastasis. In another embodiment of the methods provided, the PSMA-expressing, taxane-resistant cancer is metastatic.</div>
    <div id="p-0022" num="0021" class="description-paragraph style-scope patent-text">In another embodiment of the methods provided, the antibody or antigen-binding fragment thereof is conjugated to at least 2 monomethylauristatin norephedrine or monomethylauristatin phenylalanine molecules. In yet another embodiment of the methods provided, the antibody or antigen-binding fragment thereof is conjugated to at least 3 monomethylauristatin norephedrine or monomethylauristatin phenylalanine molecules. In still another embodiment of the methods provided, the antibody or antigen-binding fragment thereof is conjugated to at least 4 monomethylauristatin norephedrine or monomethylauristatin phenylalanine molecules.</div>
    <div id="p-0023" num="0022" class="description-paragraph style-scope patent-text">In a further embodiment of the methods provided, the monomethylauristatin norephedrine or monomethylauristatin phenylalanine is conjugated to the antibody or antigen-binding fragment thereof with a compound of the formula -A<sub class="style-scope patent-text">n</sub>-Y<sub class="style-scope patent-text">m</sub>—Z<sub class="style-scope patent-text">m</sub>—X<sub class="style-scope patent-text">n</sub>—W<sub class="style-scope patent-text">n</sub>— wherein, A is a carboxylic acyl unit; Y is an amino acid; Z is an amino acid; X and W are each a self-immolative spacer; n is an integer of 0 or 1; and m is an integer of 0 or 1, 2, 3, 4, 5 or 6.</div>
    <div id="p-0024" num="0023" class="description-paragraph style-scope patent-text">In one embodiment, A is</div>
    <div id="p-0025" num="0024" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00001" num="00001" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/1c/ad/02/deed09c72df17b/US09242012-20160126-C00001.png" class="style-scope patent-text"><img id="EMI-C00001" he="20.66mm" wi="29.21mm" file="US09242012-20160126-C00001.TIF" alt="Figure US09242012-20160126-C00001" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="117" height="83" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/1c/ad/02/deed09c72df17b/US09242012-20160126-C00001.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00001" attachment-type="cdx" file="US09242012-20160126-C00001.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00001" attachment-type="mol" file="US09242012-20160126-C00001.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
in which q is 1-10. In another embodiment, A is 4-(N-succinimidomethyl)cyclohexane-1-carbonyl, m-succinimidobenzoyl, 4-(p-succinimidophenyl)-butyryl, 4-(2-acetamido)benzoyl, 3-thiopropionyl, 4-(1-thioethyl)-benzoyl, 6-(3-thiopropionylamido)-hexanoyl or maleimide caproyl. In still another embodiment, A is maleimide caproyl.
</div>
    <div id="p-0026" num="0025" class="description-paragraph style-scope patent-text">In another embodiment, Y is alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan or proline. In yet another embodiment, Y is valine.</div>
    <div id="p-0027" num="0026" class="description-paragraph style-scope patent-text">In a further embodiment, Z is lysine, lysine protected with acetyl or formyl, arginine, arginine protected with tosyl or nitro groups, histidine, ornithine, ornithine protected with acetyl or formyl, or citrulline. In yet a further embodiment, Z is citrulline.</div>
    <div id="p-0028" num="0027" class="description-paragraph style-scope patent-text">In one embodiment, Y<sub class="style-scope patent-text">m</sub>—Z<sub class="style-scope patent-text">m </sub>is valine-citrulline. In another embodiment, Y<sub class="style-scope patent-text">m</sub>—Z<sub class="style-scope patent-text">m </sub>is a protein sequence which is selectively cleavable by a protease.</div>
    <div id="p-0029" num="0028" class="description-paragraph style-scope patent-text">In still another embodiment, X is a compound having the formula</div>
    <div id="p-0030" num="0029" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00002" num="00002" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/4c/08/73/144323b0a022b8/US09242012-20160126-C00002.png" class="style-scope patent-text"><img id="EMI-C00002" he="18.71mm" wi="44.87mm" file="US09242012-20160126-C00002.TIF" alt="Figure US09242012-20160126-C00002" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="179" height="75" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/4c/08/73/144323b0a022b8/US09242012-20160126-C00002.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00002" attachment-type="cdx" file="US09242012-20160126-C00002.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00002" attachment-type="mol" file="US09242012-20160126-C00002.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
in which T is O, N, or S. In yet another embodiment, X is a compound having the formula —HN—R<sup class="style-scope patent-text">1</sup>—COT in which R<sup class="style-scope patent-text">1 </sup>is C<sub class="style-scope patent-text">1</sub>-C<sub class="style-scope patent-text">5 </sub>alkyl, T is O, N or S. In a further embodiment, X is a compound having the formula
</div>
    <div id="p-0031" num="0030" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00003" num="00003" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d1/8d/55/961eba1922cb81/US09242012-20160126-C00003.png" class="style-scope patent-text"><img id="EMI-C00003" he="12.11mm" wi="22.44mm" file="US09242012-20160126-C00003.TIF" alt="Figure US09242012-20160126-C00003" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="90" height="48" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d1/8d/55/961eba1922cb81/US09242012-20160126-C00003.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00003" attachment-type="cdx" file="US09242012-20160126-C00003.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00003" attachment-type="mol" file="US09242012-20160126-C00003.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
in which T is O, N, or S, R<sup class="style-scope patent-text">2 </sup>is H or C<sub class="style-scope patent-text">1</sub>-C<sub class="style-scope patent-text">5 </sub>alkyl. In yet a further embodiment, X is p-aminobenzylcarbamoyloxy. In still a further embodiment, X is p-aminobenzylalcohol. In another embodiment, X is p-aminobenzylcarbamate. In still another embodiment, X is p-aminobenzyloxycarbonyl. In yet another embodiment, X is γ-aminobutyric acid; α,α-dimethyl γ-aminobutyric acid or β,β-dimethyl γ-aminobutyric acid.
</div>
    <div id="p-0032" num="0031" class="description-paragraph style-scope patent-text">In one embodiment, W is</div>
    <div id="p-0033" num="0032" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00004" num="00004" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/68/14/ff5b63b74d574d/US09242012-20160126-C00004.png" class="style-scope patent-text"><img id="EMI-C00004" he="20.74mm" wi="63.25mm" file="US09242012-20160126-C00004.TIF" alt="Figure US09242012-20160126-C00004" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="253" height="83" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/68/14/ff5b63b74d574d/US09242012-20160126-C00004.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00004" attachment-type="cdx" file="US09242012-20160126-C00004.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00004" attachment-type="mol" file="US09242012-20160126-C00004.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
in which T is O, S or N.
</div>
    <div id="p-0034" num="0033" class="description-paragraph style-scope patent-text">In another embodiment, m and n are 0.</div>
    <div id="p-0035" num="0034" class="description-paragraph style-scope patent-text">In still another embodiment of the methods provided, the antibody-drug conjugate is AB-PG1-XG1-006-maleimide caproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethylauristatin norephedrine. In another embodiment of the methods provided, the antibody-drug conjugate is AB-PG1-XG1-006-maleimide caproyl-valine-citrulline-p-aminobenzylcarbamate-monomethylauristatin norephedrine. In yet another embodiment, the antibody-drug conjugate is AB-PG1-XG1-006-maleimide caproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethylauristatin phenylalanine. In another embodiment, the antibody-drug conjugate is AB-PG1-XG1-006-maleimide caproyl-valine-citrulline-p-aminobenzylcarbamate-monomethylauristatin phenylalanine. In a further embodiment, the antibody-drug conjugate is AB-PG1-XG1-006-maleimide caproyl-monomethylauristatin phenylalanine. In still a further embodiment, the antibody-drug conjugate is AB-PG1-XG1-026-maleimide caproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethylauristatin norephedrine. In another embodiment, the antibody-drug conjugate is AB-PG1-XG1-026-maleimide caproyl-valine-citrulline-p-aminobenzylcarbamate-monomethylauristatin norephedrine. In yet a further embodiment, the antibody-drug conjugate is AB-PG1-XG1-026-maleimide caproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethylauristatin phenylalanine. In yet a further embodiment, the antibody-drug conjugate is AB-PG1-XG1-026-maleimide caproyl-valine-citrulline-p-aminobenzylcarbamate-monomethylauristatin phenylalanine. In another embodiment, the antibody-drug conjugate is AB-PG1-XG1-026-maleimide caproyl-monomethylauristatin phenylalanine.</div>
    <div id="p-0036" num="0035" class="description-paragraph style-scope patent-text">In one embodiment of the methods provided, the monoclonal antibody or antigen-binding fragment thereof specifically binds to an extracellular domain of PSMA. In another embodiment, the monoclonal antibody or antigen-binding fragment thereof specifically binds to a conformational epitope of PSMA. In still another embodiment, the monoclonal antibody or antigen-binding fragment thereof binds live cells. In a further embodiment, the monoclonal antibody or antigen-binding fragment thereof does not require cell lysis to bind PSMA. In still a further embodiment, the monoclonal antibody or antigen-binding fragment thereof binds to cells of the neovasculature of a tumor.</div>
    <div id="p-0037" num="0036" class="description-paragraph style-scope patent-text">In another embodiment of the methods provided, the antibody or antigen-binding fragment thereof competitively inhibits the specific binding of a second antibody to its target epitope on PSMA, wherein the second antibody is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antibodies comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13, or (c) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 14, 18, 22, 26 and 30, and d) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 16, 20, 24, 28 and 32.</div>
    <div id="p-0038" num="0037" class="description-paragraph style-scope patent-text">In still another embodiment of the methods provided, the antibody or antigen-binding fragment thereof binds to an epitope on PSMA defined by an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antibodies comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13, or (c) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 14, 18, 22, 26 and 30, and d) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 16, 20, 24, 28 and 32.</div>
    <div id="p-0039" num="0038" class="description-paragraph style-scope patent-text">In one embodiment, the second antibody is selected from the group consisting of AB-PG1-XG1-006, AB-PG1-XG1-026 and antibodies comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2 and 3, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8 and 9, or (c) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 14 and 18, and d) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 16 and 20. In another embodiment, the second antibody comprises (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 2, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 8, or (c) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 14, and d) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 16. In still another embodiment, the second antibody comprises (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 3, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 9, or (c) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 18, and d) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 20.</div>
    <div id="p-0040" num="0039" class="description-paragraph style-scope patent-text">In a further embodiment of the methods provided, the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least 90% identical to a nucleotide sequence encoding an antibody selected from the group consisting of: AB-PG1-XG1-006, AB-PG1-XG1-026 and antibodies comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2 and 3, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8 and 9, or (c) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 14 and 18, and d) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 16 and 20. In another embodiment, the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least 95% identical. In still another embodiment, the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least 97% identical. In yet another embodiment, the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least 98% identical. In a further embodiment, the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least 99% identical.</div>
    <div id="p-0041" num="0040" class="description-paragraph style-scope patent-text">In another embodiment of the methods provided, the antibody or antigen-binding fragment thereof is selected from the group consisting of antibodies comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2 and 3, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8 and 9, or (c) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 14 and 18, and d) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 16 and 20, and antigen-binding fragments thereof. In still another embodiment, the antibody or antigen-binding fragment thereof comprises (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 2, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 8, or (c) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 14, and d) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 16, and antigen-binding fragments thereof. In yet another embodiment, the antibody or antigen-binding fragment thereof comprises (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 3, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 9, or (c) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 18, and d) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 20, and antigen-binding fragments thereof.</div>
    <div id="p-0042" num="0041" class="description-paragraph style-scope patent-text">In yet a further embodiment of the methods provided, the antibody or antigen-binding fragment thereof is AB-PG1-XG1-006, AB-PG1-XG1-026 or an antigen-binding fragment thereof.</div>
    <div id="p-0043" num="0042" class="description-paragraph style-scope patent-text">In still a further embodiment of the methods provided, the human antibody is an IgG1 comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 2, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 8.</div>
    <div id="p-0044" num="0043" class="description-paragraph style-scope patent-text">In a further aspect, provided is an antibody-drug conjugate comprising an antibody, or antigen-binding fragment thereof, that specifically binds PSMA, conjugated to a <figure-callout id="10" label="dolastatin" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">dolastatin</a></figure-callout> 10 derivative, for use in a method of treating a PSMA-expressing, taxane-resistant cancer. Preferably, said method involves killing PSMA-expressing, taxane-resistant cancer cells. In another embodiment, the method involves delaying or inhibiting progression of the cancer. In still another embodiment, the method involves increasing survival of the subject as compared to the median survival of subjects not been treated with the PSMA ADC and that have progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. In yet another embodiment, the method involves decreasing a circulating level of circulating tumor cells (CTCs) compared to a baseline level. In a further embodiment, the method involves decreasing or stabilizing a serum level of PSA compared to a baseline level of PSA. It is also preferred that the PSMA-expressing, taxane-resistant cancer cells are killed by the conjugate. The PSMA preferably has the sequence set forth in SEQ ID NO: 1. The conjugate is preferably for treating progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. The <figure-callout id="10" label="dolastatin" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">dolastatin</a></figure-callout> 10 derivative can be an auristatin, and is preferably MMAE (also referred to herein as monomethylauristatin E or monomethylauristatin norephedrine) or MMAF (also referred to herein as monomethylauristatin F or monomethylauristatin phenylalanine). In preferred embodiments of this further aspect, the conjugate can have any of the features of the conjugate employed in other aspects of the invention defined herein. The method involved in this further aspect, moreover, can involve the administration of an effective amount of the conjugate, as defined with reference to other aspects defined herein. It can also have any of the features of any of the methods for treating a subject that are described herein.</div>
    
    
    <description-of-drawings class="style-scope patent-text">
      <heading id="h-0004" class="style-scope patent-text">BRIEF DESCRIPTION OF THE FIGURES</heading>
      <div id="p-0045" num="0044" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1</figref> presents a schematic showing the sub-cellular localization of PSMA in normal prostate versus prostate cancer. PSMA is a 750 residue, type II transmembrane glycoprotein that is highly expressed in prostate cancer cells and has limited expression in normal non-prostatic tissues. In the normal prostate, PSMA is expressed predominantly as a cytoplasmic splice variant (PSM′) that is retained in the cytoplasm. In prostate cancer, PSMA is expressed as a membrane-anchored, noncovalently associated homodimer.</div>
      <div id="p-0046" num="0045" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2</figref> presents a schematic of a number of prostate cancer treatment options. The approved chemotherapy, docetaxel (Taxotere) in combination with prednisone, for advanced prostate cancer provides a modest increase in survival (2-3 months) with significant side effects.</div>
      <div id="p-0047" num="0046" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3</figref> presents a schematic showing antibody-drug conjugate (ADC) targeted therapy.</div>
      <div id="p-0048" num="0047" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 4</figref> provides the chemical structures of three examples of drug linkers that can be conjugated to an antibody or antigen-binding fragment thereof that specifically binds PSMA and form an antibody-drug conjugate.</div>
      <div id="p-0049" num="0048" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5</figref> demonstrates the potent and specific cytotoxicity of PSMA ADC to PSMA-expressing prostate cancer cells. PSMA-positive and PSMA-negative cells were exposed to PSMA ADC in 96-well microplates at various concentrations. After 96-hours, percent cell survival (compared to cells in medium) was assayed using fluorescent Alamar Blue.</div>
      <div id="p-0050" num="0049" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 6</figref> presents a table that demonstrates the potent and specific cytotoxicity of PSMA ADC to PSMA-expressing prostate cancer cells.</div>
      <div id="p-0051" num="0050" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7</figref> shows tumor volume over time in nude mice treated with PSMA ADC versus control. Nude mice bearing human prostate cancer tumors were randomized at <figure-callout id="11" label="day" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 11 into two groups, PBS vehicle control (filled diamond, n=15, 108.9 mm<sup class="style-scope patent-text">3</sup>) and PSMA ADC (filled triangle, n=15, 108.7 mm<sup class="style-scope patent-text">3</sup>), according to tumor volume. The animals received intravenous injections of PBS or PSMA ADC at 6 mg/kg on <figure-callout id="12" label="day" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="15" label="day" filenames="US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="18" label="day" filenames="US09242012-20160126-D00008.png,US09242012-20160126-D00010.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="22" label="day" filenames="US09242012-20160126-D00008.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="25" label="day" filenames="US09242012-20160126-D00012.png,US09242012-20160126-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> </a></figure-callout> </a></figure-callout> </a></figure-callout> </a></figure-callout> 12, 15, 18, 22, 25 and 29. The mean tumor volume was plotted for the PBS vehicle control group until the first animal was sacrificed at day 33 due to tumor size limitation (&gt;2000 mm<sup class="style-scope patent-text">3</sup>).</div>
      <div id="p-0052" num="0051" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8</figref> shows the effect of PSMA ADC treatment on tumor volume with an initial and second PSMA ADC treatment. Tumors of four mice from the PSMA ADC treatment group were grown back and were treated with PSMA ADC at the same dose level of 6 mg/kg. PSMA ADC effectively reduced the tumor volume to &lt;100 mm<sup class="style-scope patent-text">3 </sup>from large tumor of 894 mm<sup class="style-scope patent-text">3</sup>. The dotted lines indicate initial PSMA ADC treatment (6 dosings twice per week), and the solid lines show second PSMA ADC treatment (13 weekly dosings).</div>
      <div id="p-0053" num="0052" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 9</figref> demonstrates the effects in a nude mouse having a tumor size of ˜500 mm<sup class="style-scope patent-text">3 </sup>and treated with 12 doses of docetaxel given intraperitoneally (IP) at 12 mg/kg weekly as indicated by dotted lines. The tumor responded to the docetaxel initially and then relapsed. Starting at <figure-callout id="100" label="day" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 100 with tumor volume of 800 mm<sup class="style-scope patent-text">3</sup>, PSMA ADC was given intravenously (IV) at 6 mg/kg for an additional 12 doses weekly (solid lines). PSMA ADC reduced the tumor volume from 800 mm<sup class="style-scope patent-text">3 </sup>to 50 mm<sup class="style-scope patent-text">3</sup>.</div>
      <div id="p-0054" num="0053" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 10</figref> shows a scheme of randomization for testing PSMA ADC effectiveness after docetaxel treatment failure. At the first randomization, the animals were assigned to vehicle control group or docetaxel treatment group. If tumor volume exceeded 400 mm<sup class="style-scope patent-text">3 </sup>in the docetaxel treated group, the animals were randomized (the second randomization) at a 1:1 ratio to two subgroups: continued docetaxel treatment or PSMA ADC treatment. The tumor volumes of the animals were measured over time.</div>
      <div id="p-0055" num="0054" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 11</figref> shows the tumor volume over time in nude mice treated with docetaxel versus control. Nude mice bearing human prostate cancer tumors were randomized at <figure-callout id="14" label="day" filenames="US09242012-20160126-D00008.png,US09242012-20160126-D00016.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 14 according to tumor volume into two groups, vehicle control (filled diamond, n=10) and docetaxel (filled circle, n=50). The animals received intravenous injections of PBS or docetaxel at 2 mg/kg/IV weekly. The average tumor volume for the two groups was plotted until the second randomization was initiated. Docetaxel treatment reduced tumor growth compared to control at least by day 21 (p=0.025) and beyond.</div>
      <div id="p-0056" num="0055" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 12</figref> shows the comparison of tumor volume in two subgroups after failure of initial docetaxel treatment: (1) continued docetaxel treatment, filled triangle, (2) PSMA ADC treatment, 6 mg/kg, filled squares. Since the mice were assigned to different groups at different times, time of treatment (days post second randomization) was aligned at day 0 (initiation of PSMA ADC or continuation of docetaxel post second randomization).</div>
      <div id="p-0057" num="0056" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 13</figref> shows a schematic of the design of an in vivo study.</div>
      <div id="p-0058" num="0057" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 14</figref> shows the tumor volume of each animal. When the tumor volume of an animal in the docetaxel-treated group exceeded 400 mm<sup class="style-scope patent-text">3</sup>, the animal was randomized at a 1:1 ratio into two subgroups: 1) switched to PSMA ADC treatment at 6 mg/kg/IV weekly (solid squares, mean: 515±103 mm<sup class="style-scope patent-text">3</sup>, range 410-727 mm<sup class="style-scope patent-text">3</sup>) and 2) continued treatment with docetaxel at 2 mg/kg (filled triangles, mean: 495±80 mm<sup class="style-scope patent-text">3</sup>, range: 401-650 mm<sup class="style-scope patent-text">3</sup>) The tumor size of each animal and time of randomization are shown. Tumor volumes at the second randomization were not significantly different between the two groups (p=0.518, t-test).</div>
      <div id="p-0059" num="0058" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 15</figref> shows the tumor size for each individual animal in two groups after second randomization. The tumor volumes of animals with PSMA ADC treatment (panel A) and continued docetaxel treatment (panel B) were plotted as a function of time following the second randomization (day 0). The tumors shrank when PSMA ADC treatment was initiated (panel A). However, even with continued docetaxel treatment, tumors continued to progress except in one animal (panel B).</div>
      <div id="p-0060" num="0059" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 16</figref> shows a comparison of the mean tumor volumes in animals receiving PSMA ADC treatment (filled squares) and in animals receiving continued docetaxel treatment (filled triangles). Mean tumor volume was compared as a function of time following the second randomization (day 0). Tumor sizes of the two groups were significantly different (p&lt;0.007).</div>
      <div id="p-0061" num="0060" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 17</figref> shows a comparison of the survival of animals over time post second randomization for animals receiving PSMA ADC treatment (solid line) and animals receiving continued docetaxel treatment (dotted line). At day 157 post second randomization, all 18 animals in the PSMA ADC treatment group were still alive. However, 16 of 18 animals in the continued docetaxel treatment group were sacrificed due to their large tumors (&gt;2,000 mm<sup class="style-scope patent-text">3</sup>) with a median survival of 45 days. PSMA ADC significantly increased the overall survival (p&lt;0.0001).</div>
      <div id="p-0062" num="0061" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 18</figref> shows a comparison of the average body weights post second randomization in animals receiving PSMA ADC treatment (solid squares) and animals receiving continued docetaxel treatment (solid triangles). Overall, animals gained weight in the PSMA ADC treatment group, while animals lost weight in the continued docetaxel treatment group. The body weight change was significantly different (p&lt;0.001) between these two groups.</div>
      <div id="p-0063" num="0062" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 19</figref> illustrates antitumor activity in 4 of 9 subjects as reflected by reductions in PSA, CTC and/or bone pain.</div>
      <div id="p-0064" num="0063" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 20</figref> illustrates the maximum PSA response by dose.</div>
      <div id="p-0065" num="0064" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 21</figref> provides pharmacokinetic data following IV dosing.</div>
    </description-of-drawings>
    
    
    <heading id="h-0005" class="style-scope patent-text">DETAILED DESCRIPTION OF THE INVENTION</heading>
    <div id="p-0066" num="0065" class="description-paragraph style-scope patent-text">The present invention relates, in part, to the surprising discovery that antibody-drug conjugates (ADCs) comprising an antibody or antigen-binding fragment thereof that specifically binds PSMA conjugated to a <figure-callout id="10" label="dolastatin" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">dolastatin</a></figure-callout> 10 derivative, in particular auristatins such as, MMAE (also referred to herein as monomethylauristatin E or monomethylauristatin norephedrine) or MMAF (also referred to herein as monomethylauristatin F or monomethylauristatin phenylalanine) can be used to kill PSMA-expressing, taxane-resistant cancer cells. As described further below, it was unexpectedly found that PSMA expressing cancer cells which had become resistant to the effects of an anti-cancer agent that acts by disrupting the microtubular network in cells, were sensitive to the effects of a second anti-cancer agent that also targets microtubules. Specifically disclosed herein, the auristatin, MMAE, a potent tubulin inhibitor, in the form of an antibody-drug conjugate, when delivered to PSMA-expressing prostate tumors that had become resistant to docetaxel was able to kill the docetaxel resistant cancer cells such that tumor volume was significantly decreased.</div>
    <div id="p-0067" num="0066" class="description-paragraph style-scope patent-text">As used herein, “PSMA-expressing cancer cells” is intended to refer to cancer cells that express PSMA (e.g., human PSMA). PSMA is a 100 kD Type II membrane glycoprotein expressed in prostate tissues (Horoszewicz et al., 1987<i class="style-scope patent-text">, Anticancer Res. </i>7:927-935; U.S. Pat. No. 5,162,504). PSMA was characterized as a type II transmembrane protein having sequence identity with the transferrin receptor (Israeli et al., 1994<i class="style-scope patent-text">, Cancer Res. </i>54:1807-1811) and with NAALADase activity (Carter et al., 1996<i class="style-scope patent-text">, Proc. Natl. Acad. Sci. U.S.A. </i>93:749-753). More importantly, PSMA is expressed in increased amounts in prostate cancer, and elevated levels of PSMA are also detectable in the sera of these patients (Horoszewicz et al., 1987; Rochon et al., 1994<i class="style-scope patent-text">, Prostate </i>25:219-223; Murphy et al., 1995<i class="style-scope patent-text">, Prostate </i>26:164-168; and Murphy et al., 1995<i class="style-scope patent-text">, Anticancer Res. </i>15:1473-1479). PSMA expression in cancerous prostate is approximately 10-fold greater than that in normal prostate. Expression in normal prostate is approximately 10-fold greater than that in the brain and is 50- to 100-fold greater than that of the liver or kidney. In most normal tissues, no expression of PSMA is observed. PSMA expression increases with disease progression, becoming highest in metastatic, hormone-refractory disease. In addition, PSMA is also abundantly expressed on the neovasculature of a variety of non-prostate tumors, including bladder, breast, colon, pancreas, sarcoma, melanoma, renal, liver, lung (e.g., non-small cell lung carcinoma), and kidney tumors, but not on normal vasculature. PSMA-expressing cancer cells, therefore, include, for example, prostate cancer cells as well as endothelial cells of the neovasculature of a number of non-prostate cancers.</div>
    <div id="p-0068" num="0067" class="description-paragraph style-scope patent-text">“Taxane-resistant cancer cells” refers to cancer cells of a cancer that has been treated with a taxane but that has become resistant to treatment with the taxane (i.e., further treatment with the taxane would not slow or halt the progression of the cancer and/or would no longer provide a significant benefit to a subject with the cancer). A “subject with a taxane-resistant cancer” is one that has received prior treatment with a taxane but no longer experiences a significant benefit from further treatment with the taxane (e.g., no longer experiences a significant reduction in the number of cancer cells, in tumor volume, in tumor length, in the number of metastases and/or in other markers of disease progression and/or no longer experiences an improvement in quality of life and/or increased survival as compared to the expected survival time without further treatment with the taxane).</div>
    <div id="p-0069" num="0068" class="description-paragraph style-scope patent-text">Therefore, in one embodiment the PSMA ADC is administered to a subject with progressive, metastatic, hormone-refractory prostate cancer resistant to taxane following prior taxane chemotherapy. In another embodiment, such subject is a human.</div>
    <div id="p-0070" num="0069" class="description-paragraph style-scope patent-text">As used herein, “taxanes” are anti-cancer agents that interfere with or disrupt microtubule stability, formation and/or function. Such agents include paclitaxel and docetaxel as well as derivatives thereof, wherein the derivatives function against microtubules by the same mode of action as the taxanes from which they are derived.</div>
    <div id="p-0071" num="0070" class="description-paragraph style-scope patent-text">The ADC can comprise an antibody or antigen-binding fragment thereof conjugated to the auristatin MMAE or MMAF. Auristatins are synthetic pentapeptide molecules that are structurally related to dolastatin 10, a natural product derived from a marine animal. MMAE and other auristatins act by inhibiting polymerization of tubulins, thereby preventing formation of the mitotic spindle. Apoptotic cell death is triggered when the cell cycle is arrested. The antibody or antigen-binding fragment thereof can be, in some embodiments, conjugated to MMAE or MMAF with a compound of the following formula (Formula 1): -A<sub class="style-scope patent-text">n</sub>-Y<sub class="style-scope patent-text">m</sub>—Z<sub class="style-scope patent-text">m</sub>—X<sub class="style-scope patent-text">n</sub>—W<sub class="style-scope patent-text">n</sub>—, wherein A is a carboxylic acyl unit; Y is an amino acid; Z is an amino acid; X and W are each a self-immolative spacer; n is an integer of 0 or 1; and m is an integer of 0 or 1, 2, 3, 4, 5 or 6. The ADC, in some embodiments, is represented by the formula (Formula 2): L-{A<sub class="style-scope patent-text">n</sub>-Y<sub class="style-scope patent-text">m</sub>—Z<sub class="style-scope patent-text">m</sub>—X<sub class="style-scope patent-text">n</sub>—W<sub class="style-scope patent-text">n</sub>-D}<sub class="style-scope patent-text">p </sub>wherein L is an antibody or antigen-binding fragment thereof that binds PSMA, D is MMAE or MMAF and p is an integer of 1, 2, 3, 4, 5, 6, 7 or 8. The other components are as described above. In one embodiment, the carboxylic unit “A<sub class="style-scope patent-text">n</sub>” is linked to the antibody or antigen-binding fragment via a sulfur atom derived from the antibody or antigen-binding fragment:</div>
    <div id="p-0072" num="0071" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00005" num="00005" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/6b/88/5c/ad69be89acd144/US09242012-20160126-C00005.png" class="style-scope patent-text"><img id="EMI-C00005" he="6.94mm" wi="42.50mm" file="US09242012-20160126-C00005.TIF" alt="Figure US09242012-20160126-C00005" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="170" height="28" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/6b/88/5c/ad69be89acd144/US09242012-20160126-C00005.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00005" attachment-type="cdx" file="US09242012-20160126-C00005.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00005" attachment-type="mol" file="US09242012-20160126-C00005.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <div id="p-0073" num="0072" class="description-paragraph style-scope patent-text">In one embodiment, A is</div>
    <div id="p-0074" num="0073" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00006" num="00006" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e8/90/e9/f1c220c17862a9/US09242012-20160126-C00006.png" class="style-scope patent-text"><img id="EMI-C00006" he="20.66mm" wi="29.21mm" file="US09242012-20160126-C00006.TIF" alt="Figure US09242012-20160126-C00006" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="117" height="83" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e8/90/e9/f1c220c17862a9/US09242012-20160126-C00006.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00006" attachment-type="cdx" file="US09242012-20160126-C00006.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00006" attachment-type="mol" file="US09242012-20160126-C00006.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
in which q is 1-10. Therefore, in one embodiment, the conjugate is:
</div>
    <div id="p-0075" num="0074" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00007" num="00007" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/f6/9c/17/49fcb2d2763dc2/US09242012-20160126-C00007.png" class="style-scope patent-text"><img id="EMI-C00007" he="21.59mm" wi="65.62mm" file="US09242012-20160126-C00007.TIF" alt="Figure US09242012-20160126-C00007" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="262" height="86" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/f6/9c/17/49fcb2d2763dc2/US09242012-20160126-C00007.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00007" attachment-type="cdx" file="US09242012-20160126-C00007.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00007" attachment-type="mol" file="US09242012-20160126-C00007.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
wherein L, Y, Z, X, W, D, n, m, q and p are as previously defined.
</div>
    <div id="p-0076" num="0075" class="description-paragraph style-scope patent-text">In another embodiment, A is 4-(N-succinimidomethyl)cyclohexane-1-carbonyl, m-succinimidobenzoyl, 4-(p-succinimidophenyl)-butyryl, 4-(2-acetamido)benzoyl, 3-thiopropionyl, 4-(1-thioethyl)-benzoyl, 6-(3-thiopropionylamido)-hexanoyl or maleimide caproyl. In a further embodiment, A is maleimide caproyl. Representative examples of various carboxylic acyl units and methods for their synthesis and attachment are described in U.S. Pat. No. 6,214,345, the entire contents of which, but in particular the examples and methods for their synthesis and attachment, are herein incorporated by reference.</div>
    <div id="p-0077" num="0076" class="description-paragraph style-scope patent-text">In another embodiment, Y is alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan or proline. In yet another embodiment, Y is valine. In a further embodiment, Z is lysine, lysine protected with acetyl or formyl, arginine, arginine protected with tosyl or nitro groups, histidine, ornithine, ornithine protected with acetyl or formyl, or citrulline. In still a further embodiment, Z is citrulline. In one embodiment Y<sub class="style-scope patent-text">m</sub>—Z<sub class="style-scope patent-text">m </sub>is valine-citrulline. In another embodiment, Y<sub class="style-scope patent-text">m</sub>—Z<sub class="style-scope patent-text">m </sub>is a protein sequence which is selectively cleavable by a protease.</div>
    <div id="p-0078" num="0077" class="description-paragraph style-scope patent-text">In a further embodiment, X is a compound having the formula</div>
    <div id="p-0079" num="0078" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00008" num="00008" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/bd/8e/1e/da73400f698146/US09242012-20160126-C00008.png" class="style-scope patent-text"><img id="EMI-C00008" he="18.71mm" wi="44.87mm" file="US09242012-20160126-C00008.TIF" alt="Figure US09242012-20160126-C00008" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="179" height="75" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/bd/8e/1e/da73400f698146/US09242012-20160126-C00008.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00008" attachment-type="cdx" file="US09242012-20160126-C00008.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00008" attachment-type="mol" file="US09242012-20160126-C00008.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
in which T is O, N, or S. In another embodiment, X is a compound having the formula —HN—R<sup class="style-scope patent-text">1</sup>—COT in which R<sup class="style-scope patent-text">1 </sup>is C<sub class="style-scope patent-text">1</sub>-C<sub class="style-scope patent-text">5 </sub>alkyl, T is O, N or S. In a further embodiment, X is a compound having the formula
</div>
    <div id="p-0080" num="0079" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00009" num="00009" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/28/0c/d4/3d15f1dd5d5622/US09242012-20160126-C00009.png" class="style-scope patent-text"><img id="EMI-C00009" he="12.11mm" wi="22.44mm" file="US09242012-20160126-C00009.TIF" alt="Figure US09242012-20160126-C00009" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="90" height="48" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/28/0c/d4/3d15f1dd5d5622/US09242012-20160126-C00009.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00009" attachment-type="cdx" file="US09242012-20160126-C00009.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00009" attachment-type="mol" file="US09242012-20160126-C00009.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
in which T is O, N, or S, R<sup class="style-scope patent-text">2 </sup>is H or C<sub class="style-scope patent-text">1</sub>-C<sub class="style-scope patent-text">5 </sub>alkyl. In one embodiment, X is p-aminobenzylcarbamoyloxy. In another embodiment, X is p-aminobenzylalcohol. In a further embodiment, X is p-aminobenzylcarbamate. In yet a further embodiment, X is p-aminobenzyloxycarbonyl. In another embodiment, X is γ-aminobutyric acid; α,α-dimethyl γ-aminobutyric acid or β,β-dimethyl γ-aminobutyric acid.
</div>
    <div id="p-0081" num="0080" class="description-paragraph style-scope patent-text">In some embodiments, W is</div>
    <div id="p-0082" num="0081" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00010" num="00010" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/15/e3/ad/d062fdbae5b070/US09242012-20160126-C00010.png" class="style-scope patent-text"><img id="EMI-C00010" he="20.74mm" wi="63.25mm" file="US09242012-20160126-C00010.TIF" alt="Figure US09242012-20160126-C00010" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="253" height="83" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/15/e3/ad/d062fdbae5b070/US09242012-20160126-C00010.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00010" attachment-type="cdx" file="US09242012-20160126-C00010.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00010" attachment-type="mol" file="US09242012-20160126-C00010.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
in which T is O, S or N.
</div>
    <div id="p-0083" num="0082" class="description-paragraph style-scope patent-text">In one embodiment, the compound of <figure-callout id="1" label="Formula" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Formula</a></figure-callout> 1 is maleimidocaproyl. Maleimidocaproyl has been used for conjugation of two specific auristatins to an anti-CD30 mAb (AC10) (Doronina, Svetlana et al. “Novel Linkers for Monoclonal Antibody-Mediated Delivery of Anticancer Agents”, AACR, Anaheim, Calif., Abstract No. 1421, Apr. 16-20, 2005). Maleimidocaproyl reacts with thiol groups to form a thioether.</div>
    <div id="p-0084" num="0083" class="description-paragraph style-scope patent-text">MMAE or MMAF can be conjugated to an antibody or antigen-binding fragment thereof using methods known to those of ordinary skill in the art (e.g., See, Niemeyer, C M, <i class="style-scope patent-text">Bioconjugation Protocols, Strategies and Methods</i>, Humana Press, 2004) or as described herein. In some embodiments, more than one MMAE or MMAF molecule is conjugated to the antibody or antigen-binding fragment thereof. In other embodiments, 1, 2, 3, 4, 5, 6, 7 or 8 MMAE or MMAF molecules are conjugated to the antibody or antigen-binding fragment thereof. In still other embodiments, at least 2, 3, 4 or 5 MMAE or MMAF molecules are conjugated to the antibody or antigen-binding fragment thereof. In further embodiments, 2, 3, 4 or 5 MMAE or MMAF molecules are conjugated to the antibody or antigen-binding fragment thereof.</div>
    <div id="p-0085" num="0084" class="description-paragraph style-scope patent-text">The antibodies or antigen-binding fragments thereof of the ADCs are any antibody or antigen-binding fragment thereof that specifically binds PSMA. In one embodiment the antibody or an antigen-binding fragment thereof specifically binds PSMA (e.g., specifically binds an extracellular domain of PSMA, specifically binds a conformational epitope of PSMA, etc.) and can competitively inhibit the specific binding of a second antibody to its target epitope on PSMA, wherein the second antibody is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antibodies comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13. The second antibody, therefore, include any of the antibodies produced by the hybridomas or encoded by the plasmids shown below in Table 1. These hybridomas and plasmids were deposited pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the American Type Culture Collection (“ATCC”) as an International Depository Authority and given the Patent Deposit Designations shown above and in Table 1.</div>
    <div id="p-0086" num="0085" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00001" num="00001" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="4" rowsep="1" class="description-td style-scope patent-text" colspan="4">TABLE 1</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Patent</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Deposit</td>
                <td class="description-td style-scope patent-text">Date of</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Antibody</td>
                <td class="description-td style-scope patent-text">Hybridoma/Plasmid</td>
                <td class="description-td style-scope patent-text">Designation</td>
                <td class="description-td style-scope patent-text">Deposit</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PSMA 3.7</td>
                <td class="description-td style-scope patent-text">PSMA 3.7</td>
                <td class="description-td style-scope patent-text">PTA-3257</td>
                <td class="description-td style-scope patent-text">Apr. 5, 2001</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PSMA 3.9</td>
                <td class="description-td style-scope patent-text">PSMA 3.9</td>
                <td class="description-td style-scope patent-text">PTA-3258</td>
                <td class="description-td style-scope patent-text">Apr. 5, 2001</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PSMA 3.11</td>
                <td class="description-td style-scope patent-text">PSMA 3.11</td>
                <td class="description-td style-scope patent-text">PTA-3269</td>
                <td class="description-td style-scope patent-text">Apr. 10, 2001</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PSMA 5.4</td>
                <td class="description-td style-scope patent-text">PSMA 5.4</td>
                <td class="description-td style-scope patent-text">PTA-3268</td>
                <td class="description-td style-scope patent-text">Apr. 10, 2001</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PSMA 7.1</td>
                <td class="description-td style-scope patent-text">PSMA 7.1</td>
                <td class="description-td style-scope patent-text">PTA-3292</td>
                <td class="description-td style-scope patent-text">Apr. 18, 2001</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PSMA 7.3</td>
                <td class="description-td style-scope patent-text">PSMA 7.3</td>
                <td class="description-td style-scope patent-text">PTA-3293</td>
                <td class="description-td style-scope patent-text">Apr. 18, 2001</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PSMA 10.3</td>
                <td class="description-td style-scope patent-text">PSMA 10.3</td>
                <td class="description-td style-scope patent-text">PTA-3347</td>
                <td class="description-td style-scope patent-text">May 1, 2001</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">PSMA 10.3 HC in</td>
                <td class="description-td style-scope patent-text">PTA-4413</td>
                <td class="description-td style-scope patent-text">May 29, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">pcDNA (SEQ ID NO: 7)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">PSMA 10.3 Kappa in</td>
                <td class="description-td style-scope patent-text">PTA-4414</td>
                <td class="description-td style-scope patent-text">May 29, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">pcDNA (SEQ ID NO: 13)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PSMA 1.8.3</td>
                <td class="description-td style-scope patent-text">PSMA 1.8.3</td>
                <td class="description-td style-scope patent-text">PTA-3906</td>
                <td class="description-td style-scope patent-text">Dec. 5, 2001</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PSMA A3.1.3</td>
                <td class="description-td style-scope patent-text">PSMA A3.1.3</td>
                <td class="description-td style-scope patent-text">PTA-3904</td>
                <td class="description-td style-scope patent-text">Dec. 5, 2001</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PSMA A3.3.1</td>
                <td class="description-td style-scope patent-text">PSMA A3.3.1</td>
                <td class="description-td style-scope patent-text">PTA-3905</td>
                <td class="description-td style-scope patent-text">Dec. 5, 2001</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.248.2</td>
                <td class="description-td style-scope patent-text">Abgenix 4.248.2</td>
                <td class="description-td style-scope patent-text">PTA-4427</td>
                <td class="description-td style-scope patent-text">Jun. 4, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.360.3</td>
                <td class="description-td style-scope patent-text">Abgenix 4.360.3</td>
                <td class="description-td style-scope patent-text">PTA-4428</td>
                <td class="description-td style-scope patent-text">Jun. 4, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.7.1</td>
                <td class="description-td style-scope patent-text">Abgenix 4.7.1</td>
                <td class="description-td style-scope patent-text">PTA-4429</td>
                <td class="description-td style-scope patent-text">Jun. 4, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.4.1</td>
                <td class="description-td style-scope patent-text">Abgenix 4.4.1</td>
                <td class="description-td style-scope patent-text">PTA-4556</td>
                <td class="description-td style-scope patent-text">Jul. 18, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.177.3</td>
                <td class="description-td style-scope patent-text">Abgenix 4.177.3</td>
                <td class="description-td style-scope patent-text">PTA-4557</td>
                <td class="description-td style-scope patent-text">Jul. 18, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.16.1</td>
                <td class="description-td style-scope patent-text">Abgenix 4.16.1</td>
                <td class="description-td style-scope patent-text">PTA-4357</td>
                <td class="description-td style-scope patent-text">May 16, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.22.3</td>
                <td class="description-td style-scope patent-text">Abgenix 4.22.3</td>
                <td class="description-td style-scope patent-text">PTA-4358</td>
                <td class="description-td style-scope patent-text">May 16, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.28.3</td>
                <td class="description-td style-scope patent-text">Abgenix 4.28.3</td>
                <td class="description-td style-scope patent-text">PTA-4359</td>
                <td class="description-td style-scope patent-text">May 16, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.40.2</td>
                <td class="description-td style-scope patent-text">Abgenix 4.40.2</td>
                <td class="description-td style-scope patent-text">PTA-4360</td>
                <td class="description-td style-scope patent-text">May 16, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.48.3</td>
                <td class="description-td style-scope patent-text">Abgenix 4.48.3</td>
                <td class="description-td style-scope patent-text">PTA-4361</td>
                <td class="description-td style-scope patent-text">May 16, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.49.1</td>
                <td class="description-td style-scope patent-text">Abgenix 4.49.1</td>
                <td class="description-td style-scope patent-text">PTA-4362</td>
                <td class="description-td style-scope patent-text">May 16, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.209.3</td>
                <td class="description-td style-scope patent-text">Abgenix 4.209.3</td>
                <td class="description-td style-scope patent-text">PTA-4365</td>
                <td class="description-td style-scope patent-text">May 16, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.219.3</td>
                <td class="description-td style-scope patent-text">Abgenix 4.219.3</td>
                <td class="description-td style-scope patent-text">PTA-4366</td>
                <td class="description-td style-scope patent-text">May 16, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.288.1</td>
                <td class="description-td style-scope patent-text">Abgenix 4.288.1</td>
                <td class="description-td style-scope patent-text">PTA-4367</td>
                <td class="description-td style-scope patent-text">May 16, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.333.1</td>
                <td class="description-td style-scope patent-text">Abgenix 4.333.1</td>
                <td class="description-td style-scope patent-text">PTA-4368</td>
                <td class="description-td style-scope patent-text">May 16, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.54.1</td>
                <td class="description-td style-scope patent-text">Abgenix 4.54.1</td>
                <td class="description-td style-scope patent-text">PTA-4363</td>
                <td class="description-td style-scope patent-text">May 16, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.153.1</td>
                <td class="description-td style-scope patent-text">Abgenix 4.153.1</td>
                <td class="description-td style-scope patent-text">PTA-4388</td>
                <td class="description-td style-scope patent-text">May 23, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.232.3</td>
                <td class="description-td style-scope patent-text">Abgenix 4.232.3</td>
                <td class="description-td style-scope patent-text">PTA-4389</td>
                <td class="description-td style-scope patent-text">May 23, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.292.3</td>
                <td class="description-td style-scope patent-text">Abgenix 4.292.3</td>
                <td class="description-td style-scope patent-text">PTA-4390</td>
                <td class="description-td style-scope patent-text">May 23, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abgenix 4.304.1</td>
                <td class="description-td style-scope patent-text">Abgenix 4.304.1</td>
                <td class="description-td style-scope patent-text">PTA-4391</td>
                <td class="description-td style-scope patent-text">May 23, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">AB-PG1-XG1-006</td>
                <td class="description-td style-scope patent-text">AB-PG1-XG1-006 Heavy</td>
                <td class="description-td style-scope patent-text">PTA-4403</td>
                <td class="description-td style-scope patent-text">May 29, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Chain (SEQ ID NO: 2)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">AB-PG1-XG1-006 Light</td>
                <td class="description-td style-scope patent-text">PTA-4404</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Chain (SEQ ID NO: 8)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">AB-PG1-XG1-026</td>
                <td class="description-td style-scope patent-text">AB-PG1-XG1-026 Heavy</td>
                <td class="description-td style-scope patent-text">PTA-4405</td>
                <td class="description-td style-scope patent-text">May 29, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Chain (SEQ ID NO: 3)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">AB-PG1-XG1-026 Light</td>
                <td class="description-td style-scope patent-text">PTA-4406</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Chain (SEQ ID NO: 9)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">AB-PG1-XG1-051</td>
                <td class="description-td style-scope patent-text">AB-PG1-XG1-051 Heavy</td>
                <td class="description-td style-scope patent-text">PTA-4407</td>
                <td class="description-td style-scope patent-text">May 29, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Chain (SEQ ID NO: 4)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">AB-PG1-XG1-051 Light</td>
                <td class="description-td style-scope patent-text">PTA-4408</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Chain (SEQ ID NO: 10)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">AB-PG1-XG1-069</td>
                <td class="description-td style-scope patent-text">AB-PG1-XG1-069 Heavy</td>
                <td class="description-td style-scope patent-text">PTA-4409</td>
                <td class="description-td style-scope patent-text">May 29, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Chain (SEQ ID NO: 5)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">AB-PG1-XG1-069 Light</td>
                <td class="description-td style-scope patent-text">PTA-4410</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Chain (SEQ ID NO: 11)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">AB-PG1-XG1-077</td>
                <td class="description-td style-scope patent-text">AB-PG1-XG1-077 Heavy</td>
                <td class="description-td style-scope patent-text">PTA-4411</td>
                <td class="description-td style-scope patent-text">May 29, 2002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Chain (SEQ ID NO: 6)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">AB-PG1-XG1-077 Light</td>
                <td class="description-td style-scope patent-text">PTA-4412</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Chain (SEQ ID NO: 12)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-0087" num="0086" class="description-paragraph style-scope patent-text">To determine competitive inhibition, a variety of assays known to one of ordinary skill in the art can be employed. For example, cross-competition assays can be used to determine if an antibody or antigen-binding fragment thereof competitively inhibits binding to PSMA by another antibody or antigen-binding fragment thereof. These include cell-based methods employing flow cytometry or solid phase binding analysis. Other assays that evaluate the ability of antibodies or antigen-binding fragments thereof to cross-compete for PSMA molecules that are not expressed on the surface of cells, in solid phase or in solution phase, also can be used.</div>
    <div id="p-0088" num="0087" class="description-paragraph style-scope patent-text">In some embodiments, the antibodies or antigen-binding fragments thereof competitively inhibit the specific binding of a second antibody to its target epitope on PSMA by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99%. Inhibition can be assessed at various molar ratios or mass ratios; for example competitive binding experiments can be conducted with a 2-fold, 3-fold, 4-fold, 5-fold, 7-fold, 10-fold or more molar excess of a first antibody or antigen-binding fragment thereof over a second antibody or antigen-binding fragment thereof.</div>
    <div id="p-0089" num="0088" class="description-paragraph style-scope patent-text">In another embodiment the antibody or an antigen-binding fragment thereof specifically binds to an epitope on PSMA defined by an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, 4.248.2, 4.360.3, 4.7.1, 4.4.1, 4.177.3, 4.16.1, 4.22.3, 4.28.3, 4.40.2, 4.48.3, 4.49.1, 4.209.3, 4.219.3, 4.288.1, 4.333.1, 4.54.1, 4.153.1, 4.232.3, 4.292.3, 4.304.1, 4.78.1, and 4.152.1. PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antibodies comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13. The antibodies or antigen-binding fragments of the ADCs, therefore, include those that specifically bind to an epitope on PSMA defined by the antibodies produced by the hybridomas or encoded by the plasmids provided above in Table 1.</div>
    <div id="p-0090" num="0089" class="description-paragraph style-scope patent-text">To determine the epitope, one can use standard epitope mapping methods known in the art. For example, fragments (peptides) of PSMA antigen (e.g., synthetic peptides) that bind the antibody can be used to determine whether a candidate antibody or antigen-binding fragment thereof binds the same epitope. For linear epitopes, overlapping peptides of a defined length (e.g., 8 or more amino acids) are synthesized. The peptides can be offset by 1 amino acid, such that a series of peptides covering every 8 amino acid fragment of the PSMA protein sequence are prepared. Fewer peptides can be prepared by using larger offsets, e.g., 2 or 3 amino acids. In addition, longer peptides (e.g., 9-, 10- or 11-mers) can be synthesized. Binding of peptides to antibodies or antigen-binding fragments can be determined using standard methodologies including surface plasmon resonance (BIACORE) and ELISA assays. For examination of conformational epitopes, larger PSMA fragments can be used. Other methods that use mass spectrometry to define conformational epitopes have been described and can be used (see, e.g., Baerga-Ortiz et al., <i class="style-scope patent-text">Protein Science </i>11:1300-1308, 2002 and references cited therein). Still other methods for epitope determination are provided in standard laboratory reference works, such as Unit 6.8 (“Phage Display Selection and Analysis of B-cell Epitopes”) and Unit 9.8 (“Identification of Antigenic Determinants Using Synthetic Peptide Combinatorial Libraries”) of <i class="style-scope patent-text">Current Protocols in Immunology</i>, Coligan et al., eds., John Wiley &amp; Sons. Epitopes can be confirmed by introducing point mutations or deletions into a known epitope and then testing binding with one or more antibodies or antigen-binding fragments to determine which mutations reduce binding of the antibodies or antigen-binding fragments.</div>
    <div id="p-0091" num="0090" class="description-paragraph style-scope patent-text">In particular embodiments, the antibodies of the ADCs, or from which the antigen-binding fragments of the ADCs are derived, are those produced by hybridomas referred to herein as PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, and Abgenix 4.152.1, respectively. In other embodiments, the antibodies are those encoded by the plasmids listed in Table 1. In still other embodiments, the antibodies are those that comprise a heavy chain encoded by a nucleic acid molecule comprising the heavy chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and a light chain encoded by a nucleic acid molecule comprising the light chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13.</div>
    <div id="p-0092" num="0091" class="description-paragraph style-scope patent-text">As used herein, the names of the deposited hybridomas or plasmids may be used interchangeably with the names of the antibodies. It will be clear to one of ordinary skill in the art when the name is intended to refer to the antibody or when it refers to the plasmids or hybridomas that encode or produce the antibodies, respectively. Additionally, the antibody names may be an abbreviated form of the name shown in Table 1. For instance, antibody AB-PG1-XG1-006 may be referred to as AB-PG1-XG1-006, PG1-XG1-006, XG1-006, 006, etc. In another example, the antibody name PSMA 4.232.3 may be referred to as PSMA 4.232.3, 4.232.1, 4.232, etc. It is intended that all of the variations in the name of the antibody refer to the same antibody and not a different one.</div>
    <div id="p-0093" num="0092" class="description-paragraph style-scope patent-text">The antibodies of the ADCs, or from which the antigen-binding fragments of the ADCs are derived, include those encoded by particular sets of heavy and light chain sequences. In one embodiment, the antibody (AB-PG1-XG1-006) is encoded by a nucleic acid molecule which comprises the coding region or regions of the nucleic acid sequences set forth as SEQ ID NOs: 2 and 8. In another embodiment, the antibody (AB-PG1-XG1-026) is encoded by a nucleic acid molecule which comprises the coding region or regions of the nucleic acid sequences set forth as SEQ ID NOs: 3 and 9. In still another embodiment, the antibody (AB-PG1-XG1-051) is encoded by a nucleic acid molecule which comprises the coding region or regions of the nucleic acid sequences set forth as SEQ ID NOs: 4 and 10. In yet another embodiment, the antibody (AB-PG1-XG1-069) is encoded by a nucleic acid molecule which comprises the coding region or regions of the nucleic acid sequences set forth as SEQ ID NOs: 5 and 11. In another embodiment, the antibody (AB-PG1-XG1-077) is encoded by a nucleic acid molecule which comprises the coding region or regions of the nucleic acid sequences set forth as SEQ ID NOs: 6 and 12. In yet another embodiment, the antibody (PSMA 10.3) is encoded by a nucleic acid molecule which comprises the coding region or regions of the nucleic acid sequences set forth as SEQ ID NOs: 7 and 13. In other embodiments, the antibodies of the ADCs, or from which the antigen-binding fragments of the ADCs are derived, include a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 14, 18, 22, 26 and 30, and a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 16, 20, 24, 28 and 32. In one embodiment, the antibody (AB-PG1-XG1-006) includes an immunoglobulin variable sequence encoded by nucleic acid molecules which comprise the coding region or regions of the nucleic acid sequences set forth as SEQ ID NOs: 14 and 16. Likewise, the antibody can be one that includes an immunoglobulin variable sequence which comprises the amino acid sequences set forth as SEQ ID NOs: 15 and 17. In another embodiment, the antibody (AB-PG1-XG1-026) includes an immunoglobulin variable sequence encoded by nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as SEQ ID NOs: 18 and 20 or includes an immunoglobulin variable sequence which comprises the amino acid sequences set forth as <figure-callout id="21" label="SEQ ID NOs" filenames="US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">SEQ ID NOs</a></figure-callout> 19 and 21. In still another embodiment, the antibody (AB-PG1-XG1-051) includes an immunoglobulin variable sequence encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as SEQ ID NOs: 22 and 24 or includes an immunoglobulin variable sequence which comprises the amino acid sequences set forth as SEQ ID NOs: 23 and 25. In yet another embodiment, the antibody (AB-PG1-XG1-069) includes an immunoglobulin variable sequence encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as SEQ ID NOs: 26 and 28 or includes an immunoglobulin variable sequence which comprises the amino acid sequences set forth as SEQ ID NOs: 27 and 29. In another embodiment, the antibody (AB-PG1-XG1-077) includes an immunoglobulin variable sequence encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as SEQ ID NOs: 30 and 32 or includes an immunoglobulin variable sequence which comprises the amino acid sequences set forth as SEQ ID NOs: 31 and 33. In other embodiments, the antibody includes a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and 31, and a light chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33.</div>
    <div id="p-0094" num="0093" class="description-paragraph style-scope patent-text">As used herein, a “coding region” refers to a region of a nucleotide sequence that encodes a polypeptide sequence. Its use herein is consistent with the recognized meaning known in the art.</div>
    <div id="p-0095" num="0094" class="description-paragraph style-scope patent-text">In certain embodiments, the antibodies of the ADCs, or from which the antigen-binding fragments of the ADCs are derived, are those that are encoded by nucleic acid molecules that are highly homologous to the foregoing nucleic acids. The homologous nucleic acid molecule can, in some embodiments, comprise a nucleotide sequence that is at least about 90% identical to the nucleotide sequence provided herein. In other embodiments, the nucleotide sequence is at least about 95% identical, at least about 97% identical, at least about 98% identical, or at least about 99% identical to a nucleotide sequence provided herein. The homology can be calculated using various, publicly available software tools well known to one of ordinary skill in the art. Exemplary tools include the BLAST system available from the website of the National Center for Biotechnology Information (NCBI) at the National Institutes of Health.</div>
    <div id="p-0096" num="0095" class="description-paragraph style-scope patent-text">One method of identifying highly homologous nucleotide sequences is via nucleic acid hybridization. Thus, the antibodies of the ADCs, or from which the antigen-binding fragments of the ADCs are derived, include antibodies having a PSMA-binding property and/or other functional properties described herein, which are encoded by nucleic acid molecules that hybridize under high stringency conditions to the foregoing nucleic acid molecules. Identification of related sequences can also be achieved using polymerase chain reaction (PCR) and other amplification techniques suitable for cloning related nucleic acid sequences. PCR primers can be selected to amplify portions of a nucleic acid sequence of interest, such as a CDR.</div>
    <div id="p-0097" num="0096" class="description-paragraph style-scope patent-text">The term “high stringency conditions”, as used herein, refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references that compile such methods, e.g. <i class="style-scope patent-text">Molecular Cloning: A Laboratory Manual</i>, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, or <i class="style-scope patent-text">Current Protocols in Molecular Biology</i>, F. M. Ausubel, et al., eds., John Wiley &amp; Sons, Inc., New York. One example of high-stringency conditions is hybridization at 65° C. in hybridization buffer (3.5×SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5 mM NaH<sub class="style-scope patent-text">2</sub>PO<sub class="style-scope patent-text">4</sub>(pH7), 0.5% SDS, 2 mM EDTA). SSC is 0.15M sodium chloride/0.015M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, a membrane upon which the nucleic acid is transferred is washed, for example, in 2×SSC at room temperature and then at 0.1-0.5×SSC/0.1×SDS at temperatures up to 68° C.</div>
    <div id="p-0098" num="0097" class="description-paragraph style-scope patent-text">As used herein, the term “antibody” refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or V<sub class="style-scope patent-text">H</sub>) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, <figure-callout id="1" label="C" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">C<sub class="style-scope patent-text"> </sub> </a></figure-callout> <sub class="style-scope patent-text">H</sub>1, <figure-callout id="2" label="C" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">C<sub class="style-scope patent-text"> </sub> </a></figure-callout> <sub class="style-scope patent-text">H</sub>2 and <figure-callout id="3" label="C" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">C<sub class="style-scope patent-text"> </sub> </a></figure-callout> <sub class="style-scope patent-text">H</sub>3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or V<sub class="style-scope patent-text">L</sub>) and a light chain constant region. The light chain constant region is comprised of one domain, C<sub class="style-scope patent-text">L</sub>. The V<sub class="style-scope patent-text">H </sub>and V<sub class="style-scope patent-text">L </sub>regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each V<sub class="style-scope patent-text">H </sub>and V<sub class="style-scope patent-text">L </sub>is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.</div>
    <div id="p-0099" num="0098" class="description-paragraph style-scope patent-text">The term “antigen-binding fragment” of an antibody as used herein, refers to one or more portions of an antibody that retain the ability to specifically bind to an antigen (i.e., PSMA). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term “antigen-binding fragment” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the V<sub class="style-scope patent-text">L</sub>, V<sub class="style-scope patent-text">H</sub>, C<sub class="style-scope patent-text">L </sub>and <figure-callout id="1" label="C" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">C<sub class="style-scope patent-text"> </sub> </a></figure-callout> <sub class="style-scope patent-text">H</sub>1 domains; (ii) a F(ab′)<sub class="style-scope patent-text">2 </sub>fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V<sub class="style-scope patent-text">H </sub>and <figure-callout id="1" label="C" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">C<sub class="style-scope patent-text"> </sub> </a></figure-callout> <sub class="style-scope patent-text">H</sub>1 domains; (iv) a Fv fragment consisting of the V<sub class="style-scope patent-text">L </sub>and V<sub class="style-scope patent-text">H </sub>domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) <i class="style-scope patent-text">Nature </i>341:544-546) which consists of a V<sub class="style-scope patent-text">H </sub>domain; and (vi) an isolated complementarity determining region (CDR). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3 contribute to antibody specificity. Because these CDR regions and in particular the CDR3 region confer antigen specificity on the antibody, these regions may be incorporated into other antibodies or antigen-binding fragments to confer the identical antigen specificity onto that antibody or peptide. Furthermore, although the two domains of the Fv fragment, V and V<sub class="style-scope patent-text">H</sub>, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V<sub class="style-scope patent-text">L </sub>and V<sub class="style-scope patent-text">H </sub>regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) <i class="style-scope patent-text">Science </i>242:423-426; and Huston et al. (1988) <i class="style-scope patent-text">Proc. Natl. Acad. Sci. USA </i>85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term “antigen-binding fragment” of an antibody. These antibody fragments are obtained using conventional procedures, such as proteolytic fragmentation procedures, as described in J. Goding, Monoclonal Antibodies: Principles and Practice, pp 98-118 (N.Y. Academic Press 1983), which is hereby incorporated by reference as well as by other techniques known to those with skill in the art. The fragments are screened for utility in the same manner as are intact antibodies.</div>
    <div id="p-0100" num="0099" class="description-paragraph style-scope patent-text">The antibodies, or antigen-binding fragments thereof, of the ADCs are, in some embodiments, isolated. “Isolated”, as used herein, is intended to refer to an antibody (or antigen-binding fragment thereof), which is substantially free of other antibodies (or antigen-binding fragments) having different antigenic specificities (e.g., an isolated antibody that specifically binds to PSMA is substantially free of antibodies that specifically bind antigens unrelated to PSMA). An isolated antibody that specifically binds to an epitope, isoform or variant of PSMA may, however, have cross-reactivity to other related antigens, e.g., from other species (e.g., PSMA species homologs). For example, PSMA homologs have been found in other species, such as the pig (GenBank Accession Number O77564 (amino acid)) and rat (GenBank Accession Numbers U75973 (mRNA) and AAC53423 (amino acid)). In some embodiments, the antibodies or antigen-binding fragments provided herein specifically bind both human PSMA as well as a PSMA homolog from another species. In other embodiments, the antibodies or antigen-binding fragments thereof specifically bind human PSMA but do not cross-react with PSMA homologs from another species.</div>
    <div id="p-0101" num="0100" class="description-paragraph style-scope patent-text">Moreover, an isolated antibody (or antigen-binding fragment thereof) may be substantially free of other cellular material and/or chemicals. The term “substantially pure” means that an antibody (or antigen-binding fragment thereof) is essentially free of other substances with which they may be found in nature or in vivo systems to an extent practical and appropriate for their intended use. Substantially pure antibodies or antigen-binding fragments thereof may be produced by techniques well known in the art. Because an isolated antibody (or antigen-binding fragment thereof) may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the antibody (or antigen-binding fragment thereof) may comprise only a small percentage by weight of the preparation. The antibody (or antigen-binding fragment thereof) is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.</div>
    <div id="p-0102" num="0101" class="description-paragraph style-scope patent-text">As used herein, “specific binding” refers to antibody binding to a predetermined antigen, in this case PSMA (e.g., human PSMA). Typically, the antibody binds with an affinity that is at least two-fold greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein), which is an antigen other than PSMA, an isoform or variant of PSMA, or a closely-related antigen.</div>
    <div id="p-0103" num="0102" class="description-paragraph style-scope patent-text">The antibodies encompass various antibody isotypes, such as IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE. As used herein, “isotype” refers to the antibody class (e.g., IgM or IgG1) that is encoded by heavy chain constant region genes. The antibodies can be full length or can include only an antigen-binding fragment such as the antibody constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD or IgE or could consist of a Fab fragment, a F(ab′)<sub class="style-scope patent-text">2 </sub>fragment and a Fv fragment.</div>
    <div id="p-0104" num="0103" class="description-paragraph style-scope patent-text">The antibodies of the ADCs, or from which the antigen-binding fragments of the ADCs are derived, are, in some embodiments monoclonal. The antibodies can be produced by a variety of techniques well known in the art. Monoclonal antibody production may be effected by techniques which are well known in the art. The term “monoclonal antibody”, as used herein, refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody displays a single binding specificity and affinity for a particular epitope. The process of monoclonal antibody production involves obtaining immune somatic cells with the potential for producing antibody, in particular B lymphocytes, which have been previously immunized with the antigen of interest either in vivo or in vitro and that are suitable for fusion with a B-cell myeloma line.</div>
    <div id="p-0105" num="0104" class="description-paragraph style-scope patent-text">Mammalian lymphocytes typically are immunized by in vivo immunization of the animal (e.g., a mouse) with the desired protein or polypeptide. Such immunizations are repeated as necessary at intervals of up to several weeks to obtain a sufficient titer of antibodies. Once immunized, animals can be used as a source of antibody-producing lymphocytes. Following the last antigen boost, the animals are sacrificed and spleen cells removed. Mouse lymphocytes give a higher percentage of stable fusions with the mouse myeloma lines described herein. For example, of the BALB/c mouse. However, other mouse strains, rabbit, hamster, sheep and frog may also be used as hosts for preparing antibody-producing cells. See; Goding (in Monoclonal Antibodies: Principles and Practice, 2d ed., pp. 60-61, Orlando, Fla., Academic Press, 1986). In particular, mouse strains that have human immunoglobulin genes inserted in the genome (and which cannot produce mouse immunoglobulins) can be used. Examples include the HuMAb mouse strains produced by Medarex/GenPharm International, and the XenoMouse strains produced by Abgenix. Such mice produce fully human immunoglobulin molecules in response to immunization. In some embodiments, therefore, the ADCs comprise a fully human monoclonal antibody or an antigen-binding fragment thereof that binds PSMA.</div>
    <div id="p-0106" num="0105" class="description-paragraph style-scope patent-text">Those antibody-producing cells that are in the dividing plasmablast stage fuse preferentially. Somatic cells may be obtained from the lymph nodes, spleens and peripheral blood of antigen-primed animals, and the lymphatic cells of choice depend to a large extent on their empirical usefulness in the particular fusion system. The antibody-secreting lymphocytes are then fused with (mouse) B cell myeloma cells or transformed cells, which are capable of replicating indefinitely in cell culture, thereby producing an immortal, immunoglobulin-secreting cell line. The resulting fused cells, or hybridomas, are cultured, and the resulting colonies screened for the production of the desired monoclonal antibodies. Colonies producing such antibodies are cloned, and grown either in vivo or in vitro to produce large quantities of antibody. A description of the theoretical basis and practical methodology of fusing such cells is set forth in Kohler and Milstein, <i class="style-scope patent-text">Nature </i>256:495 (1975), which is hereby incorporated by reference.</div>
    <div id="p-0107" num="0106" class="description-paragraph style-scope patent-text">Alternatively, human somatic cells capable of producing antibody, specifically B lymphocytes, are suitable for fusion with myeloma cell lines. While B lymphocytes from biopsied spleens, tonsils or lymph nodes of an individual may be used, the more easily accessible peripheral blood B lymphocytes can also be used. The lymphocytes may be derived from patients with diagnosed prostate carcinomas or another PSMA-expressing to cancer. In addition, human B cells may be directly immortalized by the Epstein-Barr virus (Cole et al., 1995, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Although somatic cell hybridization procedures can be used, in principle, other techniques for producing monoclonal antibodies can be employed such as viral or oncogenic transformation of B lymphocytes.</div>
    <div id="p-0108" num="0107" class="description-paragraph style-scope patent-text">Myeloma cell lines suited for use in hybridoma-producing fusion procedures can be non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of the desired hybridomas. Examples of such myeloma cell lines that may be used for the production of fused cell lines include P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 4.1, Sp2/0-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7, S194/5XX0 Bul, all derived from mice; R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210 derived from rats and U-266, GM1500-GRG2, LICR-LON-HMy2, UC729-6, all derived from humans (Goding, in Monoclonal Antibodies: Principles and Practice, 2d ed., pp. 65-66, Orlando, Fla., Academic Press, 1986; Campbell, in Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology Vol. 13, Burden and Von Knippenberg, eds. pp. 75-83, Amsterdam, Elseview, 1984).</div>
    <div id="p-0109" num="0108" class="description-paragraph style-scope patent-text">Fusion with mammalian myeloma cells or other fusion partners capable of replicating indefinitely in cell culture is effected by standard and well-known techniques, for example, by using polyethylene glycol (“PEG”) or other fusing agents (See Milstein and Kohler, <i class="style-scope patent-text">Eur. J. Immunol. </i>6:511 (1976), which is hereby incorporated by reference).</div>
    <div id="p-0110" num="0109" class="description-paragraph style-scope patent-text">In other embodiments, the antibodies of the ADCs, or from which the antigen-binding fragments of the ADCs are derived, are recombinant antibodies. The term “recombinant antibody”, as used herein, is intended to include antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from an animal (e.g., a mouse) that is transgenic for another species' immunoglobulin genes, antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial antibody library, or antibodies prepared, expressed, created or isolated by any other means that involves splicing of immunoglobulin gene sequences to other DNA sequences.</div>
    <div id="p-0111" num="0110" class="description-paragraph style-scope patent-text">In yet other embodiments, the antibodies are chimeric or humanized antibodies. As used herein, the term “chimeric antibody” refers to an antibody, that combines the murine variable or hypervariable regions with the human constant region or constant and variable framework regions. As used herein, the term “humanized antibody” refers to an antibody that to retains only the antigen-binding CDRs from the parent antibody in association with human framework regions (see, Waldmann, 1991<i class="style-scope patent-text">, Science </i>252:1657). Such chimeric or humanized antibodies retaining binding specificity of the murine antibody are expected to have reduced immunogenicity when administered in vivo as provided herein.</div>
    <div id="p-0112" num="0111" class="description-paragraph style-scope patent-text">According to an alternative embodiment, the monoclonal antibodies of the ADCs can be in the form of a bispecific antibody or a multispecific antibody. The term “bispecific antibody” is intended to include any agent, e.g., a protein, peptide, or protein or peptide complex, which has two different binding specificities which bind to, or interact with (a) a cell surface antigen and (b) an Fc receptor on the surface of an effector cell. The term “multispecific antibody” is intended to include any agent, e.g., a protein, peptide, or protein or peptide complex, which has more than two different binding specificities which bind to, or interact with (a) a cell surface antigen, (b) an Fc receptor on the surface of an effector cell, and (c) at least one other component. Accordingly, the antibodies include, but are not limited to, bispecific, trispecific, tetraspecific, and other multispecific antibodies which are directed to PSMA and to Fc receptors on effector cells. The term “bispecific antibodies” further includes diabodies. Diabodies are bivalent, bispecific antibodies in which the V<sub class="style-scope patent-text">H </sub>and V<sub class="style-scope patent-text">L </sub>domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen-binding sites (see e.g., Holliger, P., et al. (1993) <i class="style-scope patent-text">Proc. Natl. Acad. Sci. USA </i>90:6444-6448; Poijak, R. J., et al. (1994) <i class="style-scope patent-text">Structure </i>2:1121-1123).</div>
    <div id="p-0113" num="0112" class="description-paragraph style-scope patent-text">A bispecific antibody can be formed of an antigen-binding region specific for PSMA and an antigen-binding region specific for an effector cell which has tumoricidal or tumor inhibitory activity. The two antigen-binding regions of the bispecific antibody are either chemically linked or can be expressed by a cell genetically engineered to produce the bispecific antibody. (See generally, Fanger et al., 1995 <i class="style-scope patent-text">Drug News </i>&amp; <i class="style-scope patent-text">Perspec. </i>8(3):133-137). Suitable effector cells having tumoricidal activity include but are not limited to cytotoxic T-cells (primarily CD8<sup class="style-scope patent-text">+</sup> cells), natural killer cells, etc. An effective amount of a bispecific antibody can be administered to a subject with cancer, and the bispecific antibody kills and/or inhibits proliferation of the cancer cells after localization at sites of primary or metastatic tumors bearing PSMA.</div>
    <div id="p-0114" num="0113" class="description-paragraph style-scope patent-text">In certain embodiments, the antibodies of the ADCs, or from which the antigen-binding fragments of the ADCs are derived, are human antibodies. The term “human antibody”, as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies can include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term “human antibody”, as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences (referred to herein as “humanized antibodies”). Human antibodies directed against PSMA can be generated using transgenic mice carrying parts of the human immune system rather than the mouse system. Some examples of which are described elsewhere herein.</div>
    <div id="p-0115" num="0114" class="description-paragraph style-scope patent-text">Fully human monoclonal antibodies also can be prepared by immunizing mice transgenic for large portions of human immunoglobulin heavy and light chain loci. See, e.g., U.S. Pat. Nos. 5,591,669, 5,598,369, 5,545,806, 5,545,807, 6,150,584, and references cited therein, the contents of which are incorporated herein by reference. These animals have been genetically modified such that there is a functional deletion in the production of endogenous (e.g., murine) antibodies. The animals are further modified to contain all or a portion of the human germ-line immunoglobulin gene locus such that immunization of these animals results in the production of fully human antibodies to the antigen of interest. Following immunization of these mice (e.g., XenoMouse (Abgenix), HuMAb mice (Medarex/GenPharm)), monoclonal antibodies can be prepared according to standard hybridoma technology. These monoclonal antibodies have human immunoglobulin amino acid sequences and, therefore, will not provoke human anti-mouse antibody (HAMA) responses when administered to humans. In general, but not intended to be limiting, the mice are 6-16 weeks of age upon the first immunization. For example, a purified or enriched preparation of PSMA antigen (e.g., recombinant PSMA or PSMA-expressing cells) can be used to immunize the mice intraperitoneally (IP), although other routes of immunization known to one of ordinary skill in the art are also possible. PSMA antigen can be injected in combination with an adjuvant, such as complete Freund's adjuvant, and, in some embodiments, the initial injection is followed by booster immunizations with antigen in an adjuvant, such as incomplete Freund's adjuvant. The immune response can be monitored over the course of the immunization protocol with plasma samples obtained by, for example, retroorbital bleeds. The plasma can be screened by ELISA, and mice with sufficient titers of anti-PSMA human immunoglobulin can be used for fusions. Mice can be boosted intravenously with <figure-callout id="3" label="antigen" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">antigen</a></figure-callout> 3 days before sacrifice and removal of the spleen.</div>
    <div id="p-0116" num="0115" class="description-paragraph style-scope patent-text">The antibody or antigen-binding fragment thereof of the ADCs can, in some embodiments, be selected for the ability to bind live PSMA-expressing cells. In order to demonstrate binding to live PSMA-expressing cells, flow cytometry can be used. For example, PSMA-expressing cells lines (grown under standard growth conditions) or prostate cancer cells that express PSMA can be mixed with various concentrations of monoclonal antibodies in PBS containing 0.1<figure-callout id="80" label="% Tween" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="20" label="% Tween" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">% Tween</a></figure-callout> </a></figure-callout> 80 and 20% mouse serum and incubated at 37° C. for 1 hour. After washing, the cells can be reacted with fluorescein-labeled anti-human IgG secondary antibody (if human anti-PSMA antibodies were used) under the same conditions as the primary antibody staining. The samples can be analyzed by a fluorescence activated cell sorter (FACS) instrument using light and side scatter properties to gate on single cells. An alternative assay using fluorescence microscopy can be used (in addition to or instead of) the flow cytometry assay. Cells can be stained and examined by fluorescence microscopy. This method allows visualization of individual cells but may have diminished sensitivity depending on the density of the antigen. It follows, that the ADCs, in some embodiments, bind live cells. The ADCs, in some embodiments, therefore, do not require cell lysis to bind PSMA.</div>
    <div id="p-0117" num="0116" class="description-paragraph style-scope patent-text">The antibodies can, in some embodiments, promote cytolysis of PSMA-expressing cells. Cytolysis can be complement-mediated or can be mediated by effector cells. In one embodiment, the cytolysis is carried out in a living organism, such as a mammal, and the live cell is a tumor cell. Examples of tumors which can be targeted with the antibodies or antigen-binding fragments thereof include, any tumor that expresses PSMA (this includes tumors with neovasculature expressing PSMA), such as, prostate, bladder, breast, pancreas, liver, lung (e.g., non-small cell lung carcinoma), colon and kidney tumors as well as melanomas and sarcomas. In one embodiment, the tumor cell is a prostate tumor cell.</div>
    <div id="p-0118" num="0117" class="description-paragraph style-scope patent-text">The testing of cytolytic activity in vitro by chromium release assay can provide an initial screening prior to testing in vivo models. This testing can be carried out using standard chromium release assays. Briefly, polymorphonuclear cells (PMN), or other effector cells, from healthy donors can be purified by Ficoll Hypaque density centrifugation, followed by lysis of contaminating erythrocytes. Washed PMNs can be suspended in RPMI supplemented with 10% heat-inactivated fetal calf serum and mixed with <sup class="style-scope patent-text">51</sup>Cr labeled cells expressing PSMA, at various ratios of effector cells to tumor cells (effector cells:tumor cells). Purified anti-PSMA IgGs can then be added at various concentrations. Irrelevant IgG can be used as a negative control. Assays can be carried out for 0-120 minutes at 37° C. Samples can be assayed for cytolysis by measuring <sup class="style-scope patent-text">51</sup>Cr release into the culture supernatant. Anti-PSMA monoclonal antibodies and/or ADCs can also be tested in combinations with each other to determine whether cytolysis is enhanced with multiple monoclonal antibodies and/or ADCs. Antibodies that bind to PSMA and/or ADCs also can be tested in an in vivo model (e.g., in mice) to determine their efficacy in mediating cytolysis and killing of cancer cells expressing PSMA, e.g., prostate tumor cells.</div>
    <div id="p-0119" num="0118" class="description-paragraph style-scope patent-text">The antibodies of the ADCs, or from which the antigen-binding fragments of the ADCs are derived, can be selected, for example, based on the following criteria, which are not intended to be exclusive:
</div> <ul class="style-scope patent-text"> <li id="ul0001-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0002-0001" num="0119" class="style-scope patent-text">1) binding to live cells expressing PSMA;</li> <li id="ul0002-0002" num="0120" class="style-scope patent-text">2) high affinity of binding to PSMA;</li> <li id="ul0002-0003" num="0121" class="style-scope patent-text">3) binding to a unique epitope on PSMA (i.e., an epitope not recognized by a previously produced antibody);</li> <li id="ul0002-0004" num="0122" class="style-scope patent-text">4) opsonization of cells expressing PSMA;</li> <li id="ul0002-0005" num="0123" class="style-scope patent-text">5) mediation of growth inhibition, phagocytosis and/or killing of cells expressing PSMA in the presence of effector cells;</li> <li id="ul0002-0006" num="0124" class="style-scope patent-text">6) modulation (inhibition or enhancement) of NAALADase, folate hydrolase, dipeptidyl peptidase IV and/or γ-glutamyl hydrolase activities;</li> <li id="ul0002-0007" num="0125" class="style-scope patent-text">7) growth inhibition, cell cycle arrest and/or cytotoxicity in the absence of effector cells;</li> <li id="ul0002-0008" num="0126" class="style-scope patent-text">8) internalization of PSMA;</li> <li id="ul0002-0009" num="0127" class="style-scope patent-text">9) binding to a conformational epitope on PSMA;</li> <li id="ul0002-0010" num="0128" class="style-scope patent-text">10) minimal cross-reactivity with cells or tissues that do not express PSMA; and</li> <li id="ul0002-0011" num="0129" class="style-scope patent-text">11) preferential binding to dimeric forms of PSMA rather than monomeric forms of PSMA.
<br class="style-scope patent-text">
The antibodies of the ADCs, or from which the antigen-binding fragments of the ADCs are derived, can meet one or more, and possibly all, of these criteria.
</li> </ul> </li> </ul>

    <div id="p-0120" num="0130" class="description-paragraph style-scope patent-text">In one embodiment, the antibody or antigen-binding fragment thereof binds to a conformational epitope, such as a conformational epitope within the extracellular domain of PSMA. To determine if an anti-PSMA antibody or antigen-binding fragment thereof binds to conformational epitopes, each antibody can be tested in assays using native protein (e.g., non-denaturing immunoprecipitation, flow cytometric analysis of cell surface binding) and denatured protein (e.g., Western blot, immunoprecipitation of denatured proteins). A comparison of the results will indicate whether the antibody or antigen-binding fragment thereof binds a conformational epitope. Antibodies or antigen-binding fragments thereof that bind to native protein but not denatured protein are, in some embodiments, those that bind conformational epitopes. It follows, that the ADCs, in some embodiments, bind conformational epitopes of PSMA.</div>
    <div id="p-0121" num="0131" class="description-paragraph style-scope patent-text">In another embodiment, the antibody or antigen-binding fragment thereof binds to a dimer-specific epitope on PSMA (i.e., a conformational, dimer-specific epitope unique to the quaternary structure of dimeric PSMA). Generally, antibodies or antigen-binding fragments thereof which bind to a dimer-specific epitope preferentially bind the PSMA dimer rather than the PSMA monomer. To determine if an antibody or antigen-binding fragment thereof binds preferentially (i.e., selectively and/or specifically) to a PSMA dimer, the antibody or antigen-binding fragment thereof can be tested in assays (e.g., immunoprecipitation followed by Western blotting) using native dimeric PSMA protein and dissociated monomeric PSMA protein. A comparison of the results will indicate whether the antibody or antigen-binding fragment thereof binds preferentially to the dimer. In some embodiments, the antibodies or antigen-binding fragments thereof bind to the PSMA dimer but not to the monomeric PSMA protein. It follows, that the ADCs, in some embodiments, bind to a dimer-specific epitope on PSMA.</div>
    <div id="p-0122" num="0132" class="description-paragraph style-scope patent-text">The ADCs provided include those that selectively bind PSMA multimers. As used herein, particularly with respect to the binding of PSMA multimers by the ADCs, “selectively binds” means that an antibody or antigen-binding fragment thereof of the ADCs preferentially binds to a PSMA protein multimer (e.g., with greater avidity, greater binding affinity) rather than to a PSMA protein monomer. In some embodiments, the ADCs of the invention bind to a PSMA protein multimer with an avidity and/or binding affinity that is 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 7-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 70-fold, 100-fold, 200-fold, 300-fold, 500-fold, 1000-fold or more than that exhibited by the ADC for a PSMA protein monomer. The ADC can, in some embodiments, selectively bind a PSMA protein multimer, and not a PSMA protein monomer, i.e., exclusively binds to a PSMA protein multimer. In some embodiments, the ADC selectively binds a PSMA protein dimer.</div>
    <div id="p-0123" num="0133" class="description-paragraph style-scope patent-text">A PSMA protein multimer, as used herein, is a protein complex of at least two PSMA proteins or fragments thereof. The PSMA protein multimers can be composed of various combinations of full-length PSMA proteins (e.g., SEQ ID NO: 1), recombinant soluble PSMA (rsPSMA, e.g., amino acids 44-750 of SEQ ID NO: 1) and fragments of the foregoing that form multimers (i.e., that retain the protein domain required for forming dimers and/or higher order multimers of PSMA). In some embodiments, at least one of the PSMA proteins forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide. The PSMA protein multimers can be dimers, such as those formed from recombinant soluble PSMA protein. In one embodiment, the dimer is a rsPSMA homodimer. The PSMA protein multimers referred to herein are believed to assume a native conformation and can have such a conformation. The PSMA proteins in certain embodiments are noncovalently bound together to form the PSMA protein multimer. It has been discovered that PSMA protein noncovalently associates to form dimers under non-denaturing conditions. The PSMA protein multimers can retain the activities of PSMA. The PSMA activity may be an enzymatic activity, such as folate hydrolase activity, NAALADase activity, dipeptidyl peptidase IV activity or γ-glutamyl hydrolase activity. Methods for testing the PSMA activity of multimers are well known in the art (reviewed by O'Keefe et al. in: <i class="style-scope patent-text">Prostate Cancer: Biology, Genetics, and the New Therapeutics</i>, L. W. K. Chung, W. B. Isaacs and J. W. Simons (eds.) Humana Press, Totowa, N.J., 2000, pp. 307-326).</div>
    <div id="p-0124" num="0134" class="description-paragraph style-scope patent-text">The antibody or antigen-binding fragment thereof of the ADCs can bind to and be internalized with PSMA expressed on cells. The mechanism by which the antibody or antigen-binding fragment thereof is internalized with PSMA is not critical to the practice of the methods provided herein. For example, the antibody or antigen-binding fragment thereof can induce internalization of PSMA. Alternatively, internalization of the antibody or antigen-binding fragment thereof can be the result of routine internalization of PSMA. It follows that the ADC can be internalized with PSMA expressed on cells.</div>
    <div id="p-0125" num="0135" class="description-paragraph style-scope patent-text">The antibodies or antigen-binding fragments thereof, and, therefore, the ADCs can, in some embodiments, specifically bind cell-surface PSMA and/or rsPSMA with sub-nanomolar affinity. The binding affinities can be about 1×10<sup class="style-scope patent-text">−9</sup>M or less, about 1×10<sup class="style-scope patent-text">−10</sup>M or less, or about 1×10<sup class="style-scope patent-text">−11</sup>M or less. In one embodiment, the binding affinity is less than about 5×10<sup class="style-scope patent-text">−10</sup>M.</div>
    <div id="p-0126" num="0136" class="description-paragraph style-scope patent-text">The antibodies or antigen-binding fragments thereof can, in some embodiments, modulate at least one enzymatic activity of PSMA. The activity can be selected from the group consisting of N-acetylated α-linked acidic dipeptidase (NAALADase), folate hydrolase, dipeptidyl dipeptidase IV, γ-glutamyl hydrolase activity and combinations thereof in vitro or in vivo. The modulation may be enhancement or inhibition of at least one enzymatic activity of PSMA.</div>
    <div id="p-0127" num="0137" class="description-paragraph style-scope patent-text">Tissue levels of NAALADase activity can be determined by detergent solubilizing homogenizing tissues, pelleting the insoluble material by centrifugation and measuring the NAALADase activity in the remaining supernatant. Likewise, the NAALADase activity in bodily fluids can also be measured by first pelleting the cellular material by centrifugation and performing a typical enzyme assay for NAALADase activity on the supernatant. NAALADase enzyme assays have been described by Frieden, 1959<i class="style-scope patent-text">, J. Biol, Chem., </i>234:2891. In this assay, the reaction product of the NAALADase enzyme is glutamic acid. This is derived from the enzyme catalyzed cleavage of N-acetylaspartylglutamate to yield N-acetylaspartic acid and glutamic acid. Glutamic acid, in a NAD(P)<sup class="style-scope patent-text">+</sup> requiring step, yields 2-oxoglutarate plus NAD(P)H in a reaction catalyzed by glutamate dehydrogenase. Progress of the reaction can easily and conveniently be measured by the change in absorbance at 340 nm due to the conversion of NAD(P)<sup class="style-scope patent-text">+</sup> to NAD(P)H.</div>
    <div id="p-0128" num="0138" class="description-paragraph style-scope patent-text">Folate hydrolase activity of PSMA can be measured by performing enzyme assays as described by Heston and others (e.g., <i class="style-scope patent-text">Clin. Cancer Res. </i>2(9):1445-51, 1996<i class="style-scope patent-text">; Urology </i>49(3A Suppl):104-12, 1997). Folate hydrolases such as PSMA remove the gamma-linked glutamates from polyglutamated folates. Folate hydrolase activity can be measured using substrates such as methotrexate tri-gamma glutamate (MTXGlu3), methotrexate di-gamma glutamate (MTXGlu2) or pteroylpentaglutamate (PteGlu5), for example using capillary electrophoresis (see <i class="style-scope patent-text">Clin. Cancer Res. </i>2(9):1445-51, 1996). Timed incubations of PSMA with polyglutamated substrates can be followed by separation and detection of hydrolysis products.</div>
    <div id="p-0129" num="0139" class="description-paragraph style-scope patent-text">As mentioned above, the ADCs provided have surprisingly been found to kill PSMA-expressing, taxane-resistant cancer cells and can be used to treat PSMA-expressing, taxane-resistant cancer. Methods are, therefore, provided wherein an ADC is administered to a subject with a PSMA-expressing, taxane-resistant cancer. The cancer cells of the PSMA-expressing, taxane-resistant cancer, in some embodiments, can be cells of a tumor (e.g., primary malignant tumor) or cells of one or more metastases.</div>
    <div id="p-0130" num="0140" class="description-paragraph style-scope patent-text">In some embodiments, the methods provided result in the delay or inhibition of progression of the cancer in the subject. As used herein, “delay or inhibition of progression of the cancer” is intended to refer to any slowing or halting of the progression of the cancer in the subject. A slowing or halting of the progression of the cancer includes a reduction or stabilization in the number of cancer cells, the number of tumors, and/or the number of metastases in a subject. A slowing or halting is also intended to include a reduction or stabilization in the size (e.g., length or volume) of tumors and/or size of metastases in a subject. Methods for assessing the progression of cancer in a subject will be apparent to one of ordinary skill in the art. In addition, in some embodiments, the delay or inhibition of progression of the cancer can be demonstrated by a change in at least one biomarker for bone metastasis or bone metabolism compared to a baseline value prior to treatment with the ADC in the subject. In some embodiments the biomarker is N-telopeptide, bone alkaline phosphatase, osteocalcin, calcitonin, calcium, pyridinoline or deoxypyridinoline. In further embodiments, the delay or inhibition of progression of the cancer is demonstrated by radiographic image changes in tumor burden compared to a baseline radiographic image in the subject prior to ADC treatment. Methods for assessing radiographic changes, include, for example, bone scan, computerized axial tomography (CT) scan and magnetic resonance imaging (MRI). Other methods will be well known to those of ordinary skill in the art. In some embodiments, the delay or inhibition of progression is evidenced by a radiographic image change of at least 10%, 20%, 30%, 40%, 50% or 60% or more.</div>
    <div id="p-0131" num="0141" class="description-paragraph style-scope patent-text">Treatment with the ADCs provided can also result in the increase in survival of subjects with a PSMA-expressing, taxane-resistant cancer. In some embodiments, the survival of such a subject is increased by 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28 or 32 weeks or more as compared to the median survival of subjects with the PSMA-expressing, taxane-resistant cancer not administered the ADC. In other embodiments, the survival is increased 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28 or 32 weeks or more as compared to the expected survival time for the subject prior to treatment with the ADC. In other embodiments of either of the foregoing, the survival of the subject is increased by 10, 12, 14, 16, 18, 20, 22 or 24 months or more according to either comparison. In one embodiment, the subject treated with an ADC is one that has progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy, and the increase in survival of the subject is as compared to the median survival of subjects having progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy and not treated with the ADC. In another embodiment, the subject treated with an ADC is one that has progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy, and the increase in survival of the subject is as compared to the expected survival time for the subject prior to treatment with the ADC.</div>
    <div id="p-0132" num="0142" class="description-paragraph style-scope patent-text">In other embodiments, treatment with an ADC as provided results in an increase in the quality of life for the subject as compared to the quality of life experienced by the subject prior to treatment with the ADC. As used herein “an increase in the quality of life” refers to any improvement in the subject's comfort, level of energy and/or ability to function in an activity as a result of the administration of an ADC as provided herein.</div>
    <div id="p-0133" num="0143" class="description-paragraph style-scope patent-text">In still other embodiments, treatment with an ADC can result in a decrease in the circulating level of circulating tumor cells (CTCs) compared to a baseline level. In further embodiments, treatment with an ADC can result in a decrease or stabilization (no significant increase or decrease) in a serum level of prostate-specific antigen (PSA) compared to a baseline level of PSA. Methods for assessing the circulating level of CTCs or the serum level of PSA are well known to those of ordinary skill in the art.</div>
    <div id="p-0134" num="0144" class="description-paragraph style-scope patent-text">It was also surprising to discover that in subjects with a PSMA-expressing, taxane-resistant cancer, a reduction in tumor volume for even very large tumors can be achieved with the administration of an ADC. Therefore, in some embodiments, the subject has a tumor with a tumor volume that is at least 100 mm<sup class="style-scope patent-text">3</sup>, 200 mm<sup class="style-scope patent-text">3</sup>, 300 mm<sup class="style-scope patent-text">3</sup>, 400 mm<sup class="style-scope patent-text">3</sup>, 500 mm<sup class="style-scope patent-text">3</sup>, 600 mm<sup class="style-scope patent-text">3</sup>, 700 mm<sup class="style-scope patent-text">3</sup>, 800 mm<sup class="style-scope patent-text">3</sup>, 900 mm<sup class="style-scope patent-text">3</sup>, 1000 mm<sup class="style-scope patent-text">3</sup>, 1100 mm<sup class="style-scope patent-text">3</sup>, 1200 mm<sup class="style-scope patent-text">3</sup>, 1300 mm<sup class="style-scope patent-text">3</sup>, 1400 mm<sup class="style-scope patent-text">3</sup>, 1500 mm<sup class="style-scope patent-text">3</sup>, 1600 mm<sup class="style-scope patent-text">3</sup>, 1700 mm<sup class="style-scope patent-text">3</sup>, 1800 mm<sup class="style-scope patent-text">3</sup>, 1900 mm<sup class="style-scope patent-text">3 </sup>or 2000 mm<sup class="style-scope patent-text">3</sup>. In some embodiments, the subject has a tumor volume that is greater than 700 mm<sup class="style-scope patent-text">3</sup>. In other embodiments, the subject has a tumor with a length of at least 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, 24 mm, 25 mm or 30 mm or more. In other embodiments, the tumor volume or length is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97% or 99% as a result of treatment with an ADC as provided herein. In a further embodiment, the tumor is eradicated. Techniques for determining the presence of a tumor and for measuring its size are well known to those of ordinary skill in the art.</div>
    <div id="p-0135" num="0145" class="description-paragraph style-scope patent-text">In one aspect, a method for alleviating or decreasing pain in a subject (e.g., a human patient) having progressive, castration resistant, taxane-resistant metastatic prostate cancer comprising administering PSMA ADC in an amount effective to alleviate or decrease the level of pain (e.g., bone pain) in the subject, wherein the antibody-drug conjugate comprises a monoclonal antibody or antigen-binding fragment thereof that specifically binds to prostate-specific membrane antigen (PSMA) conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine, and wherein the sequence of PSMA is the sequence set forth in SEQ ID NO: 1, is also provided. In one embodiment, the amount effective to alleviate or decrease the level of pain (e.g., bone pain) in the subject is a dose of PSMA ADC of at least 1.6 mg/kg or greater. In another embodiment, the amount effective is a dose of at least 1.8 mg·kg or greater. In yet another embodiment, the amount effective is a dose of at least 2.0 mg/kg or greater. In one embodiment, the dose is administered at 1, 2, 3 or 4 week intervals or more. In another embodiment, the dose is administered intravenously at 3 week intervals. In still other embodiments, the treatment is effective to reduce pain (e.g., bone pain) and the number of CTC cells in a subject. In yet another embodiment, the treatment is effective to reduce pain (e.g., bone pain) and PSA levels in a subject. In still other embodiments, the treatment is effective to reduce pain (e.g., bone pain), the number of CTC cells and PSA levels in a subject.</div>
    <div id="p-0136" num="0146" class="description-paragraph style-scope patent-text">The ADCs can be used in various in vitro and in vivo methods for effecting the aforementioned therapeutic endpoints. The methods provided can be used to kill PSMA-expressing, taxane-resistant cancer cells in vitro or in vivo. Methods are also provided for treating any PSMA-expressing, taxane-resistant cancer. Such a cancer is, for example, prostate cancer. Such a cancer can also be, for example, a cancer in which PSMA is expressed on the cells of the tumor neovasculature. An exemplary list of such cancers is provided elsewhere herein.</div>
    <div id="p-0137" num="0147" class="description-paragraph style-scope patent-text">In some embodiments, two or more different ADCs are used in combination. In another embodiment, one or more unconjugated anti-PSMA antibodies or antigen-binding fragments thereof can be combined with one or more ADCs in a single therapy to achieve a desired therapeutic effect. As an illustration, an unconjugated anti-PSMA antibody that mediates highly effective killing of target cells in the presence of effector cells and/or that inhibits the growth of cells expressing PSMA can be used with one or more ADCs. In yet another embodiment, the ADCs can be combined with one or more additional antitumor agents, such as corticosteroids, such as prednisone or hydrocortisone; immunostimulatory agents; immunomodulators; or some combination thereof.</div>
    <div id="p-0138" num="0148" class="description-paragraph style-scope patent-text">Antitumor agents include cytotoxic agents, chemotherapeutic agents and agents that act on tumor neovasculature. Cytotoxic agents include cytotoxic radionuclides, chemical toxins and protein toxins. The cytotoxic radionuclide or radiotherapeutic isotope can be an alpha-emitting isotope such as <sup class="style-scope patent-text">225</sup>Ac, <sup class="style-scope patent-text">211</sup>At, <sup class="style-scope patent-text">212</sup>Bi, <sup class="style-scope patent-text">213</sup>Bi, <sup class="style-scope patent-text">212</sup>Pb, <sup class="style-scope patent-text">224</sup>Ra or <sup class="style-scope patent-text">223</sup>Ra. Alternatively, the cytotoxic radionuclide can be a beta-emitting isotope such as <sup class="style-scope patent-text">186</sup>Rh, <sup class="style-scope patent-text">188</sup>Rh, <sup class="style-scope patent-text">177</sup>Lu, <sup class="style-scope patent-text">90</sup>Y, <sup class="style-scope patent-text">131</sup>I, <sup class="style-scope patent-text">67</sup>Cu, <sup class="style-scope patent-text">64</sup>Cu, <sup class="style-scope patent-text">153</sup>Sm or <sup class="style-scope patent-text">166</sup>Ho. Further, the cytotoxic radionuclide can emit Auger and low energy electrons and include the isotopes <sup class="style-scope patent-text">125</sup>I, <sup class="style-scope patent-text">123</sup>I or <sup class="style-scope patent-text">77</sup>Br.</div>
    <div id="p-0139" num="0149" class="description-paragraph style-scope patent-text">Suitable chemical toxins or chemotherapeutic agents include members of the enediyne family of molecules, such as calicheamicin and esperamicin. Chemical toxins can also be taken from the group consisting of methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin and 5-fluorouracil. Other antineoplastic agents include dolastatins (U.S. Pat. Nos. 6,034,065 and 6,239,104) and derivatives thereof. Dolastatins and derivatives thereof include dolastatin 10 (dolavaline-valine-dolaisoleuine-dolaproine-dolaphenine) and the derivatives auristatin PHE (dolavaline-valine-dolaisoleuine-dolaproine-phenylalanine-methyl ester) (Pettit, G. R. et al., <i class="style-scope patent-text">Anticancer Drug Des. </i>13(4):243-277, 1998; Woyke, T. et al., <i class="style-scope patent-text">Antimicrob. Agents Chemother. </i>45(12):3580-3584, 2001), and aurastatin E and the like. Toxins also include poisonous lectins, plant toxins such as ricin, abrin, modeccin, botulina and diphtheria toxins. Other chemotherapeutic agents are known to those skilled in the art.</div>
    <div id="p-0140" num="0150" class="description-paragraph style-scope patent-text">Agents that act on the tumor vasculature include tubulin-binding agents such as combrestatin A4 (Griggs et al., <i class="style-scope patent-text">Lancet Oncol. </i>2:82, 2001), angiostatin and endostatin (reviewed in Rosen, <i class="style-scope patent-text">Oncologist </i>5:20, 2000, incorporated by reference herein) and interferon inducible protein 10 (U.S. Pat. No. 5,994,292). A number of other antiangiogenic agents are also contemplated and include: 2ME2, Angiostatin, Angiozyme, Anti-VEGF RhuMAb, Apra (CT-2584), Avicine, Benefin, BMS275291, Carboxyamidotriazole, CC4047, CC5013, CC7085, CDC801, CGP-41251 (PKC 412), CM101, Combretastatin A-4 Prodrug, EMD 121974, Endostatin, Flavopiridol, Genistein (GCP), Green Tea Extract, IM-862, ImmTher, Interferon alpha, Interleukin-12, Iressa (ZD1839), Marimastat, Metastat (Col-3), Neovastat, Octreotide, Paclitaxel, Penicillamine, Photofrin, Photopoint, PI-88, Prinomastat (AG-3340), PTK787 (ZK22584), RO317453, Solimastat, Squalamine, SU 101, SU 5416, SU-6668, Suradista (FCE 26644), Suramin (Metaret), Tetrathiomolybdate, Thalidomide, TNP-470 and Vitaxin. Additional antiangiogenic agents are described by Kerbel, J. Clin. Oncol. 19(18s):45s-51s, 2001, which is incorporated by reference herein.</div>
    <div id="p-0141" num="0151" class="description-paragraph style-scope patent-text">The ADCs can be administered with one or more immunostimulatory agents to induce or enhance an immune response, such as IL-2 and immunostimulatory oligonucleotides (e.g., those containing CpG motifs). Immunostimulatory agents can, in some embodiments, stimulate specific arms of the immune system, such as natural killer (NK) cells that mediate antibody-dependent cell cytotoxicity (ADCC). Immunostimulatory agents include interleukin-2, α-interferon, γ-interferon, tumor necrosis factor alpha (TNFα), immunostimulatory oligonucleotides or a combination thereof. Immunomodulators include cytokines, chemokines, adjuvants or a combination thereof. Chemokines useful in increasing immune responses include but are not limited to SLC, ELC, MIP3α, MIP3β, IP-10, MIG, and combinations thereof.</div>
    <div id="p-0142" num="0152" class="description-paragraph style-scope patent-text">The other therapeutic agent can also be a vaccine. In some embodiments, the vaccine immunizes a subject against PSMA. Such vaccines, in some embodiments, include antigens, such as PSMA dimers, with, optionally, one or more adjuvants to induce or enhance an immune response. An adjuvant is a substance which potentiates the immune response. Adjuvants of many kinds are well known in the art. Specific examples of adjuvants include monophosphoryl lipid A (MPL, SmithKline Beecham); saponins including QS21 (SmithKline Beecham); immunostimulatory oligonucleotides (e.g., CpG oligonucleotides described by Kreig et al., <i class="style-scope patent-text">Nature </i>374:546-9, 1995); incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; vitamin E and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol, Quil A, Ribi Detox, CRL-1005, L-121, and combinations thereof. Formulations, such as those described in U.S. application Ser. No. 10/976,352, are also contemplated for use as vaccines in the methods provided herein. The disclosure of such formulations are incorporated herein by reference.</div>
    <div id="p-0143" num="0153" class="description-paragraph style-scope patent-text">The vaccines can, in some embodiments, include one or more of the isolated PSMA protein multimers described herein, such as the PSMA protein dimer. In some embodiments, a PSMA protein multimer composition contains at least about 10% PSMA protein multimer (of the total amount of PSMA protein in the composition). In other embodiments, the PSMA protein multimer composition contains at least about 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% PSMA protein multimer. In one embodiment, the PSMA protein multimer composition contains substantially pure PSMA protein multimer, with substantially no PSMA protein monomer. It is understood that the list of specific percentages includes by inference all of the unnamed percentages between the recited percentages.</div>
    <div id="p-0144" num="0154" class="description-paragraph style-scope patent-text">Cytokines can also be used in vaccination protocols as a result of their lymphocyte regulatory properties. Many cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-2 (IL-2); IL-4; IL-5; IL-12, which has been shown to enhance the protective effects of vaccines (see, e.g., <i class="style-scope patent-text">Science </i>268: 1432-1434, 1995); GM-CSF; IL-15; IL-18; combinations thereof, and the like. Thus cytokines can be administered in conjunction with antigen, chemokines and/or adjuvants to increase an immune response.</div>
    <div id="p-0145" num="0155" class="description-paragraph style-scope patent-text">The other therapeutic agents can be used in the methods provided in unconjugated form or in conjugated form, such as conjugated to an anti-PSMA antibody or antigen-binding fragment thereof. Coupling of one or more toxin molecules to the anti-PSMA antibody or antigen-binding fragment thereof can include many chemical mechanisms, for instance covalent binding, affinity binding, intercalation, coordinate binding and complexation.</div>
    <div id="p-0146" num="0156" class="description-paragraph style-scope patent-text">The covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules. Many bivalent or polyvalent agents are useful in coupling protein molecules to other proteins, peptides or amine functions, etc. For example, the literature is replete with coupling agents such as carbodiimides, diisocyanates, glutaraldehyde, diazobenzenes, and hexamethylene diamines. This list is not intended to be exhaustive of the various coupling agents known in the art but, rather, is exemplary of the more common coupling agents.</div>
    <div id="p-0147" num="0157" class="description-paragraph style-scope patent-text">In some embodiments, it is contemplated that one may wish to first derivatize the antibody, and then attach the therapeutic agent to the derivatized product. Suitable cross-linking agents for use in this manner include, for example, SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), and SMPT, 4-succinimidyl-oxycarbonyl-methyl-(2-pyridyldithio)toluene.</div>
    <div id="p-0148" num="0158" class="description-paragraph style-scope patent-text">In addition, protein toxins can be fused to the anti-PSMA antibody or antigen-binding fragment thereof by genetic methods to form a hybrid immunotoxin fusion protein. The fusion proteins can include additional peptide sequences, such as peptide spacers which operatively attach, for example, the anti-PSMA antibody and toxin, as long as such additional sequences do not appreciably affect the targeting or toxin activities of the fusion protein. The proteins can be attached by a peptide linker or spacer, such as a glycine-serine spacer peptide, or a peptide hinge, as is well known in the art. Thus, for example, the C-terminus of an anti-PSMA antibody or antigen-binding fragment thereof can be fused to the N-terminus of the protein toxin molecule to form an immunotoxin that retains the binding properties of the anti-PSMA antibody. Other fusion arrangements will be known to one of ordinary skill in the art. To express the fusion immunotoxin, the nucleic acid encoding the fusion protein is inserted into an expression vector in accordance with standard methods, for stable expression of the fusion protein, such as in mammalian cells, such as CHO cells. The fusion protein can be isolated and purified from the cells or culture supernatant using standard methodology, such as a PSMA affinity column.</div>
    <div id="p-0149" num="0159" class="description-paragraph style-scope patent-text">Radionuclides typically are coupled to an antibody or antigen-binding fragment thereof by chelation. For example, in the case of metallic radionuclides, a bifunctional chelator is commonly used to link the isotope to the antibody or other protein of interest. Typically, the chelator is first attached to the antibody, and the chelator-antibody conjugate is contacted with the metallic radioisotope. A number of bifunctional chelators have been developed for this purpose, including the diethylenetriamine pentaacetic acid (DTPA) series of amino acids described in U.S. Pat. Nos. 5,124,471, 5,286,850 and 5,434,287, which are incorporated herein by reference. As another example, hydroxamic acid-based bifunctional chelating agents are described in U.S. Pat. No. 5,756,825, the contents of which are incorporated herein. Another example is the chelating agent termed p-SCN-Bz-HEHA (1,4,7,10,13,16-hexaazacyclo-octadecane-N,N′,N″,N′″,N″″,N′″″-hexaacetic acid) (Deal et al., <i class="style-scope patent-text">J. Med. Chem. </i>42:2988, 1999), which is an effective chelator of radiometals such as <sup class="style-scope patent-text">225</sup>Ac. Yet another example is DOTA (1,4,7,10-tetraazacyclododecane N,N′,N″,N′″-tetraacetic acid), which is a bifunctional chelating agent (see McDevitt et al., Science 294:1537-1540, 2001) that can be used in a two-step method for labeling followed by conjugation.</div>
    <div id="p-0150" num="0160" class="description-paragraph style-scope patent-text">Other therapeutic agents also include replication-selective viruses. Replication-competent virus such as the p53 pathway targeting adenovirus mutant d11520, ONYX-015, kills tumor cells selectively (Biederer, C. et al., J. Mol. Med. 80(3):163-175, 2002). The virus can, in some embodiments, be conjugated to PSMA antibodies or antigen-binding fragments thereof.</div>
    <div id="p-0151" num="0161" class="description-paragraph style-scope patent-text">The methods provided can further comprise the use of other therapeutic treatment modalities. Such other treatments include surgery, radiation, cryosurgery, thermotherapy, hormone treatment, chemotherapy, vaccines and other immunotherapies.</div>
    <div id="p-0152" num="0162" class="description-paragraph style-scope patent-text">The ADCs of the invention, such as through their antibody or antigen-binding fragment thereof, can be linked to a label. Labels include, for example, fluorescent labels, enzyme labels, radioactive labels, nuclear magnetic resonance active labels, luminescent labels or chromophore labels.</div>
    <div id="p-0153" num="0163" class="description-paragraph style-scope patent-text">The compositions provided can include a physiologically or pharmaceutically acceptable carrier, excipient or stabilizer mixed with the ADC. In some embodiments, when a composition comprises two or more different ADCs, each of the antibodies or antigen-binding fragments thereof of the ADCs binds to a distinct conformational epitope of PSMA.</div>
    <div id="p-0154" num="0164" class="description-paragraph style-scope patent-text">Pharmaceutical compositions can be administered in combination therapy, i.e., combined with other agents. For example, the combination therapy can include an ADC with at least one anti-tumor agent, immunomodulator, immunostimulatory agent or other conventional therapy. The other agent can be conjugated to or formed as a recombinant fusion molecule with a PSMA antibody or antigen-binding fragment thereof for directed targeting of the agent to PSMA-expressing cells. In another embodiment the other therapeutic agent can be unconjugated. Additional therapeutic agents can be administered or contacted with the PSMA-expressing cells through co-administration. “Co-administering,” as used herein, refers to administering two or more therapeutic agents simultaneously as an admixture in a single composition, or sequentially, and close enough in time so that the compounds may exert an additive or even synergistic effect. In still other embodiments, an additional therapeutic agent can be administered before, during or after the administration of one or more ADCs or compositions thereof.</div>
    <div id="p-0155" num="0165" class="description-paragraph style-scope patent-text">As used herein, “pharmaceutically acceptable carrier” or “physiologically acceptable carrier” includes any and all salts, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In some embodiments, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound, can be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.</div>
    <div id="p-0156" num="0166" class="description-paragraph style-scope patent-text">When administered, the pharmaceutical compositions are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions. The term “pharmaceutically acceptable” means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents, such as supplementary immune potentiating agents including adjuvants, chemokines and cytokines. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.</div>
    <div id="p-0157" num="0167" class="description-paragraph style-scope patent-text">A salt retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see e.g., Berge, S. M., et al. (1977) <i class="style-scope patent-text">J. Pharm. Sci. </i>66: 1-19). Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous and the like, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium and the like, as well as from nontoxic organic amines, such as N,N′-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine and the like.</div>
    <div id="p-0158" num="0168" class="description-paragraph style-scope patent-text">An ADC can be combined, if desired, with a pharmaceutically-acceptable carrier. The term “pharmaceutically-acceptable carrier” as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term “carrier” denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.</div>
    <div id="p-0159" num="0169" class="description-paragraph style-scope patent-text">The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.</div>
    <div id="p-0160" num="0170" class="description-paragraph style-scope patent-text">The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; and parabens.</div>
    <div id="p-0161" num="0171" class="description-paragraph style-scope patent-text">The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.</div>
    <div id="p-0162" num="0172" class="description-paragraph style-scope patent-text">Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of the compounds, which is, in some embodiments, isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulations suitable for oral, subcutaneous, intravenous, intramuscular, etc. administration can be found in <i class="style-scope patent-text">Remington's Pharmaceutical Sciences</i>, Mack Publishing Co., Easton, Pa.</div>
    <div id="p-0163" num="0173" class="description-paragraph style-scope patent-text">The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., <i class="style-scope patent-text">Sustained and Controlled Release Drug Delivery Systems</i>, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.</div>
    <div id="p-0164" num="0174" class="description-paragraph style-scope patent-text">The therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time (e.g., the ADC in saline infused over 90 minutes). The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, intratumor, or transdermal. When compounds containing antibodies are used therapeutically, routes of administration include intravenous and by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing antibodies are well known to those of skill in the art. Generally, such systems should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope binding capacity (see, for example, Sciarra and Cutie, “Aerosols,” in <i class="style-scope patent-text">Remington's Pharmaceutical Sciences, </i>18th edition, 1990, pp. 1694-1712; incorporated by reference). Those of skill in the art can readily determine the various parameters and conditions for producing antibody aerosols without resorting to undue experimentation.</div>
    <div id="p-0165" num="0175" class="description-paragraph style-scope patent-text">The compositions of the invention are administered in effective amounts. An “effective amount” is that amount of any of the ADCs provided herein that alone, or together with further doses and/or other therapeutic agents, produces the desired response. This can involve any of the therapeutic endpoints mentioned herein. In one embodiment, this involves only slowing the progression of the disease temporarily, although in some embodiments, it involves halting the progression of the disease permanently. In other embodiments, it involves eradicating the disease altogether. The desired therapeutic endpoint can be monitored by routine methods known to those of ordinary skill in the art. An amount that is effective can be the amount of an ADC alone which produces the desired therapeutic endpoint. An amount that is effective is also the amount of an ADC in combination with another agent that produces the desired result.</div>
    <div id="p-0166" num="0176" class="description-paragraph style-scope patent-text">Such amounts will depend, of course, on the particular cancer being treated, the severity of the cancer, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.</div>
    <div id="p-0167" num="0177" class="description-paragraph style-scope patent-text">The pharmaceutical compositions used in the methods can be sterile and contain an effective amount of an ADC, alone or in combination with another agent, for producing the desired response in a unit of weight or volume suitable for administration to a patient. The response can, for example, be measured by determining the physiological effects of the ADC composition, such as a reduction in tumor volume, reduction in the size or number of metastases, an increase in survival, an improvement in quality of life and/or reduction of cancer symptoms, etc. Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response.</div>
    <div id="p-0168" num="0178" class="description-paragraph style-scope patent-text">The doses of ADCs administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits.</div>
    <div id="p-0169" num="0179" class="description-paragraph style-scope patent-text">In general, doses can range from about 10 μg/kg to about 100,000 μg/kg. In some embodiments, the doses can range from about 0.1 mg/kg to about 20 mg/kg. In still other embodiments, the doses range from about 0.1 mg/kg to 5 mg/kg, 0.1 mg/kg to 10 mg/kg or 0.1 mg/kg to 15 mg/kg. In yet other embodiments, the doses range from about 1 mg/kg to 5 mg/kg, 5 mg/kg to 10 mg/kg, 10 mg/kg to 15 mg/kg or 15 mg/kg to 20 mg/kg. In further embodiments, the dose is about 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg, 7 mg/kg, 10 mg/kg, 12 mg/kg, 15 mg/kg, 17 mg/kg, 20 mg/kg, 25 mg/kg or 30 mg/kg. In a further embodiment, the dose is about 0.4 mg/kg, 0.7 mg/kg. 1.1 mg/kg, 1.6 mg/kg, 1.8 mg/kg, 2.4 mg/kg, 2.9 mg/kg, 3.0 mg/kg, 3.5 mg/kg or 4.0 mg/kg. In a further embodiment, the dose is about 0.6 mg/kg, 0.9 mg/kg, 1.2 mg/kg or 1.5 mg/kg. In another embodiment, the dose is about 1 mg/kg, 3 mg/kg, 5 mg/kg or 6 mg/kg. Based upon the composition, the dose can be delivered continuously, such as by continuous pump, or at periodic intervals. In some embodiments, when the ADC is administered intravenously, the dose is between 0.1 and 20 mg/kg or any value in between. Desired time intervals of multiple doses of a particular composition can be determined without undue experimentation by one skilled in the art. Other protocols for the administration of the compositions provided will be known to one of ordinary skill in the art, in which the dose amount, schedule of administration, site(s) of administration, mode of administration and the like vary from the foregoing. In some embodiments, subjects are administered the ADC with a dose regimen of q4d×3 or q4d×6. In one embodiment, the dose is administered intravenously. In another embodiment, the dose regimen is a single intravenous dose.</div>
    <div id="p-0170" num="0180" class="description-paragraph style-scope patent-text">Administration of an ADC or a composition comprising an ADC to mammals other than humans, e.g., for testing purposes or veterinary therapeutic purposes, etc. is carried out under substantially the same conditions as described above.</div>
    <div id="p-0171" num="0181" class="description-paragraph style-scope patent-text">The compositions of the present invention have in vitro and in vivo therapeutic utilities. For example, these molecules can be administered to cells in culture, e.g. in vitro or ex vivo, or in a subject, e.g., in vivo, to treat a variety of cancers as provided herein. As used herein, the term “subject” is intended to include humans and non-human animals. Non-human animals include, e.g., dogs, cats, horses, cows, pigs, mice and rats. Subjects include a human patient having a PSMA-expressing, taxane-resistant cancer. The subject, in one embodiment, has progressive, castration-resistant, metastatic prostate cancer that has been treated with taxane but has progressed. In another embodiment, the subject is one that meets the entry criteria as defined in the Examples below (e.g., Examples 5, 7 and 9).</div>
    <div id="p-0172" num="0182" class="description-paragraph style-scope patent-text">Use of the methods provided has a number of benefits. Since the ADCs preferentially target PSMA e.g., on prostate cancer cells, other tissue can be spared. As a result, treatment with such biological agents is safer, particularly for elderly patients. Treatment according to the present invention is expected to be particularly effective, in some embodiments, because it can direct high levels of ADCs to the bone marrow and lymph nodes where cancer metastases, such as prostate cancer metastases, can predominate. Treatment in accordance with the present invention can be effectively monitored with clinical parameters such as serum prostate specific antigen and/or pathological features of a patient's cancer, including stage, Gleason score, extracapsular, seminal, vesicle or perineural invasion, positive margins, involved lymph nodes, etc. Alternatively, these parameters can be used to indicate when such treatment should be employed.</div>
    <div id="p-0173" num="0183" class="description-paragraph style-scope patent-text">The compositions for use in the methods provided herein can be in lyophilized form or provided in an aqueous medium.</div>
    <div id="p-0174" num="0184" class="description-paragraph style-scope patent-text">The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference. However, the citation of any reference is not intended to be admission that said reference is prior art.</div>
    <heading id="h-0006" class="style-scope patent-text">EXAMPLES</heading>
    <heading id="h-0007" class="style-scope patent-text">Example 1</heading>
    <heading id="h-0008" class="style-scope patent-text">Potent and Specific Cytotoxicity to PSMA-Expressing Prostate Cancer Cells</heading>
    <div id="p-0175" num="0185" class="description-paragraph style-scope patent-text">PSMA-positive and PSMA-negative cells were exposed to PSMA ADC in 96-well microplates at various concentrations. After 96-hours, percent cell survival (compared to cells in medium) was assayed using fluorescent Alamar Blue (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5</figref>).</div>
    <div id="p-0176" num="0186" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 6</figref> presents a table showing cytotoxicity to PSMA-expressing prostate cancer cell lines following exposure to PSMA ADC.</div>
    <heading id="h-0009" class="style-scope patent-text">Example 2</heading>
    <heading id="h-0010" class="style-scope patent-text">PSMA ADC is Effective to Treat Large Tumors and to Treat Docetaxel-Resistant Tumors</heading>
    <div id="p-0177" num="0187" class="description-paragraph style-scope patent-text">The in vivo therapeutic efficacy of PSMA ADC in a subcutaneous xenograft model of human prostate cancer was assessed. Male athymic nude mice, 6-8 weeks old, obtained from Charles River Laboratories, Inc. (Wilmington, Mass.) were implanted subcutaneously with 5 million C4-2 cells (provided by Warren D. W. Heston of The Cleveland Clinic, Cleveland, Ohio). C4-2 is an androgen-independent human prostate cancer cell line. At <figure-callout id="11" label="day" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 11, the tumor size of each mouse was measured, by length and width in millimeters, using a caliper (Mitutoyo, Aurora, Ill.). The tumor volume was calculated using the following formula:
<br class="style-scope patent-text">
Volume(mm<sup class="style-scope patent-text">3</sup>)=[(Length)×(Width)<sup class="style-scope patent-text">2</sup>]/2
</div>
    <div id="p-0178" num="0188" class="description-paragraph style-scope patent-text">Animals with a tumor volume between 80-140 mm<sup class="style-scope patent-text">3 </sup>were randomized according to tumor volume into two groups for treatment with either PBS buffer (vehicle control, n=15) or PSMA ADC (n=15). The mean tumor size was 108.9 and 108.7 mm<sup class="style-scope patent-text">3 </sup>with a p-value of 0.452 (student t-test) for the PBS and PSMA ADC groups, respectively, at randomization. All animals then received intravenous injections of PBS or PSMA ADC (Progenics, Tarrytown, N.Y., toxicology lot P10306) at 6 mg/kg via tail vein in a volume of 0.1 mL on <figure-callout id="12" label="day" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 12 through 29 twice per week for three weeks. Tumor sizes were measured twice per week or weekly for 100 days after tumor implantation, and the mean tumor volume for the two groups was plotted over time post tumor implantation (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7</figref>).</div>
    <div id="p-0179" num="0189" class="description-paragraph style-scope patent-text">Tumor size reduction was observed in PSMA ADC treated animals. The first animal was sacrificed at day 33 in the vehicle control group due to the large size of tumor (&gt;2000 mm<sup class="style-scope patent-text">3</sup>); mean tumor volume for the vehicle group and the PSMA ADC treated group were 925.7 mm<sup class="style-scope patent-text">3 </sup>and 92.5 mm<sup class="style-scope patent-text">3 </sup>(p=0.00005, student t-test), respectively. The experiment was followed for 100 days, and all mice were sacrificed except 4 animals in the PSMA ADC treated group.</div>
    <div id="p-0180" num="0190" class="description-paragraph style-scope patent-text">Among the 15 animals in the PSMA ADC treated group with a mean tumor size of 72.5 mm<sup class="style-scope patent-text">3 </sup>at <figure-callout id="75" label="day" filenames="US09242012-20160126-D00012.png,US09242012-20160126-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 75 as shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7</figref>, there were 4 mice (<figure-callout id="8" label="mouse #" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="11" label="mouse #" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="12" label="mouse #" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mouse #</a></figure-callout> </a></figure-callout> </a></figure-callout>8, 11, 12 and 14) with tumors that started to grow at day 75 (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8</figref>). On day 99, the average tumor volume was 688.7 mm<sup class="style-scope patent-text">3 </sup>(893.8, 445.3, 666.7, 749.0 mm<sup class="style-scope patent-text">3</sup>) for the 4 mice. The animals were treated again with PSMA ADC at 6 mg/kg from day 99, once a week for 13 weeks. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8</figref> shows the tumor volume over 180 days for the 4 mice. The dotted lines indicate initial PSMA ADC treatment, and the solid lines indicate second PSMA ADC treatment. Tumor size reduction was observed immediately in all 4 mice after the second PSMA ADC treatment, and the tumor volume continued to shrink while dosing. At <figure-callout id="180" label="day" filenames="US09242012-20160126-D00006.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 180, the tumor volume was reduced to &lt;100 mm<sup class="style-scope patent-text">3 </sup>with a mean volume of 50 mm<sup class="style-scope patent-text">3</sup>.</div>
    <div id="p-0181" num="0191" class="description-paragraph style-scope patent-text">These results show that PSMA ADC is effective to treat large-sized tumors (˜900 mm<sup class="style-scope patent-text">3</sup>) and also can be used to treat relapsed tumors using the same dose level from an initial PSMA ADC treatment.</div>
    <div id="p-0182" num="0192" class="description-paragraph style-scope patent-text">One mouse that was not included in the PSMA ADC experiment described above had a tumor size of ˜500 mm<sup class="style-scope patent-text">3 </sup>at <figure-callout id="21" label="day" filenames="US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 21. It was given 12 doses of docetaxel, IP, at 12 mg/kg weekly. As shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3</figref> and Table 2, the animal initially responded to the docetaxel treatment, the tumor volume was reduced to ˜300 mm<sup class="style-scope patent-text">3 </sup>at <figure-callout id="60" label="day" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 60, but then it progressed to ˜800 mm<sup class="style-scope patent-text">3 </sup>at <figure-callout id="100" label="day" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 100. The treatment of docetaxel was stopped, and PSMA ADC was given IV at 6 mg/kg for an additional 12 doses, weekly. The tumor volume was drastically reduced from 800 mm<sup class="style-scope patent-text">3 </sup>to ˜50 mm<sup class="style-scope patent-text">3 </sup>at <figure-callout id="180" label="day" filenames="US09242012-20160126-D00006.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 180 when PSMA ADC was given. PSMA ADC can treat tumors that fail docetaxel treatment.</div>
    <div id="p-0183" num="0193" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00002" num="00002" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE 2</td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Measurement of tumor over time in an animal treated with 12 doses of 12 mg/kg</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">docetaxel followed by 12 doses of 6 mg/kg PSMA ADC. The tumor responded to docetaxel</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">treatment initially and then relapsed. The treatment was switched to PSMA ADC and then</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">significant tumor volume reduction was observed.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Days</td>
                <td class="description-td style-scope patent-text">Tumor</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">post tumor implantation</td>
                <td class="description-td style-scope patent-text">Length (mm)</td>
                <td class="description-td style-scope patent-text">Width (mm)</td>
                <td class="description-td style-scope patent-text">Volume (mm<sup class="style-scope patent-text">3</sup>)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">21</td>
                <td class="description-td style-scope patent-text">12.22</td>
                <td class="description-td style-scope patent-text">9.22</td>
                <td class="description-td style-scope patent-text">519.4</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">26</td>
                <td class="description-td style-scope patent-text">13.07</td>
                <td class="description-td style-scope patent-text">9.27</td>
                <td class="description-td style-scope patent-text">561.6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">28</td>
                <td class="description-td style-scope patent-text">12.61</td>
                <td class="description-td style-scope patent-text">9.11</td>
                <td class="description-td style-scope patent-text">523.3</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">39</td>
                <td class="description-td style-scope patent-text">12.06</td>
                <td class="description-td style-scope patent-text">9.14</td>
                <td class="description-td style-scope patent-text">503.7</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">47</td>
                <td class="description-td style-scope patent-text">10.89</td>
                <td class="description-td style-scope patent-text">7.80</td>
                <td class="description-td style-scope patent-text">331.3</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">49</td>
                <td class="description-td style-scope patent-text">11.17</td>
                <td class="description-td style-scope patent-text">7.67</td>
                <td class="description-td style-scope patent-text">328.6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">56</td>
                <td class="description-td style-scope patent-text">11.10</td>
                <td class="description-td style-scope patent-text">8.26</td>
                <td class="description-td style-scope patent-text">378.7</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">61</td>
                <td class="description-td style-scope patent-text">11.16</td>
                <td class="description-td style-scope patent-text">7.44</td>
                <td class="description-td style-scope patent-text">308.9</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">63</td>
                <td class="description-td style-scope patent-text">10.59</td>
                <td class="description-td style-scope patent-text">7.84</td>
                <td class="description-td style-scope patent-text">325.5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">67</td>
                <td class="description-td style-scope patent-text">11.67</td>
                <td class="description-td style-scope patent-text">7.46</td>
                <td class="description-td style-scope patent-text">324.7</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">70</td>
                <td class="description-td style-scope patent-text">12.48</td>
                <td class="description-td style-scope patent-text">8.12</td>
                <td class="description-td style-scope patent-text">411.4</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">77</td>
                <td class="description-td style-scope patent-text">13.30</td>
                <td class="description-td style-scope patent-text">9.77</td>
                <td class="description-td style-scope patent-text">634.8</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">84</td>
                <td class="description-td style-scope patent-text">13.77</td>
                <td class="description-td style-scope patent-text">10.39</td>
                <td class="description-td style-scope patent-text">743.3</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">91</td>
                <td class="description-td style-scope patent-text">14.09</td>
                <td class="description-td style-scope patent-text">10.08</td>
                <td class="description-td style-scope patent-text">715.8</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">95</td>
                <td class="description-td style-scope patent-text">14.70</td>
                <td class="description-td style-scope patent-text">10.30</td>
                <td class="description-td style-scope patent-text">779.8</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">99</td>
                <td class="description-td style-scope patent-text">14.51</td>
                <td class="description-td style-scope patent-text">10.67</td>
                <td class="description-td style-scope patent-text">826.0</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">103</td>
                <td class="description-td style-scope patent-text">13.62</td>
                <td class="description-td style-scope patent-text">10.40</td>
                <td class="description-td style-scope patent-text">736.6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">106</td>
                <td class="description-td style-scope patent-text">14.13</td>
                <td class="description-td style-scope patent-text">10.14</td>
                <td class="description-td style-scope patent-text">726.4</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">110</td>
                <td class="description-td style-scope patent-text">12.70</td>
                <td class="description-td style-scope patent-text">8.42</td>
                <td class="description-td style-scope patent-text">450.2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">113</td>
                <td class="description-td style-scope patent-text">9.61</td>
                <td class="description-td style-scope patent-text">7.96</td>
                <td class="description-td style-scope patent-text">304.5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">119</td>
                <td class="description-td style-scope patent-text">8.78</td>
                <td class="description-td style-scope patent-text">6.77</td>
                <td class="description-td style-scope patent-text">201.2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">126</td>
                <td class="description-td style-scope patent-text">8.67</td>
                <td class="description-td style-scope patent-text">6.33</td>
                <td class="description-td style-scope patent-text">173.7</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">134</td>
                <td class="description-td style-scope patent-text">7.12</td>
                <td class="description-td style-scope patent-text">6.46</td>
                <td class="description-td style-scope patent-text">148.6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">141</td>
                <td class="description-td style-scope patent-text">6.20</td>
                <td class="description-td style-scope patent-text">5.70</td>
                <td class="description-td style-scope patent-text">100.7</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">148</td>
                <td class="description-td style-scope patent-text">6.46</td>
                <td class="description-td style-scope patent-text">5.32</td>
                <td class="description-td style-scope patent-text">91.4</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">154</td>
                <td class="description-td style-scope patent-text">5.65</td>
                <td class="description-td style-scope patent-text">4.78</td>
                <td class="description-td style-scope patent-text">64.5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">162</td>
                <td class="description-td style-scope patent-text">5.60</td>
                <td class="description-td style-scope patent-text">4.30</td>
                <td class="description-td style-scope patent-text">51.8</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">167</td>
                <td class="description-td style-scope patent-text">5.70</td>
                <td class="description-td style-scope patent-text">4.00</td>
                <td class="description-td style-scope patent-text">45.6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">173</td>
                <td class="description-td style-scope patent-text">5.50</td>
                <td class="description-td style-scope patent-text">3.80</td>
                <td class="description-td style-scope patent-text">39.7</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">180</td>
                <td class="description-td style-scope patent-text">5.60</td>
                <td class="description-td style-scope patent-text">4.15</td>
                <td class="description-td style-scope patent-text">48.2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <heading id="h-0011" class="style-scope patent-text">Example 3</heading>
    <heading id="h-0012" class="style-scope patent-text">PSMA ADC is Effective to Treat Tumors in Animals Which Failed Docetaxel Treatment</heading>
    <div id="p-0184" num="0194" class="description-paragraph style-scope patent-text">An experiment (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 10</figref>) was designed to evaluate PSMA ADC effectiveness after docetaxel treatment failure. Male athymic nude mice, 6-8 weeks old, obtained from Charles River Laboratories, Inc. were implanted subcutaneously with 5 million C4-2 cells. At <figure-callout id="14" label="day" filenames="US09242012-20160126-D00008.png,US09242012-20160126-D00016.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 14, animals having a tumor volume between 100-200 mm<sup class="style-scope patent-text">3 </sup>were randomized (randomization #1) into two treatment arms: (1) vehicle control (PBS buffer, n=10); (2) docetaxel at 2 mg/kg/IV weekly (n=50) according to tumor volume. The mean tumor volume was 138.0 and 138.1 mm<sup class="style-scope patent-text">3 </sup>for the vehicle control and docetaxel treatment groups, respectively, at randomization.</div>
    <div id="p-0185" num="0195" class="description-paragraph style-scope patent-text">All animals then received intravenous injections of PBS or docetaxel (Sigma, St. Louis, Mo.) at 2 mg/kg via tail vein in a volume of 0.1 mL. Tumor sizes were measured twice per week after tumor implantation, and the average tumor volume for the two groups before the second randomization was initiated were plotted (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 11</figref>). Overall, docetaxel treatment reduced tumor growth compared to control.</div>
    <div id="p-0186" num="0196" class="description-paragraph style-scope patent-text">When the tumor volume of an animal in the docetaxel treatment group exceeded 400 mm<sup class="style-scope patent-text">3</sup>, this animal was randomized, at a 1:1 ratio, into one of the two treatment subgroups: one group continued to receive docetaxel at 2 mg/kg, and the second group was switched to PSMA ADC treatment at 6 mg/kg/IV weekly. Animals were randomized into these two treatment subgroups continuously over the period of 28 days to 70 days post tumor implantation. By the end of <figure-callout id="70" label="day" filenames="US09242012-20160126-D00006.png,US09242012-20160126-D00010.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 70, there were 28 mice whose tumor volume had exceeded 400 mm<sup class="style-scope patent-text">3</sup>, with 14 mice randomized into the PSMA ADC treatment subgroup (mean tumor volume of 695 mm<sup class="style-scope patent-text">3 </sup>and 14 mice randomized into the continued docetaxel treatment subgroup (mean tumor volume of 642 mm<sup class="style-scope patent-text">3 </sup>with a p-value of 0.28 (student t-test)).</div>
    <div id="p-0187" num="0197" class="description-paragraph style-scope patent-text">The effect of PSMA ADC treatment on tumor growth after docetaxel failure was assessed by comparing tumor reduction after the second randomization. The tumor volumes of animals in the two subgroups were plotted (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 12</figref>). The results show that tumors grew continuously while on docetaxel treatment. However, the tumor volume was significantly reduced when PSMA ADC treatment was initiated. Therefore, PSMA ADC is effective in treating animals with tumors which failed docetaxel treatment.</div>
    <heading id="h-0013" class="style-scope patent-text">Example 4</heading>
    <heading id="h-0014" class="style-scope patent-text">In Vivo Study Design</heading>
    <div id="p-0188" num="0198" class="description-paragraph style-scope patent-text">The study design is shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 13</figref>. Male athymic nude mice, 6-8 weeks old, obtained from Charles River Laboratories, Inc., were implanted with Matrigel subcutaneously into the right flank of each mouse with 5 million C4-2 cells (androgen-independent human prostate cancer cell line). At <figure-callout id="14" label="day" filenames="US09242012-20160126-D00008.png,US09242012-20160126-D00016.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 14, tumor size was measured by length and width in mm (millimeter). The volume was calculated using the formula: volume (mm<sup class="style-scope patent-text">3</sup>)=[(length)×(width)<sup class="style-scope patent-text">2</sup>]/2. The animals were randomized into two groups with similar tumor volume (approximately 138 mm<sup class="style-scope patent-text">3</sup>): vehicle control and docetaxel at 2 mg/kg. Animals were dosed weekly through the tail vein.</div>
    <div id="p-0189" num="0199" class="description-paragraph style-scope patent-text">When the tumor volume of an animal in the docetaxel treatment group exceeded 400 mm<sup class="style-scope patent-text">3</sup>, this animal was randomized, at a 1:1 ratio, into one of the two treatment subgroups: one group continued to receive docetaxel at 2 mg/kg weekly (n=18), and the second group was switched to PSMA ADC treatment at 6 mg/kg/IV weekly (n=18). Mice whose tumors durably responded to docetaxel (≦400 mm<sup class="style-scope patent-text">3</sup>) continued to receive docetaxel at 2 mg/kg/IV weekly. Treatment effects were assessed by measuring tumor volume and overall survival. Animal body weight was also measured. Animals with tumor size ≧2000 mm<sup class="style-scope patent-text">3 </sup>were sacrificed.</div>
    <div id="p-0190" num="0200" class="description-paragraph style-scope patent-text">Mean tumor volumes were 515±103 mm<sup class="style-scope patent-text">3 </sup>and 495±80 mm<sup class="style-scope patent-text">3 </sup>for the PSMA ADC and continued docetaxel treatment groups, respectively, at the second randomization (p=0.518) (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 14</figref>). At end of the experiment, the survival rate was 100% for animals in the PSMA ADC treatment group (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 17</figref>); 94% of these mice had tumor sizes &lt;100 mm<sup class="style-scope patent-text">3 </sup>(<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 16</figref>). In contrast, the survival rate was 11% in the continued docetaxel treatment group. Therefore, PSMA ADC treatment significantly shrank tumors and increased overall survival of animals compared to continued docetaxel treatment (p&lt;0.0001). PSMA ADC was generally well tolerated in the animal (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 18</figref>). PSMA ADC demonstrated potent antitumor activity against large prostate tumors that had progressed following docetaxel treatment. Treatment with PSMA ADC significantly extended survival.</div>
    <heading id="h-0015" class="style-scope patent-text">Example 5</heading>
    <heading id="h-0016" class="style-scope patent-text">A <figure-callout id="1" label="Phase" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Phase</a></figure-callout> 1 Dose-Escalation Study of PSMA ADC in Subjects with Progressive, Castration-Resistant, Metastatic Prostate Cancer</heading>
    <div id="p-0191" num="0201" class="description-paragraph style-scope patent-text">An open-label, dose-<figure-callout id="1" label="escalation phase" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">escalation phase</a></figure-callout> 1 study of PSMA ADC IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy is initiated. Subjects will receive either 0.4 mg/kg, 0.7 mg/kg, 1.1 mg/kg, 1.8 mg/kg or 2.9 mg/kg by constant-rate 90-minute IV infusion of PSMA ADC in saline (at <figure-callout id="0" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="3" label="weeks" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="6" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> </a></figure-callout> 0, 3, 6 and 9). Additional subjects who meet the inclusion/exclusion criteria of the study will be entered into the maximum tolerated dose (MTD) cohort until it is filled per the criteria below. The maximum duration of the treatment for each subject will be 12 weeks.</div>
    <div id="p-0192" num="0202" class="description-paragraph style-scope patent-text">The dose-limiting toxicity (DLT) is defined as any National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) toxicity grade ≧3 as well as <figure-callout id="2" label="grade" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 2 allergic/immunologic toxicity (except isolated fever) for which a causal relationship to the study drug cannot be excluded. In this study, DLT will be determined after the first dose of each cohort. A dose-escalation scheme, based on the DLT, will be employed. Once an MTD is determined or the highest dose cohort is shown safe, additional subjects will be treated. These subjects will be chosen using the same inclusion/exclusion criteria employed for the study. If two or more subjects in the lowest dose cohort experience a DLT, a cohort will be enrolled at 0.2 mg/kg of PSMA ADC.</div>
    <div id="p-0193" num="0203" class="description-paragraph style-scope patent-text">Radiologic imaging will be obtained at screening and <figure-callout id="12" label="week" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">week</a></figure-callout> 12. Blood samples (5 mL) for drug concentrations will be obtained prior to infusion initiation and at 90 minutes and 4, 6, 24, 48, 96, 168, 336 and 504 hours after infusion initiation at <figure-callout id="0" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="6" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> 0 and 6. Serum concentrations of study drug (ADC) and total antibody (PSMA−mAb+ADC) will be measured by a fully-validated ELISA method and serum concentrations of free toxin (MMAE) will be measured by a fully-validated liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) method Immunogenicity will be assessed by a fully validated ELISA method for day 1 (predose) and <figure-callout id="12" label="week" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">week</a></figure-callout> 12 time points.</div>
    <div id="p-0194" num="0204" class="description-paragraph style-scope patent-text">All subjects who have completed the 12-week study, and who, in the opinion of the investigator, are likely to benefit from continued treatment with PSMA ADC, will be offered enrollment into an extension study.</div>
    <div id="h-0017" num="0000" class="description-paragraph style-scope patent-text">Diagnosis and Inclusion Criteria:</div>
    <div id="p-0195" num="0000" class="description-paragraph style-scope patent-text">
      </div> <ul class="style-scope patent-text">
        <li id="ul0003-0001" num="0000" class="style-scope patent-text">
          <ul class="style-scope patent-text">
            <li id="ul0004-0001" num="0205" class="style-scope patent-text">1. Males, age ≧18 years (or minimum adult age as determined by local regulatory authorities)</li>
            <li id="ul0004-0002" num="0206" class="style-scope patent-text">2. Eastern Cooperative Oncology Group (ECOG) status of 0 or 1</li>
            <li id="ul0004-0003" num="0207" class="style-scope patent-text">3. Histologic confirmation of prostate cancer</li>
            <li id="ul0004-0004" num="0208" class="style-scope patent-text">4. A diagnosis of progressive, castration-resistant, metastatic prostate cancer based on evidence of metastatic disease on bone scan, CT scan, or MRI at any time following the initial diagnosis of prostate cancer</li>
            <li id="ul0004-0005" num="0209" class="style-scope patent-text">5. Prior androgen-deprivation therapy consisting of either orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonists, with or without an antiandrogen and a castrate level of serum testosterone (&lt;50 ng/mL)</li>
            <li id="ul0004-0006" num="0210" class="style-scope patent-text">6. Prior therapy with taxane</li>
            <li id="ul0004-0007" num="0211" class="style-scope patent-text">7. Lab requirements:
        <ul class="style-scope patent-text"> <li id="ul0005-0001" num="0212" class="style-scope patent-text">White blood count (WBC)≧3000/mm<sup class="style-scope patent-text">3 </sup> </li> <li id="ul0005-0002" num="0213" class="style-scope patent-text">Absolute neutrophil count (ANC)≧1000/mm<sup class="style-scope patent-text">3 </sup> </li> <li id="ul0005-0003" num="0214" class="style-scope patent-text">Platelets (Plt)≧100,000 mm<sup class="style-scope patent-text">3 </sup> </li> <li id="ul0005-0004" num="0215" class="style-scope patent-text">Hemoglobin (Hgb)≧10 g/dL</li> <li id="ul0005-0005" num="0216" class="style-scope patent-text">Total bilirubin ≦2.0 mg/dL</li> <li id="ul0005-0006" num="0217" class="style-scope patent-text">Serum alanine transferase/serum aspartate transaminase (ALT/AST)≦2× the upper limit of normal</li> <li id="ul0005-0007" num="0218" class="style-scope patent-text">Serum creatinine≦2.0 mg/dL and a calculated glomerular filtration rate (GFR) of &gt;60 mL/min
<br class="style-scope patent-text">
Exclusion Criteria:
</li> </ul>
        </li>
            <li id="ul0004-0008" num="0219" class="style-scope patent-text">1. Nonprostate primary malignant neoplasm except for nonmelanoma skin cancer or low-grade papillary transitional cell carcinoma of the bladder within previous five years</li>
            <li id="ul0004-0009" num="0220" class="style-scope patent-text">2. Clinically significant cardiac disease (New York Heart Association Class III/IV) or severe debilitating pulmonary disease</li>
            <li id="ul0004-0010" num="0221" class="style-scope patent-text">3. Radiation therapy or cytotoxic chemotherapy within previous four weeks</li>
            <li id="ul0004-0011" num="0222" class="style-scope patent-text">4. Active central nervous system (CNS) or epidural metastatic disease</li>
            <li id="ul0004-0012" num="0223" class="style-scope patent-text">5. An infection requiring antibiotic treatment within seven days prior to screening and/or antibiotic treatment initiated up to the time of the first dose</li>
            <li id="ul0004-0013" num="0224" class="style-scope patent-text">6. Peripheral neuropathy of <figure-callout id="2" label="grade" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 2 or higher with any association to taxane therapy at the start of the study</li>
            <li id="ul0004-0014" num="0225" class="style-scope patent-text">7. Any prior treatment with any other therapy targeting PSMA</li>
            <li id="ul0004-0015" num="0226" class="style-scope patent-text">8. Subjects must not have participated in any other research study within 30 days</li>
            <li id="ul0004-0016" num="0227" class="style-scope patent-text">9. Prior therapy with investigational or approved mAbs or Ig fusion proteins</li>
            <li id="ul0004-0017" num="0228" class="style-scope patent-text">10. Subjects with QTc≧500 msec</li>
            <li id="ul0004-0018" num="0229" class="style-scope patent-text">11. Weight &gt;225 pounds</li>
          </ul>
        </li>
      </ul>
    
    <heading id="h-0018" class="style-scope patent-text">Example 6</heading>
    <heading id="h-0019" class="style-scope patent-text">Two-Stage Clinical Study Design</heading>
    <div id="p-0196" num="0230" class="description-paragraph style-scope patent-text">A <figure-callout id="1" label="phase" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">phase</a></figure-callout> 1, open-label, dose-escalation clinical trial will include men with progressive, hormone-refractory prostate cancer, and who had prior therapy with taxane chemotherapy drugs. The study will investigate the duration of clinical benefit derived from PSMA ADC treatment while also assessing the investigational drug's safety and tolerability. The initial 12-week period will evaluate up to five intravenous doses of PSMA ADC, individually administered at three-week intervals. The study will include evaluations of pharmacodynamics, radiographic changes in tumor burden, and changes in prostate-specific antigen (PSA) and circulating tumor cell (CTC) values compared to baseline.</div>
    <div id="p-0197" num="0231" class="description-paragraph style-scope patent-text">Following the 12-week period, patients will be offered, at their physician's discretion, the option to continue treatment for an additional 39 weeks with the same dose of PSMA ADC as administered in their initial cohort. Qualified subjects will receive up to 13 additional doses of PSMA ADC at three-week intervals.</div>
    <heading id="h-0020" class="style-scope patent-text">Example 7</heading>
    <heading id="h-0021" class="style-scope patent-text">A <figure-callout id="1" label="Phase" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Phase</a></figure-callout> 1 Dose-Escalation Study of PSMA ADC in Subjects with Progressive, Castration-Resistant, Metastatic Prostate Cancer</heading>
    <div id="p-0198" num="0232" class="description-paragraph style-scope patent-text">An open-label, dose-<figure-callout id="1" label="escalation phase" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">escalation phase</a></figure-callout> 1 study of PSMA ADC IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy was initiated. Subjects received either 0.4 mg/kg, 0.7 mg/kg, 1.1 mg/kg or 1.8 mg/kg or will receive either 2.4 mg/kg, 3.0 mg/kg, 3.5 mg/kg or 4.0 mg/kg by constant-rate IV infusion of PSMA ADC in saline administered over approximately 90 minutes (at <figure-callout id="0" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="3" label="weeks" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="6" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> </a></figure-callout> 0, 3, 6 and 9). Additional subjects who meet the inclusion/exclusion criteria of the study will be entered into the maximum tolerated dose (MTD) cohort until it is filled per the criteria below. The maximum duration of the treatment for each subject was/will be 12 weeks.</div>
    <div id="p-0199" num="0233" class="description-paragraph style-scope patent-text">The dose-limiting toxicity (DLT) can be defined as any National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) toxicity grade ≧3 with the following exception: an absolute neutrophil count (ANC)&lt;500 mm<sup class="style-scope patent-text">3 </sup>determined eight days following the first infusion of PSMA ADC. Under this circumstance, a DLT can be defined as a neutrophil count &lt;500 mm<sup class="style-scope patent-text">3 </sup>found on both <figure-callout id="8" label="study days" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="15" label="study days" filenames="US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">study days</a></figure-callout> </a></figure-callout> 8 and 15 following the first infusion of PSMA ADC. A DLT can also be defined as grade ≧2 allergic/immunologic toxicity (except isolated fever) for which a causal relationship to the study drug cannot be excluded. In this study, DLT was/will be determined after the first dose of each cohort. A dose-escalation scheme, based on the DLT, was/will be employed. Once an MTD is determined or the highest dose cohort is shown safe, additional subjects will be treated. These subjects will be chosen using the same inclusion/exclusion criteria employed for the study. If two or more subjects in the lowest dose cohort experience a DLT, a cohort will be enrolled at 0.2 mg/kg of PSMA ADC.</div>
    <div id="p-0200" num="0234" class="description-paragraph style-scope patent-text">Radiologic imaging was/will be obtained prior to infusion and within seven days prior to the <figure-callout id="12" label="week" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">week</a></figure-callout> 12 visit. Blood samples (5 mL) for drug concentrations was/will be obtained at designated time points in <figure-callout id="0" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="3" label="weeks" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="6" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="9" label="weeks" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> </a></figure-callout> </a></figure-callout> 0, 3, 6, 9 and 12 (at <figure-callout id="12" label="week" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">week</a></figure-callout> 12, sampling is at study day 85±one day). At <figure-callout id="0" label="week" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">week</a></figure-callout> 0, samples were/are collected prior to infusion initiation, immediately at the end of infusion, and at four and six hours after the infusion. Samples collected at 24, 48, 96, 168, 336 and 504 hours after infusion initiation may be collected within ±two hours of the designated time point. At <figure-callout id="3" label="weeks" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="6" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="9" label="weeks" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> </a></figure-callout> 3, 6 and 9 only predose samples were/are collected. Serum concentrations of study drug (ADC) and total antibody (PSMA−mAb+ADC) were/will be measured by a fully-validated ELISA method and serum concentrations of free toxin (MMAE) were/will be measured by a fully-validated liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) method. Immunogenicity was/will be assessed by a fully validated ELISA method for day 1 (predose) and <figure-callout id="12" label="week" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">week</a></figure-callout> 12 time points.</div>
    <div id="p-0201" num="0235" class="description-paragraph style-scope patent-text">All subjects who have completed the 12-week study, and who, in the opinion of the investigator, are likely to benefit from continued treatment with PSMA ADC, will be offered enrollment into an extension study.</div>
    <div id="h-0022" num="0000" class="description-paragraph style-scope patent-text">Diagnosis and Inclusion Criteria:</div>
    <div id="p-0202" num="0000" class="description-paragraph style-scope patent-text">
      </div> <ul class="style-scope patent-text">
        <li id="ul0006-0001" num="0000" class="style-scope patent-text">
          <ul class="style-scope patent-text">
            <li id="ul0007-0001" num="0236" class="style-scope patent-text">1. Males, age ≧18 years (or minimum adult age as determined by local regulatory authorities)</li>
            <li id="ul0007-0002" num="0237" class="style-scope patent-text">2. Eastern Cooperative Oncology Group (ECOG) status of 0 or 1</li>
            <li id="ul0007-0003" num="0238" class="style-scope patent-text">3. Histologic confirmation of prostate cancer</li>
            <li id="ul0007-0004" num="0239" class="style-scope patent-text">4. A diagnosis of progressive, castration-resistant, metastatic prostate cancer based on evidence of metastatic disease on bone scan, CT scan, or MRI at any time following the initial diagnosis of prostate cancer</li>
            <li id="ul0007-0005" num="0240" class="style-scope patent-text">5. Prior androgen-deprivation therapy consisting of either orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonists, with or without an antiandrogen and a castrate level of serum testosterone (&lt;50 ng/dL)</li>
            <li id="ul0007-0006" num="0241" class="style-scope patent-text">6. Prior therapy with taxane</li>
            <li id="ul0007-0007" num="0242" class="style-scope patent-text">7. Lab requirements:
        <ul class="style-scope patent-text"> <li id="ul0008-0001" num="0243" class="style-scope patent-text">White blood count (WBC)≧3000/mm<sup class="style-scope patent-text">3 </sup> </li> <li id="ul0008-0002" num="0244" class="style-scope patent-text">Absolute neutrophil count (ANC)≧1000/mm<sup class="style-scope patent-text">3 </sup> </li> <li id="ul0008-0003" num="0245" class="style-scope patent-text">Platelets (Plt)≧100,000 mm<sup class="style-scope patent-text">3 </sup> </li> <li id="ul0008-0004" num="0246" class="style-scope patent-text">Hemoglobin (Hgb)≧9.0 g/dL</li> <li id="ul0008-0005" num="0247" class="style-scope patent-text">Total bilirubin ≦2.0 mg/dL</li> <li id="ul0008-0006" num="0248" class="style-scope patent-text">Serum alanine transferase/serum aspartate transaminase (ALT/AST)≦2× the upper limit of normal (ULN)</li> <li id="ul0008-0007" num="0249" class="style-scope patent-text">Serum creatinine≦2.0 mg/dL and a calculated glomerular filtration rate (GFR) of &gt;60 mL/min
<br class="style-scope patent-text">
Exclusion Criteria:
</li> </ul>
        </li>
            <li id="ul0007-0008" num="0250" class="style-scope patent-text">1. Nonprostate primary malignant neoplasm except for nonmelanoma skin cancer or low-grade papillary transitional cell carcinoma of the bladder within previous five years</li>
            <li id="ul0007-0009" num="0251" class="style-scope patent-text">2. Clinically significant cardiac disease (New York Heart Association Class III/IV) or severe debilitating pulmonary disease</li>
            <li id="ul0007-0010" num="0252" class="style-scope patent-text">3. Radiation therapy or cytotoxic chemotherapy within previous six weeks</li>
            <li id="ul0007-0011" num="0253" class="style-scope patent-text">4. Active central nervous system (CNS) or epidural metastatic disease</li>
            <li id="ul0007-0012" num="0254" class="style-scope patent-text">5. Evidence of an active infection requiring ongoing antibiotic therapy</li>
            <li id="ul0007-0013" num="0255" class="style-scope patent-text">6. Peripheral neuropathy of <figure-callout id="2" label="grade" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 2 or higher with any association to taxane therapy at the start of the study</li>
            <li id="ul0007-0014" num="0256" class="style-scope patent-text">7. Any prior treatment with any other therapy targeting PSMA</li>
            <li id="ul0007-0015" num="0257" class="style-scope patent-text">8. Subjects must not have participated in any other research study within 30 days</li>
            <li id="ul0007-0016" num="0258" class="style-scope patent-text">9. Prior therapy with investigational or approved mAbs or Ig fusion proteins</li>
            <li id="ul0007-0017" num="0259" class="style-scope patent-text">10. Subjects with QTc≧500 msec</li>
            <li id="ul0007-0018" num="0260" class="style-scope patent-text">11. History of pancreatitis or surgical procedures to the pancreas</li>
            <li id="ul0007-0019" num="0261" class="style-scope patent-text">12. History of drug and/or alcohol abuse</li>
            <li id="ul0007-0020" num="0262" class="style-scope patent-text">13. Any medical condition that in the opinion of the investigator may interfere with a subject's participation in or compliance with the study</li>
          </ul>
        </li>
      </ul>
    
    <heading id="h-0023" class="style-scope patent-text">Example 8</heading>
    <heading id="h-0024" class="style-scope patent-text">Two-Stage Clinical Study Design</heading>
    <div id="p-0203" num="0263" class="description-paragraph style-scope patent-text">A <figure-callout id="1" label="phase" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">phase</a></figure-callout> 1, open-label, dose-escalation clinical trial included men with progressive, hormone-refractory prostate cancer, and who had prior therapy with taxane chemotherapy drugs. The study investigates the duration of clinical benefit derived from PSMA ADC treatment and assesses the investigational drug's safety and tolerability. PSMA ADC was individually administered at three-week intervals during a 12-week period for the evaluation of at least four intravenous doses of PSMA ADC. The study includes evaluations of pharmacodynamics, radiographic changes in tumor burden, and changes in prostate-specific antigen (PSA) and circulating tumor cell (CTC) values compared to baseline.</div>
    <div id="p-0204" num="0264" class="description-paragraph style-scope patent-text">Following the 12-week period, patients will be offered, at their physician's discretion, the option to continue treatment for an additional 39 weeks with the same dose of PSMA ADC as administered in their initial cohort. Qualified subjects will receive up to 13 additional doses of PSMA ADC at three-week intervals.</div>
    <heading id="h-0025" class="style-scope patent-text">Example 9</heading>
    <heading id="h-0026" class="style-scope patent-text">Dosage Regimen and Mode of Administration of PSMA ADC</heading>
    <div id="p-0205" num="0265" class="description-paragraph style-scope patent-text">An open-label, dose-<figure-callout id="1" label="escalation phase" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">escalation phase</a></figure-callout> 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy is initiated. Intravenous (IV) infusions of PSMA ADC will be administered to subjects in four cycles. In cohorts 1-8, IV infusions of PSMA ADC will be administered once at the start of a cycle (<figure-callout id="3" label="duration" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">duration</a></figure-callout> 3 weeks or Q3 W; <figure-callout id="1" label="weeks" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="7" label="weeks" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> 1, 4, 7 and 10) for a total of 4 doses (4 cycles) as eight progressively enrolled treatment groups: 0.4 mg/kg, 0.7 mg/kg, 1.1 mg/kg, 1.8 mg/kg, 2.4 mg/kg, 3.0 mg/kg, 3.5 mg/kg or 4.0 mg/kg. In cohorts 9-12, IV infusions of PSMA ADC will be administered to subjects once every week for the first three weeks of a four week cycle for a total of 12 doses (4 cycles or 4QW with a dose during <figure-callout id="1" label="week" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="2" label="week" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="3" label="week" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">week</a></figure-callout> </a></figure-callout> </a></figure-callout> 1, 2 and 3 in <figure-callout id="1" label="cycle" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">cycle</a></figure-callout> 1; weeks, 5, 6 and 7 in <figure-callout id="2" label="cycle" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">cycle</a></figure-callout> 2; <figure-callout id="9" label="weeks" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="10" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="11" label="weeks" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> </a></figure-callout> 9, 10 and 11 in <figure-callout id="3" label="cycle" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">cycle</a></figure-callout> 3; and <figure-callout id="14" label="weeks" filenames="US09242012-20160126-D00008.png,US09242012-20160126-D00016.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="15" label="weeks" filenames="US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> 13, 14 and 15 in cycle 4; no doses will be administered during <figure-callout id="8" label="weeks" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="12" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="16" label="weeks" filenames="US09242012-20160126-D00008.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> </a></figure-callout> 4, 8, 12 and 16 in <figure-callout id="1" label="cycles" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="2" label="cycles" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="3" label="cycles" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">cycles</a></figure-callout> </a></figure-callout> </a></figure-callout> 1, 2, 3 and 4, respectively) as four progressively enrolled treatment groups: 0.6 mg/kg, 0.9 mg/kg, 1.2 mg/kg and 1.5 mg/kg. For all treatments, PSMA ADC will be administered in saline over approximately 90 minutes. Additional subjects who meet the inclusion/exclusion criteria of the study will be entered into the MTD for each dosing regimen until it is filled as per the criteria below. The maximum duration of the treatment for subjects in cohorts 1-8 will be 13 weeks and for subjects in cohorts 9-12, 17 weeks.</div>
    <div id="p-0206" num="0266" class="description-paragraph style-scope patent-text">The dose-limiting toxicity (DLT) will be defined as any National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) toxicity grade ≧3 with the following exception: an absolute neutrophil count (ANC)&lt;500 mm<sup class="style-scope patent-text">3</sup>. For all cohorts, a DLT will be defined as a neutrophil count &lt;500 mm<sup class="style-scope patent-text">3 </sup>that persist upon <figure-callout id="3" label="repeat determination" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">repeat determination</a></figure-callout> 3 to 7 days following final PSMA ADC administration within the first cycle. For cohorts 9-12 an ANC&lt;500 mm<sup class="style-scope patent-text">3 </sup>prior to any dose in the first cycle is a DLT. A DLT is also defined as grade ≧2 allergic/immunologic toxicity (except isolated fever) for which a causal relationship to the study drug cannot be excluded. In this study, DLT will be determined after the first cycle of each cohort. A dose-escalation scheme, based on the DLT, will be employed. Determinations of DLT will occur as a separate consideration for cohorts 1-8 and 9-12. A DLT determination for cohort 1-8 will not influence enrollment in cohorts 9-12. Once an MTD is determined or the highest dose cohort is shown safe, additional subjects will be treated. These subjects will be chosen using the same inclusion/exclusion criteria employed for the study.</div>
    <div id="p-0207" num="0267" class="description-paragraph style-scope patent-text">For subjects in cohorts 1-8, radiologic imaging will be obtained prior to infusion and within seven days prior to the week 13 visit. Blood samples (5 mL) for drug concentrations will be obtained at time points in <figure-callout id="0" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="1" label="weeks" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="7" label="weeks" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="10" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> </a></figure-callout> </a></figure-callout> 0, 1, 4, 7, 10 and 13 (at week 13, sampling is at study day 85±one day). At <figure-callout id="1" label="week" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">week</a></figure-callout> 1, samples are collected prior to infusion initiation, immediately at the end of infusion, and at four and six hours after the infusion. Samples collected at 24, 48, 96, 168, 336 and 504 hours after infusion initiation may be collected within ±two hours of the designated time point. At <figure-callout id="7" label="weeks" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="10" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00006.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> 4, 7 and 10 only predose samples are collected. For subjects in cohorts 9-12, radiologic imaging will be obtained prior to the first infusion (week 1) and within seven days prior to the week 17 visit. Blood samples (5 mL) for drug concentrations will be obtained at designated time points: for week 1 (cycle 1) immediately prior to infusion initiation, immediately at the end of the infusion, and at four and at six hours after the infusion. Samples collected at 24, 48 and 96 hours after infusion initiation may be collected within ±two hours of the designated time point. Samples collected at <figure-callout id="2" label="weeks" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="3" label="weeks" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="5" label="weeks" filenames="US09242012-20160126-D00004.png,US09242012-20160126-D00016.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> </a></figure-callout> 2, 3 and 5 are collected prior to infusion. Samples are also to be obtained at week 4. Serum concentrations of study drug (ADC) and total antibody (PSMA−mAb+ADC) will be measured by a fully-validated ELISA method and serum concentrations of free toxin (MMAE) will be measured by a fully-validated liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) method. Immunogenicity will be assessed by a fully validated ELISA method for day 1 (predose) and week 13 time points for cohorts 1-8 and study day 1 (predose) and week 17 for cohorts 9-12.</div>
    <div id="p-0208" num="0268" class="description-paragraph style-scope patent-text">All subjects who have completed the 12-week study, and who, in the opinion of the investigator, are likely to benefit from continued treatment with PSMA ADC, will be offered enrollment into an extension study.</div>
    <div id="h-0027" num="0000" class="description-paragraph style-scope patent-text">Diagnosis and Inclusion Criteria:</div>
    <div id="p-0209" num="0000" class="description-paragraph style-scope patent-text">
      </div> <ul class="style-scope patent-text">
        <li id="ul0009-0001" num="0000" class="style-scope patent-text">
          <ul class="style-scope patent-text">
            <li id="ul0010-0001" num="0269" class="style-scope patent-text">1. Males, age ≧18 years (or minimum adult age as determined by local regulatory authorities)</li>
            <li id="ul0010-0002" num="0270" class="style-scope patent-text">2. Eastern Cooperative Oncology Group (ECOG) status of 0 or 1</li>
            <li id="ul0010-0003" num="0271" class="style-scope patent-text">3. Histologic confirmation of prostate cancer</li>
            <li id="ul0010-0004" num="0272" class="style-scope patent-text">4. A diagnosis of progressive, castration-resistant, metastatic prostate cancer based on evidence of metastatic disease on bone scan, CT scan, or MRI at any time following the initial diagnosis of prostate cancer</li>
            <li id="ul0010-0005" num="0273" class="style-scope patent-text">5. Prior androgen-deprivation therapy consisting of either orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonists, with or without an antiandrogen and a castrate level of serum testosterone (&lt;50 ng/dL)</li>
            <li id="ul0010-0006" num="0274" class="style-scope patent-text">6. Prior therapy with taxane</li>
            <li id="ul0010-0007" num="0275" class="style-scope patent-text">7. Lab requirements:
        <ul class="style-scope patent-text"> <li id="ul0011-0001" num="0276" class="style-scope patent-text">White blood count (WBC)≧3000/mm<sup class="style-scope patent-text">3 </sup> </li> <li id="ul0011-0002" num="0277" class="style-scope patent-text">Absolute neutrophil count (ANC)≧1000/mm<sup class="style-scope patent-text">3 </sup> </li> <li id="ul0011-0003" num="0278" class="style-scope patent-text">Platelets (Plt)≧100,000 mm<sup class="style-scope patent-text">3 </sup> </li> <li id="ul0011-0004" num="0279" class="style-scope patent-text">Hemoglobin (Hgb)≧9.0 g/dL</li> <li id="ul0011-0005" num="0280" class="style-scope patent-text">Total bilirubin ≦2.0 mg/dL</li> <li id="ul0011-0006" num="0281" class="style-scope patent-text">Serum alanine transferase/serum aspartate transaminase (ALT/AST)≦2× the upper limit of normal (ULN)</li> <li id="ul0011-0007" num="0282" class="style-scope patent-text">Serum creatinine≦2.0 mg/dL and a calculated glomerular filtration rate (GFR) of &gt;60 mL/min
<br class="style-scope patent-text">
Exclusion Criteria:
</li> </ul>
        </li>
            <li id="ul0010-0008" num="0283" class="style-scope patent-text">1. Nonprostate primary malignant neoplasm except for nonmelanoma skin cancer or low-grade papillary transitional cell carcinoma of the bladder within previous five years</li>
            <li id="ul0010-0009" num="0284" class="style-scope patent-text">2. Clinically significant cardiac disease (New York Heart Association Class III/IV) or severe debilitating pulmonary disease</li>
            <li id="ul0010-0010" num="0285" class="style-scope patent-text">3. Radiation therapy or cytotoxic chemotherapy within previous six weeks</li>
            <li id="ul0010-0011" num="0286" class="style-scope patent-text">4. Active central nervous system (CNS) or epidural metastatic disease</li>
            <li id="ul0010-0012" num="0287" class="style-scope patent-text">5. Evidence of an active infection requiring ongoing antibiotic therapy</li>
            <li id="ul0010-0013" num="0288" class="style-scope patent-text">6. Peripheral neuropathy of <figure-callout id="2" label="grade" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 2 or higher with any association to taxane therapy at the start of the study</li>
            <li id="ul0010-0014" num="0289" class="style-scope patent-text">7. Any prior treatment with any other therapy targeting PSMA</li>
            <li id="ul0010-0015" num="0290" class="style-scope patent-text">8. Subjects must not have participated in any other research study within 30 days</li>
            <li id="ul0010-0016" num="0291" class="style-scope patent-text">9. Prior therapy with investigational or approved mAbs or Ig fusion proteins</li>
            <li id="ul0010-0017" num="0292" class="style-scope patent-text">10. Subjects with QTc≧500 msec</li>
            <li id="ul0010-0018" num="0293" class="style-scope patent-text">11. History of pancreatitis or surgical procedures to the pancreas</li>
            <li id="ul0010-0019" num="0294" class="style-scope patent-text">12. History of drug and/or alcohol abuse</li>
            <li id="ul0010-0020" num="0295" class="style-scope patent-text">13. Any medical condition that in the opinion of the investigator may interfere with a subject's participation in or compliance with the study.</li>
          </ul>
        </li>
      </ul>
    
    <heading id="h-0028" class="style-scope patent-text">Example 10</heading>
    <heading id="h-0029" class="style-scope patent-text"> <figure-callout id="1" label="Phase" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Phase</a></figure-callout> 1 Dose-Escalation Study of PSMA ADC in Patients with Taxane Refractory Metastatic Prostate Cancer</heading>
    <div id="p-0210" num="0296" class="description-paragraph style-scope patent-text">An open-label, dose-<figure-callout id="1" label="escalation phase" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">escalation phase</a></figure-callout> 1 study of PSMA ADC (comprising MMAE) in patients with taxane refractory metastatic prostate cancer (metCRPC) was initiated. The objectives of the study were to (1) determine a maximum tolerated dose (MTD) for PSMA ADC administered once every 3 weeks; (2) assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PSMA ADC across the dose-escalation range; (3) assess immunogenicity; and (4) assess antitumor activity. PSMA ADC in saline was administered by IV infusion Q3 W for up to 4 cycles. Subjects received either 0.4 mg/kg, 0.7 mg/kg, 1.1 mg/kg, or 1.8 mg/kg or will receive 2.0 mg/kg (at <figure-callout id="1" label="weeks" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="7" label="weeks" filenames="US09242012-20160126-D00004.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">weeks</a></figure-callout> </a></figure-callout> 1, 4, 7 and 10).</div>
    <div id="p-0211" num="0297" class="description-paragraph style-scope patent-text">Adverse events, PK, PSA, circulating tumor cells, clinical disease progression and immunogenic response to PSMA ADC continued to be assessed (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 19-21</figref>). Serum concentrations of PSMA ADC and total antibody were measured by an enzyme-linked immunosorbent assay (ELISA) method, and free MMAE was measured by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) method. Individual patients report bone pain reduction as described below.</div>
    <div id="p-0212" num="0298" class="description-paragraph style-scope patent-text">The demographics of 15 subjects enrolled in the four dosing cohorts (0.4, 0.7, 1.1 and 1.8 mg/kg) were similar. Treatment has been generally well tolerated and the most common laboratory abnormalities were reversible changes in liver and hematological parameters. Exposure to PSMA ADC and serum half life (t½) increased in a dose-proportional manner Similar PK metrics were observed after the first and third doses. Exposure to free MMAE was also dose proportional and approximately &lt;0.1% of PSMA ADC.</div>
    <div id="p-0213" num="0299" class="description-paragraph style-scope patent-text">PSMA ADC has been generally well-tolerated at doses ≦1.8 mg/kg, and antitumor activity was observed at 1.8 mg/kg. PSMA ADC appears to exhibit dose-proportional PK and limited release of free MMAE.</div>
    <div id="h-0030" num="0000" class="description-paragraph style-scope patent-text">Diagnosis and Inclusion Criteria:</div>
    <div id="h-0031" num="0000" class="description-paragraph style-scope patent-text">1. Males, age ≧18 years (or minimum adult age as determined by local regulatory authorities)</div>
    <div id="h-0032" num="0000" class="description-paragraph style-scope patent-text">2. Eastern Cooperative Oncology Group (ECOG) status of 0 or 1</div>
    <div id="h-0033" num="0000" class="description-paragraph style-scope patent-text">3. Histological, pathological and/or cytological confirmation of prostate cancer</div>
    <div id="h-0034" num="0000" class="description-paragraph style-scope patent-text">4. Diagnosis of progressive, castration-resistant, metastatic prostate cancer based on evidence of metastatic disease</div>
    <div id="h-0035" num="0000" class="description-paragraph style-scope patent-text">5. Prior and/or ongoing androgen-deprivation therapy and a castrate level of serum testosterone (&lt;50 ng/dL)</div>
    <div id="h-0036" num="0000" class="description-paragraph style-scope patent-text">6. Prior chemotherapy regimens at least one of which contains taxane</div>
    <div id="h-0037" num="0000" class="description-paragraph style-scope patent-text">7. Adequate organ function</div>
    <div id="h-0038" num="0000" class="description-paragraph style-scope patent-text">Exclusion Criteria:</div>
    <div id="h-0039" num="0000" class="description-paragraph style-scope patent-text">1. Radiation therapy or cytotoxic therapy within previous 6 weeks</div>
    <div id="h-0040" num="0000" class="description-paragraph style-scope patent-text">Study Endpoints:</div>
    <div id="h-0041" num="0000" class="description-paragraph style-scope patent-text">Safety and Tolerability of PSMA ADC</div>
    <div id="h-0042" num="0000" class="description-paragraph style-scope patent-text">Hematology, blood chemistry, and urine values; periodic measurements of vital signs and electrocardiograms (ECGs); and the findings of physical examinations</div>
    <div id="h-0043" num="0000" class="description-paragraph style-scope patent-text">Pharmacokinetic Assessments</div>
    <div id="h-0044" num="0000" class="description-paragraph style-scope patent-text">Concentrations of PSMA ADC and its components</div>
    <div id="h-0045" num="0000" class="description-paragraph style-scope patent-text">Antibodies to PSMA ADC</div>
    <div id="h-0046" num="0000" class="description-paragraph style-scope patent-text">Assessments for Antitumor Activity</div>
    <div id="h-0047" num="0000" class="description-paragraph style-scope patent-text">Changes in serum prostate-specific antigen (PSA)</div>
    <div id="h-0048" num="0000" class="description-paragraph style-scope patent-text">Changes in the number of circulating tumor cells (CTC) from baseline</div>
    <div id="h-0049" num="0000" class="description-paragraph style-scope patent-text">Change from baseline in radiographic imaging of metastasis (bone scan, computed tomography (CT) scan, magnetic resonance imaging (MRI))</div>
    <div id="h-0050" num="0000" class="description-paragraph style-scope patent-text">Assessment of Pain</div>
    <div id="p-0214" num="0300" class="description-paragraph style-scope patent-text">A modification of the Brief Pain Inventory (BPI) assessment developed by MD Anderson Cancer Center was administered (shown below) at baseline, prior to the second dose (week four), and at week 13/End of Study Visit. All subjects who received at least one dose of PSMA ADC was included in the analyses.
<br class="style-scope patent-text">
Modified Brief Pain Inventory (BPI) Assessment:
<br class="style-scope patent-text">
1. Please rate your pain by circling the one number that best describes your pain at its worst in the last 24 hours:
<br class="style-scope patent-text">
0 1 2 3 4 5 6 7 8 9 10 (0 for No Pain, 10 for Pain as bad as you can imagine)
<br class="style-scope patent-text">
2. Please rate your pain by circling the one number that best describes your pain at its least in the last 24 hours.
<br class="style-scope patent-text">
0 1 2 3 4 5 6 7 8 9 10 (0 for No Pain, 10 for Pain as bad as you can imagine)
<br class="style-scope patent-text">
3. Please rate your pain by circling the one number that best describes your pain on the average.
<br class="style-scope patent-text">
0 1 2 3 4 5 6 7 8 9 10 (0 for No Pain, 10 for Pain as bad as you can imagine)
<br class="style-scope patent-text">
4. Please rate your pain by circling the one number that tells how much pain you have right now.
<br class="style-scope patent-text">
0 1 2 3 4 5 6 7 8 9 10 (0 for No Pain, 10 for Pain as bad as you can imagine)
</div>
    <div id="p-0215" num="0301" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00003" num="00003" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="7" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="7" rowsep="1" class="description-td style-scope patent-text" colspan="7">TABLE 3</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="7" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="7"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Dose, mg/kg</td>
                <td class="description-td style-scope patent-text">0.4</td>
                <td class="description-td style-scope patent-text">0.7</td>
                <td class="description-td style-scope patent-text">1.1</td>
                <td class="description-td style-scope patent-text">1.6</td>
                <td class="description-td style-scope patent-text">1.8</td>
                <td class="description-td style-scope patent-text">2.0</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="7" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="7"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Number of <figure-callout id="3" label="subjects" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00014.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">subjects</a></figure-callout> </td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">9</td>
                <td class="description-td style-scope patent-text">Enrolling</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">in main study</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Number of <figure-callout id="1" label="subjects" filenames="US09242012-20160126-D00005.png,US09242012-20160126-D00007.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">subjects</a></figure-callout> </td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">0</td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">entered into</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">extension study</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="7" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="7"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div id="p-0216" num="0302" class="description-paragraph style-scope patent-text">Each of the foregoing patents, patent applications and references that are recited in this application are herein incorporated in their entirety by reference. However, such recitation is not intended to be an admission that any of the foregoing patents, patent applications and references is a prior art reference. Having described the presently preferred embodiments, and in accordance with the present invention, it is believed that other modifications, variations and changes will be suggested to those skilled in the art in view of the teachings set forth herein. It is, therefore, to be understood that all such variations, modifications, and changes are believed to fall within the scope of the present invention as defined by the appended claims.</div>
    
  </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(32)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result" hidden="">translated from </div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PCLM91651807" lang="EN" load-source="patent-office" class="claims style-scope patent-text">
    <claim-statement class="style-scope patent-text">We claim: </claim-statement>
    <div class="claim style-scope patent-text"> <div id="CLM-00001" num="00001" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">1. A method of treating a subject having progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy, the method comprising:
<div class="claim-text style-scope patent-text">selecting a subject having progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy, and</div>
<div class="claim-text style-scope patent-text">administering an effective amount of a prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) to the subject, wherein the PSMA ADC comprises a human monoclonal antibody to PSMA conjugated to monomethylauristatin norephedrine (MMAE) or monomethylauristatin phenylalanine (MMAF), and wherein the effective amount is sufficient to 1) delay or inhibit progression of the cancer, 2) increase survival of the subject as compared to the median survival of subjects who have not been treated with the PSMA ADC and who have progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy, 3) decrease a circulating level of circulating tumor cells (CTCs) compared to a baseline level, or 4) decrease or stabilize a serum level of PSA compared to a baseline level of PSA.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00002" num="00002" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">2. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the effective amount is sufficient to delay or inhibit progression of the cancer.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00003" num="00003" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">3. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the effective amount is sufficient to increase survival of the subject as compared to the median survival of subjects who have not been treated with the PSMA ADC and who have progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00004" num="00004" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">4. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the effective amount is sufficient to decrease the circulating level of CTCs as compared to the baseline level.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00005" num="00005" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">5. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the effective amount is sufficient to decrease or stabilize the serum level of PSA compared to the baseline level of PSA.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00006" num="00006" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">6. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the human antibody to PSMA is conjugated to MMAE or MMAF via a valine-citrulline linker.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00007" num="00007" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">7. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the taxane is docetaxel.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00008" num="00008" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">8. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the taxane is paclitaxel.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00009" num="00009" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">9. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the human antibody is an IgG1 comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 2, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 8.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00010" num="00010" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">10. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the delay or inhibition of progression of the cancer is demonstrated by radiographic image changes in tumor burden compared to a baseline radiographic image in the subject prior to the administration of the PSMA ADC.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00011" num="00011" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">11. The method of <claim-ref idref="CLM-00010" class="style-scope patent-text">claim 10</claim-ref>, wherein the radiographic image change is a change of at least 10%.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00012" num="00012" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">12. The method of <claim-ref idref="CLM-00011" class="style-scope patent-text">claim 11</claim-ref>, wherein the radiographic image change is a change of at least 20%.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00013" num="00013" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">13. The method of <claim-ref idref="CLM-00012" class="style-scope patent-text">claim 12</claim-ref>, wherein the radiographic image change is a change of at least 30%.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00014" num="00014" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">14. The method of <claim-ref idref="CLM-00013" class="style-scope patent-text">claim 13</claim-ref>, wherein the radiographic image change is a change of at least 40%.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00015" num="00015" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">15. The method of <claim-ref idref="CLM-00014" class="style-scope patent-text">claim 14</claim-ref>, wherein the radiographic image change is a change of at least 50%.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00016" num="00016" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">16. The method of <claim-ref idref="CLM-00015" class="style-scope patent-text">claim 15</claim-ref>, wherein the radiographic image change is a change of at least 60%.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00017" num="00017" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">17. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the effective amount of the PSMA ADC is a dose of 0.1 mg/kg to 5 mg/kg.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00018" num="00018" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">18. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the effective amount of the PSMA ADC is a dose of 0.2 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.7 mg/kg, 0.9 mg/kg, 1 mg/kg, 1.1 mg/kg, 1.2 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.8 mg/kg, 2 mg/kg, 2.4 mg/kg or 2.9 mg/kg.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00019" num="00019" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">19. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the subject is administered a total of 4 doses.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00020" num="00020" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">20. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the subject is administered a total of 12 doses.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00021" num="00021" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">21. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the subject is administered a total of 17 doses.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00022" num="00022" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">22. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the subject is administered a total of 18 doses.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00023" num="00023" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">23. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the dose is administered at 1, 2, 3 or 4 week intervals.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00024" num="00024" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">24. The method of <claim-ref idref="CLM-00023" class="style-scope patent-text">claim 23</claim-ref>, wherein the dose is administered at 3 week intervals.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00025" num="00025" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">25. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the subject is administered the dose of PSMA ADC once every week for the first three weeks of a four week cycle for a total of 4 cycles.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00026" num="00026" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">26. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the subject is administered 4 doses at 3-week intervals.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00027" num="00027" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">27. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the subject is administered 5 doses at 3-week intervals.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00028" num="00028" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">28. The method of <claim-ref idref="CLM-00026" class="style-scope patent-text">claim 26</claim-ref>, wherein the subject is administered an additional 13 doses at 3-week intervals.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00029" num="00029" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">29. The method of <claim-ref idref="CLM-00027" class="style-scope patent-text">claim 27</claim-ref>, wherein the subject is administered an additional 13 doses at 3-week intervals.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00030" num="00030" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">30. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the subject is administered the PSMA ADC with a dose regimen of q4d×3.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00031" num="00031" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">31. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the subject is administered the PSMA ADC with a dose regimen of q4d×6.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00032" num="00032" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">32. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein the dose is administered intravenously. </div>
    </div>
  </div> </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (86)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1994009820A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1994009820A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-11-05</span>
                    <span class="td style-scope patent-result">1994-05-11</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Prostate-specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1996026272A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1996026272A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-02-24</span>
                    <span class="td style-scope patent-result">1996-08-29</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Prostate-specific membrane antigen and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1996039185A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1996039185A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-06-05</span>
                    <span class="td style-scope patent-result">1996-12-12</span>
                    <span class="td style-scope patent-result">Cornell Research Foundation, Inc.</span>
                    <span class="td style-scope patent-result">Treatment and diagnosis of prostate cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1997004802A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1997004802A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-07-31</span>
                    <span class="td style-scope patent-result">1997-02-13</span>
                    <span class="td style-scope patent-result">Pacific Northwest Cancer Foundation</span>
                    <span class="td style-scope patent-result">Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1997035616A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1997035616A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-03-25</span>
                    <span class="td style-scope patent-result">1997-10-02</span>
                    <span class="td style-scope patent-result">Pacific Northwest Cancer Foundation</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1998002463A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1998002463A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-07-11</span>
                    <span class="td style-scope patent-result">1998-01-22</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">THERAPEUTIC MULTISPECIFIC COMPOUNDS COMPRISED OF ANTI-FCα RECEPTOR ANTIBODIES 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1998003873A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1998003873A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-07-18</span>
                    <span class="td style-scope patent-result">1998-01-29</span>
                    <span class="td style-scope patent-result">Cornell Research Foundation, Inc.</span>
                    <span class="td style-scope patent-result">Treatment and diagnosis of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5804602A/en"><a id="link" href="#" class="style-scope state-modifier">US5804602A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-06-17</span>
                    <span class="td style-scope patent-result">1998-09-08</span>
                    <span class="td style-scope patent-result">Guilford Pharmaceuticals Inc.</span>
                    <span class="td style-scope patent-result">Methods of cancer treatment using naaladase inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5935818A/en"><a id="link" href="#" class="style-scope state-modifier">US5935818A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-02-24</span>
                    <span class="td style-scope patent-result">1999-08-10</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1999047554A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1999047554A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-03-18</span>
                    <span class="td style-scope patent-result">1999-09-23</span>
                    <span class="td style-scope patent-result">Northwest Biotherapeutics, Inc.</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1999056779A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1999056779A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-05-04</span>
                    <span class="td style-scope patent-result">1999-11-11</span>
                    <span class="td style-scope patent-result">Pacific Northwest Cancer Foundation</span>
                    <span class="td style-scope patent-result">Non-invasive methods to detect prostate cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1999061097A2/en"><a id="link" href="#" class="style-scope state-modifier">WO1999061097A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-05-26</span>
                    <span class="td style-scope patent-result">1999-12-02</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Alpha emitting constructs and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000014257A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000014257A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-09-04</span>
                    <span class="td style-scope patent-result">2000-03-16</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Fusion receptors specific for prostate-specific membrane antigen and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000062063A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000062063A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-04-13</span>
                    <span class="td style-scope patent-result">2000-10-19</span>
                    <span class="td style-scope patent-result">Northwest Biotherapeutics, Inc.</span>
                    <span class="td style-scope patent-result">Methods for the diagnosis and treatment of metastatic prostate tumors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000061605A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000061605A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-04-09</span>
                    <span class="td style-scope patent-result">2000-10-19</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Dna encoding the prostate-specific membrane antigen-like gene and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6136311A/en"><a id="link" href="#" class="style-scope state-modifier">US6136311A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-05-06</span>
                    <span class="td style-scope patent-result">2000-10-24</span>
                    <span class="td style-scope patent-result">Cornell Research Foundation, Inc.</span>
                    <span class="td style-scope patent-result">Treatment and diagnosis of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001009192A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2001009192A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-07-29</span>
                    <span class="td style-scope patent-result">2001-02-08</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Human monoclonal antibodies to prostate specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001019956A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001019956A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-09-13</span>
                    <span class="td style-scope patent-result">2001-03-22</span>
                    <span class="td style-scope patent-result">Bander Neil H</span>
                    <span class="td style-scope patent-result">A method for isolation of prostatic epithelial cells from semen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001085798A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2001085798A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-05-08</span>
                    <span class="td style-scope patent-result">2001-11-15</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Human monoclonal antibodies to dendritic cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001087325A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2001087325A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-05-12</span>
                    <span class="td style-scope patent-result">2001-11-22</span>
                    <span class="td style-scope patent-result">Northwest Biotherapeutics, Inc.</span>
                    <span class="td style-scope patent-result">Method to increase class i presentation of exogenous antigens by human dendritic cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002043661A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002043661A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-11-28</span>
                    <span class="td style-scope patent-result">2002-06-06</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Recombinant anti-cd30 antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002088172A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002088172A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-30</span>
                    <span class="td style-scope patent-result">2002-11-07</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Pentapeptide compounds and uses related thereto 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002096460A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2002096460A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-05-30</span>
                    <span class="td style-scope patent-result">2002-12-05</span>
                    <span class="td style-scope patent-result">Cornell Research Foundation, Inc.</span>
                    <span class="td style-scope patent-result">Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002098897A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2002098897A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-01</span>
                    <span class="td style-scope patent-result">2002-12-12</span>
                    <span class="td style-scope patent-result">Cornell Research Foundation, Inc.</span>
                    <span class="td style-scope patent-result">Modified antibodies to prostate-specific membrane antigen and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003024388A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003024388A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-20</span>
                    <span class="td style-scope patent-result">2003-03-27</span>
                    <span class="td style-scope patent-result">Cornell Research Foundation, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions for treating and preventing skin disorders using binding agents specific for psma 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003026577A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003026577A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-24</span>
                    <span class="td style-scope patent-result">2003-04-03</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">P-amidobenzylethers in drug delivery agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003040169A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003040169A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-11-07</span>
                    <span class="td style-scope patent-result">2003-05-15</span>
                    <span class="td style-scope patent-result">Celldex Therapeutics , Inc.</span>
                    <span class="td style-scope patent-result">Human monoclonal antibodies to dendritic cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6569432B1/en"><a id="link" href="#" class="style-scope state-modifier">US6569432B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-02-24</span>
                    <span class="td style-scope patent-result">2003-05-27</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Prostate-specific membrane antigen and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003057921A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2003057921A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-12-26</span>
                    <span class="td style-scope patent-result">2003-07-17</span>
                    <span class="td style-scope patent-result">Sloan Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Dna immunization with libraries of minigenes encoding degenerate variants of major histocompatibility class i restricted epitopes 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003064606A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003064606A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-01-28</span>
                    <span class="td style-scope patent-result">2003-08-07</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Human monoclonal antibodies to prostate specific membrane antigen (psma) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003064612A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003064612A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-01-28</span>
                    <span class="td style-scope patent-result">2003-08-07</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Identification of mutant antigens with enhanced immunogenicity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040024188A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040024188A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-03-25</span>
                    <span class="td style-scope patent-result">2004-02-05</span>
                    <span class="td style-scope patent-result">Northwest Biotherapeutics, Inc.</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004010957A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004010957A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-07-31</span>
                    <span class="td style-scope patent-result">2004-02-05</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040033229A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040033229A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-10-23</span>
                    <span class="td style-scope patent-result">2004-02-19</span>
                    <span class="td style-scope patent-result">Maddon Paul J.</span>
                    <span class="td style-scope patent-result">PSMA antibodies and protein multimers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040120958A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040120958A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-01</span>
                    <span class="td style-scope patent-result">2004-06-24</span>
                    <span class="td style-scope patent-result">Bander Neil H.</span>
                    <span class="td style-scope patent-result">Modified antibodies to prostate-specific membrane antigen and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040136998A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040136998A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-10-30</span>
                    <span class="td style-scope patent-result">2004-07-15</span>
                    <span class="td style-scope patent-result">Bander Neil H.</span>
                    <span class="td style-scope patent-result">Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004063701A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004063701A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-01-10</span>
                    <span class="td style-scope patent-result">2004-07-29</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Methods of diagnosing and treating cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040161776A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040161776A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-10-23</span>
                    <span class="td style-scope patent-result">2004-08-19</span>
                    <span class="td style-scope patent-result">Maddon Paul J.</span>
                    <span class="td style-scope patent-result">PSMA formulations and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004072262A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004072262A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-02-10</span>
                    <span class="td style-scope patent-result">2004-08-26</span>
                    <span class="td style-scope patent-result">Northwest Biotherapeutics, Inc.</span>
                    <span class="td style-scope patent-result">Cultured cd14+ antigen presenting cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004073656A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2004073656A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-02-20</span>
                    <span class="td style-scope patent-result">2004-09-02</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040253246A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040253246A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-02-23</span>
                    <span class="td style-scope patent-result">2004-12-16</span>
                    <span class="td style-scope patent-result">Israeli Ron S.</span>
                    <span class="td style-scope patent-result">Prostate-specific membrane antigen and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005001038A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2005001038A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-05-28</span>
                    <span class="td style-scope patent-result">2005-01-06</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Recombinant anti-cd30 antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1512755A2/en"><a id="link" href="#" class="style-scope state-modifier">EP1512755A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-06-10</span>
                    <span class="td style-scope patent-result">2005-03-09</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Markers for prostate cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1553414A1/en"><a id="link" href="#" class="style-scope state-modifier">EP1553414A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-04-13</span>
                    <span class="td style-scope patent-result">2005-07-13</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Methods for the diagnosis and treatment of metastatic prostate tumors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005070456A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2005070456A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-01-09</span>
                    <span class="td style-scope patent-result">2005-08-04</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005081711A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2005081711A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-11-06</span>
                    <span class="td style-scope patent-result">2005-09-09</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Monomethylvaline compounds capable of conjugation to ligands 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005084390A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2005084390A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-03-02</span>
                    <span class="td style-scope patent-result">2005-09-15</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Partially loaded antibodies and methods of their conjugation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20050215472A1/en"><a id="link" href="#" class="style-scope state-modifier">US20050215472A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-10-23</span>
                    <span class="td style-scope patent-result">2005-09-29</span>
                    <span class="td style-scope patent-result">Psma Development Company, Llc</span>
                    <span class="td style-scope patent-result">PSMA formulations and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6953668B1/en"><a id="link" href="#" class="style-scope state-modifier">US6953668B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-11-05</span>
                    <span class="td style-scope patent-result">2005-10-11</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Prostate-specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005094882A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2005094882A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-03-03</span>
                    <span class="td style-scope patent-result">2005-10-13</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Modified antibodies to prostate-specific membrane antigen and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006002438A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2006002438A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-06-03</span>
                    <span class="td style-scope patent-result">2006-01-05</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Human monoclonal antibodies to fc gamma receptor i (cd64) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006028999A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2006028999A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-09-03</span>
                    <span class="td style-scope patent-result">2006-03-16</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006039418A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2006039418A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-09-30</span>
                    <span class="td style-scope patent-result">2006-04-13</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Human monoclonal antibodies to fc gamma receptor ii (cd32) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20060088539A1/en"><a id="link" href="#" class="style-scope state-modifier">US20060088539A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-01</span>
                    <span class="td style-scope patent-result">2006-04-27</span>
                    <span class="td style-scope patent-result">Neil Bander</span>
                    <span class="td style-scope patent-result">Modified antibodies to prostate-specific membrane antigen and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7070782B1/en"><a id="link" href="#" class="style-scope state-modifier">US7070782B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-11-05</span>
                    <span class="td style-scope patent-result">2006-07-04</span>
                    <span class="td style-scope patent-result">Sloan-Kettering Institute For Cancer Research</span>
                    <span class="td style-scope patent-result">Prostate-specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006076525A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2006076525A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-01-14</span>
                    <span class="td style-scope patent-result">2006-07-20</span>
                    <span class="td style-scope patent-result">Cytogen Corporation</span>
                    <span class="td style-scope patent-result">Combination cancer therapy with anti-psma antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20060177450A1/en"><a id="link" href="#" class="style-scope state-modifier">US20060177450A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-11-05</span>
                    <span class="td style-scope patent-result">2006-08-10</span>
                    <span class="td style-scope patent-result">Israeli Ron S</span>
                    <span class="td style-scope patent-result">Prostate-specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7091186B2/en"><a id="link" href="#" class="style-scope state-modifier">US7091186B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-24</span>
                    <span class="td style-scope patent-result">2006-08-15</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">p-Amidobenzylethers in drug delivery agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006089230A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2006089230A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-02-18</span>
                    <span class="td style-scope patent-result">2006-08-24</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Human monoclonal antibodies to prostate specific membrane antigen (psma) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006089231A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2006089231A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-02-18</span>
                    <span class="td style-scope patent-result">2006-08-24</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1710256A1/en"><a id="link" href="#" class="style-scope state-modifier">EP1710256A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-07-29</span>
                    <span class="td style-scope patent-result">2006-10-11</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Human monoclonal antibodies to prostate specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006110745A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2006110745A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-04-08</span>
                    <span class="td style-scope patent-result">2006-10-19</span>
                    <span class="td style-scope patent-result">Cytogen Corporation</span>
                    <span class="td style-scope patent-result">Conjugated anti-psma antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006132670A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2006132670A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-11-12</span>
                    <span class="td style-scope patent-result">2006-12-14</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Auristatins having an aminobenzoic acid unit at the n terminus 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007002222A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2007002222A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-06-20</span>
                    <span class="td style-scope patent-result">2007-01-04</span>
                    <span class="td style-scope patent-result">Psma Development Company, Llc</span>
                    <span class="td style-scope patent-result">Psma antibody-drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007008603A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2007008603A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-07-07</span>
                    <span class="td style-scope patent-result">2007-01-18</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007008848A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2007008848A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-07-07</span>
                    <span class="td style-scope patent-result">2007-01-18</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007011968A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2007011968A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-07-18</span>
                    <span class="td style-scope patent-result">2007-01-25</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Beta-glucuronide-linker drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007038658A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2007038658A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-09-26</span>
                    <span class="td style-scope patent-result">2007-04-05</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Antibody-drug conjugates and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20070128671A1/en"><a id="link" href="#" class="style-scope state-modifier">US20070128671A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-03-25</span>
                    <span class="td style-scope patent-result">2007-06-07</span>
                    <span class="td style-scope patent-result">Medarex, Inc.</span>
                    <span class="td style-scope patent-result">Monoclonal antibody specific for the extracellular domain of prostate specific membrane antigen 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7256257B2/en"><a id="link" href="#" class="style-scope state-modifier">US7256257B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-30</span>
                    <span class="td style-scope patent-result">2007-08-14</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Pentapeptide compounds and uses related thereto 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007103288A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2007103288A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-03-02</span>
                    <span class="td style-scope patent-result">2007-09-13</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Engineered antibody drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090311225A1/en"><a id="link" href="#" class="style-scope state-modifier">US20090311225A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-11-14</span>
                    <span class="td style-scope patent-result">2009-12-17</span>
                    <span class="td style-scope patent-result">Psma Development Company, Llc</span>
                    <span class="td style-scope patent-result">Compositions of and Methods of Using Stabilized PSMA Dimers 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7750116B1/en"><a id="link" href="#" class="style-scope state-modifier">US7750116B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-02-18</span>
                    <span class="td style-scope patent-result">2010-07-06</span>
                    <span class="td style-scope patent-result">Seattle Genetics, Inc.</span>
                    <span class="td style-scope patent-result">Antibody drug conjugate metabolites 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20110250216A1/en"><a id="link" href="#" class="style-scope state-modifier">US20110250216A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-09-08</span>
                    <span class="td style-scope patent-result">2011-10-13</span>
                    <span class="td style-scope patent-result">Psma Development Company, Llc</span>
                    <span class="td style-scope patent-result">Methods for killing psma-expressing, taxane-resistant cancer cells 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5162504A/en"><a id="link" href="#" class="style-scope state-modifier">US5162504A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-06-03</span>
                    <span class="td style-scope patent-result">1992-11-10</span>
                    <span class="td style-scope patent-result">Cytogen Corporation</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB8823869D0/en"><a id="link" href="#" class="style-scope state-modifier">GB8823869D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-10-12</span>
                    <span class="td style-scope patent-result">1988-11-16</span>
                    <span class="td style-scope patent-result">Medical Res Council</span>
                    <span class="td style-scope patent-result">Production of antibodies 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5175384A/en"><a id="link" href="#" class="style-scope state-modifier">US5175384A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-12-05</span>
                    <span class="td style-scope patent-result">1992-12-29</span>
                    <span class="td style-scope patent-result">Genpharm International</span>
                    <span class="td style-scope patent-result">Transgenic mice depleted in mature t-cells and methods for making transgenic mice 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6150584A/en"><a id="link" href="#" class="style-scope state-modifier">US6150584A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-01-12</span>
                    <span class="td style-scope patent-result">2000-11-21</span>
                    <span class="td style-scope patent-result">Abgenix, Inc.</span>
                    <span class="td style-scope patent-result">Human antibodies derived from immunized xenomice 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5124471A/en"><a id="link" href="#" class="style-scope state-modifier">US5124471A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-03-26</span>
                    <span class="td style-scope patent-result">1992-06-23</span>
                    <span class="td style-scope patent-result">The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services</span>
                    <span class="td style-scope patent-result">Bifunctional dtpa-type ligand 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5545806A/en"><a id="link" href="#" class="style-scope state-modifier">US5545806A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-08-29</span>
                    <span class="td style-scope patent-result">1996-08-13</span>
                    <span class="td style-scope patent-result">Genpharm International, Inc.</span>
                    <span class="td style-scope patent-result">Ransgenic non-human animals for producing heterologous antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5756825A/en"><a id="link" href="#" class="style-scope state-modifier">US5756825A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-09-08</span>
                    <span class="td style-scope patent-result">1998-05-26</span>
                    <span class="td style-scope patent-result">Safavy; Ahmad</span>
                    <span class="td style-scope patent-result">Hydroxamic acid-based bifunctional chelating compounds 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6034065A/en"><a id="link" href="#" class="style-scope state-modifier">US6034065A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-12-03</span>
                    <span class="td style-scope patent-result">2000-03-07</span>
                    <span class="td style-scope patent-result">Arizona Board Of Regents</span>
                    <span class="td style-scope patent-result">Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6214345B1/en"><a id="link" href="#" class="style-scope state-modifier">US6214345B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-05-14</span>
                    <span class="td style-scope patent-result">2001-04-10</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Co.</span>
                    <span class="td style-scope patent-result">Lysosomal enzyme-cleavable antitumor drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0690452A3/en"><a id="link" href="#" class="style-scope state-modifier">EP0690452A3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-06-28</span>
                    <span class="td style-scope patent-result">1999-01-07</span>
                    <span class="td style-scope patent-result">Advanced Micro Devices, Inc.</span>
                    <span class="td style-scope patent-result">Electrically erasable memory and method of erasure 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5994292A/en"><a id="link" href="#" class="style-scope state-modifier">US5994292A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-05-31</span>
                    <span class="td style-scope patent-result">1999-11-30</span>
                    <span class="td style-scope patent-result">The United States Of America As Represented By The Department Of Health And Human Services</span>
                    <span class="td style-scope patent-result">Interferon-inducible protein 10 is a potent inhibitor of angiogenesis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0973540B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0973540B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-25</span>
                    <span class="td style-scope patent-result">2005-11-02</span>
                    <span class="td style-scope patent-result">Arizona Board Of Regents</span>
                    <span class="td style-scope patent-result">Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="nplCitations" class="scroll-target style-scope patent-result">
              Non-Patent Citations (107)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed] "Medarex Announces Filing of Investigational New Drug Application for MDX-070; Fully Human Anti-PSMA Antibody Candidate for Prostate Cancer." Press Release. PR Newswire. Monday, Jan. 6, 2003, 4:36 P.M. 2 pages.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed] "Medarex: Pipeline." Available at http://www.medarex.com/Development/Pipeline.html. Last accessed Mar. 17, 2009.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed] "Promising Findings" from Novel Antibody-Chemotherapeutic MLN2704 Prostate Cancer Clinical Trial . . . PSA Rising. Feb. 22, 2005. Available at http://www.psa-rising.com/med/chemo/millennium05.html. Last accessed Jan. 19, 2010. 8 pages.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed] Latest Cancer Findings Presented at ASCO Meeting by Physician-scientists. Medical News Today. http://www.medicalnewstoday.com/articles/109424.php. Jun. 2, 2008. 3 pages. Last accessed online Oct. 29, 2008.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed] New York-Presbyterian/Weill Cornell Physician-Scientists Present Latest Cancer Findings at American Society of Clinical Oncology (ASCO) Meeting http://www.nyp.org/news/hospital/nypwc-presents-asco.html. May 30, 2008. 3 pages. Last accessed Oct. 29, 2008.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed] NYP/ Weill Cornell physician-scientists present latest cancer findings at ASCO meeting. Bio-Medicine. http://bio-medicine.org/medicine-news-1/NYP-Weill-Cornell-physician-scientists-p . . . May 31, 2008. 4 pages. Last accessed Oct. 29, 2008.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed] Physician-Scientists Present Latest Cancer Findings at ASCO Meeting. Newswise. http://www.newswise.com/articles/view/541288. Released: May 30, 2008. 08:00 ET. 3 pages. Last accessed Oct. 28, 2008.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed] Progenics and Cytogen Report Positive Preclinical Results for Experimental Prostate Cancer Drug-In laboratory studies, human monoclonal antibody killed prost. Progenics Pharmaceuticals, Inc. Press Release. Washington, D.C. Sep. 23, 2002. Available at http://www.lifesciencesworld.com/life-science-news/view/535?page=1495. Last accessed Jul. 26, 2011. 1 page.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed] Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate Cancer. Progenics Pharmaceuticals Press Release. Sep. 8, 2008. 3 pages.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed] Radiolabeled J591 Antibody Delivers Lethal Hit to Advanced Prostate Cancers in Phase 1 Trial. Cancer Biol &amp; Ther. 2004;3(8):699-700.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed] Seattle Genetics and PSMA Development Company Announce Antibody-Drug Conjugate Collaboration. Business Wire. Jun. 20, 2005. Available at http://www.thefreelibrary.com/Seattle+Genetics+and+PSMA+Development+Company+Announce+Antibody-Drug . . . -a0133363839. Last accessed Jan. 24, 2011. 4 pages.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No Author Listed], FDA: Pfizer voluntarily withdraws cancer treatment Mylotarg from U.S. market. FDA News Release. Jun. 21, 2010. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216448.htm on Aug. 10, 2012. Last updated Jun. 22, 2010.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      [No author listed], Progenics Pharmaceuticals initiates Phase 2 clinical trial of PSMA ADC in prostate cancer patients. Press Release Sep. 28, 2012. 2 pages.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Abdel-Nabi et al., Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol. Feb. 1992;10(1):45-54.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ablin "Immunotherapy for prostatic cancer. Previous and Prospective Considerations1", Oncology (1975) vol. 31, 177-202.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Allen, Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. Oct. 2002;2(10):750-63.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Arlen et al., Therapeutic vaccines for prostate cancer: a review of clinical data. Curr Opin Investig Drugs. Jun. 2005;6(6):592-6.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Axelrod et al., "Preclinical results and human immunohistochemical studies with 90Y-CYT-356: A new prosate cancer therapeutic agent". AUA 87th Annual Meeting. 1992:Abstract #596.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bander et al., Phase I radioimmunotherapy (RIT) trial of humanized monoclonal (mAb) antibody J591 to the extracellular domain of prostate specific membrane antigen (PSMAext) radiolabeled with 1771eutetium (177Lu) in advanced prostate cancer (Pca). 2003 ASCO Annual Meeting. Proc Am Soc Clin Oncol. 2003;22. Abstract 1612.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bander et al., Phase I radioimmunotherapy (RIT) trials of humanized monoclonal antibody (mAb) J591 to the extracellular domain of prostate specific membrane antigen (PSMA ext) radiolabeled with 90Y or 177Lu in advanced prostate cancer (Pca). 2002 ASCO Annual Meeting. Biologic and Targeted Therapies; Antibodies. Abstract No. 18.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bander et al., Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part 1. 2007;25(18S). Abstract 15523.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bander et al., Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol. Oct. 2003;30(5):667-77.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bander, Current status of monoclonal antibodies for imaging and therapy of prostate cancer Semin Oncol. Oct. 1994;21(5):607-12.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bander, Immunotherapy of Prostate Cancer. State of the Science. Genitourinary. Dec. 13-14, 2002. 9 pages.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Basler et al., Advances in prostate cancer immunotherapies. Drugs Aging. 2007;24(3):197-221.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bhaskar et al., E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res. Oct. 1, 2003;63(19):6387-94.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bocchia et al., Antitumor vaccination: where we stand. Haematologica. Nov. 2000;85(11):1172-206.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bodey et al., Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. Jul.-Aug. 2000;20(4):2665-76.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Carter, Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. Nov. 2001;1(2):118-29.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Chang et al., Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer-focus on prostate-specific membrane antigen? Review Article. Curr Opin Urology. 1999;9(5):391-95.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Chen et al., Antibody-cytotoxic agent conjugates for cancer therapy. Expert Opin Drug Deliv. Sep. 2005;2(5):873-90.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Damle, Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin Biol Ther. Sep. 2004;4(9):1445-52.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Darshan et al., Taxanes inhibit AR nuclear accumulation and signaling in cells and metastatic prostate cancer patients. Novel Drug Targets, Agents, and Mechanisms: Poster Presentations-Proffered Abstracts. 99th AACR Annual Meeting. Apr. 12-16, 2008. Abstract 2808.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Donovan et al., Antibody and vaccine therapies targeting prostate specific membrane antigen (PSMA). Proceedings of the Annual Meeting of the AACR. New York, NY. Mar. 24, 2001;42:818. Abstract 4389.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Donovan et al., Clinical development of immunotherapies targeting prostate specific membrane antigen. 38th Annual Meeting American Society of Clinical Oncology. Alexandria, VA. May 18-21, 2002. Presentation. PSMA Development Company, LLC. Tarrytown, NY (joint venture between Progenics Pharmaceuticals, Inc. and Cytogen Corporation) and The Cleveland Clinic, Cleveland, OH. Proceedings of ASCO. 2002;21:25b. Abstract #1909.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Donovan et al., Development of PSMA-based immunotherapies for prostate cancer. AACR Meeting. San Francisco, CA. Apr. 6-10, 2002. PSMA Development Company, LLC. Tarrytown, NY (joint venture between Progenics Pharmaceuticals, Inc. and Cytogen Corporation) and The Cleveland Clinic, Cleveland, OH. Abstract 456.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Doronina et al., Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. Jul. 2003;21(7):778-84. Epub Jun. 1, 2003. Erratum.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Doronina et al., Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. Jan.-Feb. 2006;17(1):114-24.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Doronina et al., Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy. Abstracts of papers. ACS National Meeting. Aug. 2004;228:U908. Cited as AACR meeting abstracts online, Pro Amer Assoc Cancer Res v45 Experimental and Molecular Therapeutics 6: Novel Delivery Strategies, Abstract #623.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Doronina et al., Novel linkers for monoclonal antibody-mediated delivery of anticancer agents AACR. Anaheim, CA. Apr. 16-20, 2005. Abstract No. 1421.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Doronina et al., Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem. Oct. 2008;19(10):1960-3. Epub Sep. 20, 2008.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Francisco et al., cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. Aug. 15, 2003;102(4):1458-65. Epub Apr. 24, 2003.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Galsky et al., Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. May 1, 2008;26(13):2147-54. Epub Mar. 24, 2008.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ghose et al., The design of cytotoxic-agent-antibody conjugates. CRC Critical Reviews in Therapeutic Drug Carrier Systems. 2000;3:263-359.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gong et al., Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev. 1999;18(4):483-90
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Graves et al., Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody. Clin Cancer Res. Apr. 1999;5(4):899-908.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Harada et al., Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol. Aug. 2003;8(4):193-9.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Holmes, PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs. Mar. 2001;10(3):511-9.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Huang et al., Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate. Sep. 15, 2004;61(1):1-11.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Huang et al., Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res. Oct. 15, 2002;62(20):5720-6.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hynecek et al., 177Lu-J591 monoclonal antibody (Lu-J591) therapy in metastatic castrate-resistant prostate cancer (metCRPC): Correlation of antibody-tumor targeting and treatment response Oncology-Basic Science: Therapy, Metrics &amp; Intervention Imaging for Assessment of Response Therapy Planning. J Nucl Med. 2008;49(Supplement 1):144P. 2 pages.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jacobs et al., Clinical use of tumor markers in oncology. Curr Probl Cancer. Nov.-Dec. 1991;15(6):299-350.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jain et al., Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res. Mar. 1, 2007;13(5):1374-82. Epub Feb. 19, 2007.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jaracz et al., Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem. Sep. 1, 2005;13(17):5043-54.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Jayaprakash et al., Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. ChemMedChem. Mar. 2006;1(3):299-302.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Lambert, Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. Oct. 2005;5(5):543-9.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Lapidus et al., Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate. Dec. 1, 2000;45(4):350-4.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Law et al., Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res. Dec. 1, 2004;10(23):7842-51.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Li et al., Trastuzumab-auristatin immunoconjugates inhibit growth and induce apoptosis of human breast cancer cells in vitro. Department of Translational Oncology. Genentech, Inc. South San Francisco, CA. Department of Biochemistry, Seattle Genetics, Inc. Bothell, WA. Poster#6184, 2005.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Lin et al., A functional role of prostate-specific membrane antigen in prostate cancer metastasis Tumor Biology 30: Proteases: Protease Inhibitors and Cancer. Proc Amer Assoc Cancer Res. 2006;47. Abstract 4373.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ma et al., Fully human anti-PSMA antibodies for prostate cancer therapy. Proc AACR. Jul. 2003;44(2):1295. Abstract #6471.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ma et al., Fully human monoclonal antibodies to PSMA selectively target cytotoxins, radiotoxins and host immunity to prostate cancer. J Clin Oncol. ASCO Annual Meeting Proceedings. 2004;22:14S. Abstract No. 2546. Abstract Only.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ma et al., Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res. Apr. 15, 2006;12(8):2591-6.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ma et al., PSMA targeted toxin and radio-labelled antibody therapies for prostate cancer. J Urology. 2003;169:211. Poster 817.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Mays et al., MDX-070, a human anti-plasma antibody, administered as either a single dose or as multiple doses to patients with hormone-refractory prostate cancer. ASCO Annual Meeting, 2006. Abstract #14549.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      McDevitt et al., An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. Nov. 1, 2000;60(21):6095-100.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Mega et al., Prostate specific membrane antigen antibody drug conjugate (PSMA ADC): A Phase I trial in subjects with castration-resistant metastatic prostate cancer (CRMPC) previously treated with taxane. Poster presented Feb. 2012 Genitourinary Cancers Symposium.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Milowsky et al., Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. Jul. 1, 2004;22(13):2522-31. Epub Jun. 1, 2004.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Milowsky et al., Phase I trial results of yttrium-90 (90Y)-labeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 in the treatment of patients with advanced prostate cancer (PC). 2003 ASCO Annual Meeting. Proc Am Soc Clin Oncol. 2003;22. Abstract 1583.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Monson, Recent progress in the use of monoclonal antibodies for imaging and therapy. Curr Opin Gen Surg. 1993:334-9.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Moreno et al. (Urology. 2001, 58: 386-92).
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Morris et al., Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res. May 1, 2007;13(9):2707-13.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Morris et al., Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. Oct. 15, 2005;11(20):7454-61.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Muprhy et al., Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. Jul.-Aug. 1995;15(4):1473-9.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Nanus et al., Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol. Dec. 2003;170(6 Pt 2):S84-8; discussion S88-9. Abstract only.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Olson et al., Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. Sep. 2007;2(3):182-90.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Partin et al., The clinical usefulness of prostate specific antigen: update 1994. Urol. Nov. 1994;152(5 Pt 1):1358-68. Review.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Pastuskovas et al., Tissue distribution, metabolism, and excretion of the antibody-drug conjugate herceptin-monomethyl auristatin E in rats. Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, Inc. South San Francisco, CA. Seattle Genetics, Bothell, WA. Poster #5063, 2005.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Petrylak et al., Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): a phase I trial in taxane-refractory prostate cancer. Poster presented Feb. 17, 2011 Genitourinary Cancers Symposium General Poster Session B. Abstract published ASCO Meeting Abstracts Mar. 29, 2011:158. J Clin Oncol 29: Mar. 2011 (suppl 7; abstr 158).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Petrylak, BRD E18: A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). 2014 Genitourinary Cancers Symposium (abstract 83).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Riechmann et al., Reshaping human antibodies for therapy. Nature. Mar. 4, 1988;332(6162):323-7.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Saijo, What are the reasons for negative phase III trials of molecular-target-based drugs? Cancer Sci. Oct. 2004;95(10):772-6.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sanderson et al., In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. Jan. 15, 2005;11(2 Pt 1):843-52.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Schuelke et al., Human prostate specific membrane antigen (PSMA) is expressed as a non-covalent dimer and provides an attractive target for cancer immunotherapy. Eur J Cancer. Nov. 2002;38:S153. Poster 510.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Schulke et al., The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA. Oct. 28, 2003;100(22):12590-95.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Senter, Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. Jun. 2009;13(3):235-44. Epub May 4, 2009.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sharkey et al., Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. Jul.-Aug. 2006;56(4):226-43.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Small, Monoclonal antibody therapy for prostate cancer: finally a reality? J Clin Oncol. Jul. 1, 2004;22(13):2515-6. Epub Jun. 1, 2004.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Smith-Jones et al., In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. Sep. 15, 2000;60(18):5237-43.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Smith-Jones et al., Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med. Apr. 2003;44(4):610-7.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Su et al., Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res. Apr. 1, 1995;55(7):1441-3.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sweat et al., Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastatses. Urology. Oct. 1998;52(4):637-40.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tagawa et al., Phase II trial of 177Lutetium radio-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). 2008 ASCO Annual Meeting. J Clin Oncol. 2008;26(May 20 Suppl.). Abstract 5140.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Trail et al., Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother. May 2003;52(5):328-37. Epub Jan. 16, 2003.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tralongo et al., Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study. Tumori. Jan.-Feb. 2003;89(1):26-30. Abstract only.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      US 6,290,956, 09/2001, Bander (withdrawn)
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Vitetta et al., Immunotoxins. Annu Rev Immunol. 1985;3:197-212.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Vriesendorp et al., Radiolabeled immunoglobulin therapy: old barriers and new opportunities. Expert Rev Anticancer Ther. Oct. 2001;1(3):461-78.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wang et al. (Mol Cancer Ther., 2011, 10: 1728-1739).
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wang et al. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther. Sep. 2011;10(9):1728-39.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Webb et al., Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system. J Urol. Aug. 1989;142(2 Pt 1):425-32.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Weill Medical College of Cornell University: "177 Lu Radiolabeled Monoclonal Antibody HuJ591 (177 Lu-J591) and Ketoconazole in Patients with Prostate Cancer". ClinicalTrials.gov, Mar. 10, 2008, XP055139382.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Weill Medical College of Cornell University: "Docetaxel/Prednisone Plus Fractionated177 Lu-J591 Antibody for metastatic, castrate-resistant prostate cancer" ClinicalTrials.gov, Jun. 5, 2009, pp. 1-6, XP055139381.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Weiner et al., New approaches to antibody therapy. Oncogene. Dec. 11, 2000;19(53):6144-51.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Williams et al., Discontinued drugs in 2006: oncology drugs. Expert Opin Investig Drugs. Mar. 2008;17(3):269-83.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wolf, Herstellung und Charakterisierung rekombinanter Immunotoxine aus anti-PSMA single-chain-Antikörperfragmenten zur Therapie des Prostatakarzinoms. Ph.D. Thesis. Dec. 2005. 33 pages. 2 page German abstract. 31 page English translation.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wood et al., Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol. Aug. 2001;1(4):370-7.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (18)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9636413B2/en"><a id="link" href="#" class="style-scope state-modifier">US9636413B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-11-15</span>
                    <span class="td style-scope patent-result">2017-05-02</span>
                    <span class="td style-scope patent-result">Endocyte, Inc.</span>
                    <span class="td style-scope patent-result">Conjugates for treating diseases caused by PSMA expressing cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9951324B2/en"><a id="link" href="#" class="style-scope state-modifier">US9951324B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-02-25</span>
                    <span class="td style-scope patent-result">2018-04-24</span>
                    <span class="td style-scope patent-result">Purdue Research Foundation</span>
                    <span class="td style-scope patent-result">PSMA binding ligand-linker conjugates and methods for using 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10046054B2/en"><a id="link" href="#" class="style-scope state-modifier">US10046054B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-08-17</span>
                    <span class="td style-scope patent-result">2018-08-14</span>
                    <span class="td style-scope patent-result">Purdue Research Foundation</span>
                    <span class="td style-scope patent-result">PSMA binding ligand-linker conjugates and methods for using 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10188759B2/en"><a id="link" href="#" class="style-scope state-modifier">US10188759B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-01-07</span>
                    <span class="td style-scope patent-result">2019-01-29</span>
                    <span class="td style-scope patent-result">Endocyte, Inc.</span>
                    <span class="td style-scope patent-result">Conjugates for imaging 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10398791B2/en"><a id="link" href="#" class="style-scope state-modifier">US10398791B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-18</span>
                    <span class="td style-scope patent-result">2019-09-03</span>
                    <span class="td style-scope patent-result">Deutsches Krebsforschungszentrum</span>
                    <span class="td style-scope patent-result">Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20050215472A1/en"><a id="link" href="#" class="style-scope state-modifier">US20050215472A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-10-23</span>
                    <span class="td style-scope patent-result">2005-09-29</span>
                    <span class="td style-scope patent-result">Psma Development Company, Llc</span>
                    <span class="td style-scope patent-result">PSMA formulations and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2326350B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2326350B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-09-08</span>
                    <span class="td style-scope patent-result">2013-09-04</span>
                    <span class="td style-scope patent-result">Psma Development Company, L.L.C.</span>
                    <span class="td style-scope patent-result">Compounds for killing psma-expressing, taxane-resistant cancer cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20120183847A1/en"><a id="link" href="#" class="style-scope state-modifier">US20120183847A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-05-19</span>
                    <span class="td style-scope patent-result">2012-07-19</span>
                    <span class="td style-scope patent-result">Aic Blab</span>
                    <span class="td style-scope patent-result">Composite current collector and methods therefor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR112013011705B1/en"><a id="link" href="#" class="style-scope state-modifier">BR112013011705B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-11-12</span>
                    <span class="td style-scope patent-result">2022-04-05</span>
                    <span class="td style-scope patent-result">The Trustees Of The University Of Pennsylvania</span>
                    <span class="td style-scope patent-result">
  Consensus prostate antigens, nucleic acid molecule encoding the same, and vaccine and uses comprising the same
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2012138691A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2012138691A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-04-04</span>
                    <span class="td style-scope patent-result">2012-10-11</span>
                    <span class="td style-scope patent-result">Children's Medical Center Corporation</span>
                    <span class="td style-scope patent-result">Diagnosis and treatment of taxane-resistant cancers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2012245260B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2012245260B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-04-22</span>
                    <span class="td style-scope patent-result">2016-09-08</span>
                    <span class="td style-scope patent-result">Aptevo Research And Development Llc</span>
                    <span class="td style-scope patent-result">Prostate-specific membrane antigen binding proteins and related compositions and methods 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/SG11201408153YA/en"><a id="link" href="#" class="style-scope state-modifier">SG11201408153YA</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-06-07</span>
                    <span class="td style-scope patent-result">2015-01-29</span>
                    <span class="td style-scope patent-result">Ambrx Inc</span>
                    <span class="td style-scope patent-result">Prostate-specific membrane antigen antibody drug conjugates 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013188740A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013188740A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-06-14</span>
                    <span class="td style-scope patent-result">2013-12-19</span>
                    <span class="td style-scope patent-result">Ambrx, Inc.</span>
                    <span class="td style-scope patent-result">Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20150110814A1/en"><a id="link" href="#" class="style-scope state-modifier">US20150110814A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-18</span>
                    <span class="td style-scope patent-result">2015-04-23</span>
                    <span class="td style-scope patent-result">Psma Development Company, Llc</span>
                    <span class="td style-scope patent-result">Combination therapies with psma ligand conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6908964B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6908964B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-18</span>
                    <span class="td style-scope patent-result">2021-07-28</span>
                    <span class="td style-scope patent-result">ピーエスエムエー ディベロップメント カンパニー，エルエルシー</span>
                    <span class="td style-scope patent-result">
  Combination therapy with PSMA ligand conjugate
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20150147339A1/en"><a id="link" href="#" class="style-scope state-modifier">US20150147339A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-11-15</span>
                    <span class="td style-scope patent-result">2015-05-28</span>
                    <span class="td style-scope patent-result">Psma Development Company, Llc</span>
                    <span class="td style-scope patent-result">Biomarkers for psma targeted therapy for prostate cancer 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2999138C/en"><a id="link" href="#" class="style-scope state-modifier">CA2999138C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-09-21</span>
                    <span class="td style-scope patent-result">2024-05-21</span>
                    <span class="td style-scope patent-result">Aptevo Research And Development Llc</span>
                    <span class="td style-scope patent-result">Cd3 binding polypeptides 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP7284707B2/en"><a id="link" href="#" class="style-scope state-modifier">JP7284707B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-04-07</span>
                    <span class="td style-scope patent-result">2023-05-31</span>
                    <span class="td style-scope patent-result">ジュノー セラピューティクス インコーポレイテッド</span>
                    <span class="td style-scope patent-result">
  Engineered Cells Expressing Prostate-Specific Membrane Antigen (PSMA) or Modified Forms Thereof and Related Methods
 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party, ‡ Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20210023094A1/en"><a id="link" href="#" class="style-scope state-modifier">US20210023094A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-01-28</span>
                    <span class="td style-scope patent-result">Psma antibody-drug conjugates 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9242012B2/en"><a id="link" href="#" class="style-scope state-modifier">US9242012B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-01-26</span>
                    <span class="td style-scope patent-result">Methods for killing PSMA-expressing, taxane-resistant cancer cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5703447B2/en"><a id="link" href="#" class="style-scope state-modifier">JP5703447B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-04-22</span>
                    <span class="td style-scope patent-result">
  PSMA antibodies and protein multimers
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9695248B2/en"><a id="link" href="#" class="style-scope state-modifier">US9695248B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-07-04</span>
                    <span class="td style-scope patent-result">PSMA antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20150110814A1/en"><a id="link" href="#" class="style-scope state-modifier">US20150110814A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-04-23</span>
                    <span class="td style-scope patent-result">Combination therapies with psma ligand conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1691840A2/en"><a id="link" href="#" class="style-scope state-modifier">EP1691840A2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-08-23</span>
                    <span class="td style-scope patent-result">Psma formulations and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2023135666A/en"><a id="link" href="#" class="style-scope state-modifier">JP2023135666A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-09-28</span>
                    <span class="td style-scope patent-result">Combination therapies with psma ligand conjugates 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            
            <h3 id="parentApplications" class="scroll-target style-scope patent-result">
              Parent Applications (1)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Relation</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010027513A2/en"><a id="link" href="#" class="style-scope state-modifier">PCT/US2009/005064</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2008-09-08</span>
                    <span class="td nowrap style-scope patent-result">2009-09-08</span>
                    <span class="td nowrap style-scope patent-result">
                        Continuation-In-Part<template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">Methods for killing psma-expressing, taxane-resistant cancer cells 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="applicationPriorityApps" class="scroll-target style-scope patent-result">
              Priority Applications (1)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9242012B2/en"><a id="link" href="#" class="style-scope state-modifier">US13/030,105</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2008-09-08</span>
                    <span class="td nowrap style-scope patent-result">2011-02-17</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Methods for killing PSMA-expressing, taxane-resistant cancer cells 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (4)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US9530008P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2008-09-08</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US20539509P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2009-01-20</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010027513A2/en"><a id="link" href="#" class="style-scope state-modifier">PCT/US2009/005064</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2009-09-08</span>
                    <span class="td style-scope patent-result">Methods for killing psma-expressing, taxane-resistant cancer cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9242012B2/en"><a id="link" href="#" class="style-scope state-modifier">US13/030,105</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2011-02-17</span>
                    <span class="td style-scope patent-result">Methods for killing PSMA-expressing, taxane-resistant cancer cells 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2011-06-29</span>
                    <span class="td nowrap style-scope patent-result">AS</span>
                    <span class="td nowrap style-scope patent-result">Assignment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Owner name</strong>: PSMA DEVELOPMENT COMPANY, LLC, NEW YORK</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MA, DANGSHE;OLSON, WILLIAM C.;MORRIS, STEPHEN;AND OTHERS;SIGNING DATES FROM 20110422 TO 20110504;REEL/FRAME:026524/0577</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2015-12-04</span>
                    <span class="td nowrap style-scope patent-result">FEPP</span>
                    <span class="td nowrap style-scope patent-result">Fee payment procedure</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2016-01-06</span>
                    <span class="td nowrap style-scope patent-result">STCF</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent grant</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PATENTED CASE</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-07-15</span>
                    <span class="td nowrap style-scope patent-result">MAFP</span>
                    <span class="td nowrap style-scope patent-result">Maintenance fee payment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Year of fee payment</strong>: 4</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2020-08-19</span>
                    <span class="td nowrap style-scope patent-result">AS</span>
                    <span class="td nowrap style-scope patent-result">Assignment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Owner name</strong>: WELLS FARGO BANK, N.A., NORTH CAROLINA</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: SECURITY AGREEMENT;ASSIGNORS:PROGENICS PHARMACEUTICALS, INC.;MOLECULAR INSIGHT PHARMACEUTICALS, INC.;PSMA DEVELOPMENT COMPANY LLC;REEL/FRAME:053538/0666</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20200818</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2020-08-20</span>
                    <span class="td nowrap style-scope patent-result">FEPP</span>
                    <span class="td nowrap style-scope patent-result">Fee payment procedure</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2022-12-02</span>
                    <span class="td nowrap style-scope patent-result">AS</span>
                    <span class="td nowrap style-scope patent-result">Assignment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Owner name</strong>: PSMA DEVELOPMENT COMPANY, LLC, MASSACHUSETTS</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: RELEASE BY SECURED PARTY;ASSIGNOR:WELLS FARGO BANK, N.A.;REEL/FRAME:062047/0915</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20221202</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Owner name</strong>: MOLECULAR INSIGHT PHARMACEUTICALS, INC., MASSACHUSETTS</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: RELEASE BY SECURED PARTY;ASSIGNOR:WELLS FARGO BANK, N.A.;REEL/FRAME:062047/0915</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20221202</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Owner name</strong>: PROGENICS PHARMACEUTICALS, INC., MASSACHUSETTS</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: RELEASE BY SECURED PARTY;ASSIGNOR:WELLS FARGO BANK, N.A.;REEL/FRAME:062047/0915</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20221202</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Owner name</strong>: CITIZENS BANK, N.A., MASSACHUSETTS</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: SECURITY INTEREST;ASSIGNORS:LANTHEUS MEDICAL IMAGING, INC.;MOLECULAR INSIGHT PHARMACEUTICALS, INC.;PSMA DEVELOPMENT COMPANY, LLC;AND OTHERS;REEL/FRAME:062047/0960</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20221202</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2023-07-20</span>
                    <span class="td nowrap style-scope patent-result">MAFP</span>
                    <span class="td nowrap style-scope patent-result">Maintenance fee payment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Year of fee payment</strong>: 8</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
              <h3 id="concepts" class="scroll-target layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">Concepts</div>
                <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
              </h3>
              <div class="layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">
                  <span id="conceptsWarning" class="righthead tooltip-hint style-scope patent-result">machine-extracted</span>
                  <overlay-tooltip positioning-target="#conceptsWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The concepts are extracted by a computer and may be incomplete or incorrect.
    </div>
  </overlay-tooltip>
                </div>
                <span class="headerButton style-scope patent-result"><a href="#" target="_blank" style="display: inline-block;" class="style-scope patent-result"><iron-icon icon="icons:file-download" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M19 9h-4V3H9v6H5l7 7 7-7zM5 18v2h14v-2H5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download</a></span>
                <span class="style-scope patent-result">
                  <dropdown-menu multi="true" label="Filter table" show-label="true" change-action="RESULT_CONCEPT_MENU" class="style-scope patent-result">
    
    <span class="label style-scope dropdown-menu">
      <span class="style-scope dropdown-menu">Filter table</span>
      <span id="selected" class="style-scope dropdown-menu" hidden="">
        <span style="margin: 0 4px 0 2px" class="style-scope dropdown-menu">·</span>
        <span class="style-scope dropdown-menu"></span>
      </span>
      <iron-icon icon="icons:arrow-drop-down" class="style-scope dropdown-menu x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 10l5 5 5-5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><iron-icon icon="icons:arrow-drop-up" class="style-scope dropdown-menu x-scope iron-icon-0" hidden=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
    </span>
    <iron-dropdown allow-outside-scroll="" horizontal-align="left" vertical-align="top" class="style-scope dropdown-menu" aria-disabled="false" aria-hidden="true" style="outline: none; display: none;">
    

    <div id="contentWrapper" class="style-scope iron-dropdown">
      <div class="dropdown-content style-scope dropdown-menu" slot="dropdown-content" id="menu" multi="">
        <div class="style-scope dropdown-menu">
          
            <div class="item style-scope dropdown-menu">Chemical compound</div>
          <template is="dom-repeat" class="style-scope dropdown-menu"></template>
        </div>
      </div>
    </div>
  </iron-dropdown>
  </dropdown-menu>
                </span>
              </div>
              <div class="responsive-table style-scope patent-result">
                <div class="table style-scope patent-result">
                  <div class="thead style-scope patent-result">
                    <div class="tr style-scope patent-result">
                      <span class="th style-scope patent-result">Name</span>
                      <span class="th style-scope patent-result">Image</span>
                      <span class="th style-scope patent-result">Sections</span>
                      <span class="th style-scope patent-result">Count</span>
                      <span class="th style-scope patent-result">Query match</span>
                    </div>
                  </div>
                  <div class="tbody style-scope patent-result">
                    <template is="dom-repeat" initial-count="25" class="style-scope patent-result"></template>
                    
                      <div class$="tr layout horizontal conceptDomain" class="style-scope patent-result">
                        <a href="#" class="td flex style-scope patent-result">
                          Show all concepts from the description section
                        </a>
                      </div>
                    <template is="dom-if" class="style-scope patent-result"></template>
                  </div>
                </div>
              </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.485929126" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.485929126" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=287492637" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>